CROSS-REFERENCE This application is a Divisional Application of U.S. patent application Ser. No. 16/128,372, filed on Sep. 11, 2018, which claims the benefit of U.S. Provisional Patent Application No. 62/556,863 filed on Sep. 11, 2017, each of which are incorporated herein by reference in their entirety.
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 20, 2018, is named 44854-741_401_SL.txt and is 943,473 bytes in size.
BACKGROUND G protein-coupled receptors (GPCRs) are implicated in a wide variety of diseases. Raising antibodies to GPCRs has been difficult due to problems in obtaining suitable antigen because GPCRs are often expressed at low levels in cells and are very unstable when purified. Thus, there is a need for improved agents for therapeutic intervention which target GPCRs.
INCORPORATION BY REFERENCE All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF SUMMARY Provided herein are antibodies comprising a CDR-H3 comprising a sequence of any one of SEQ ID NOS: 2420 to 2436. Provided herein are antibodies comprising a CDR-H3 comprising a sequence of any one of SEQ ID NOS: 2420 to 2436; and wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Provided herein are antibodies wherein the VH domain is IGHV1-18, IGHV1-69, IGHV1-8 IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV3-74, IGHV4-39, or IGHV4-59/61. Provided herein are antibodies, wherein the VL domain is IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, or IGLV2-14. Provided herein are methods of inhibiting GLP1R activity, comprising administering the antibodies as described herein. Provided herein are methods for treatment of a metabolic disorder, comprising administering to a subject in need thereof the antibodies as described herein. In some instances, the antibody comprises a CDR-H3 comprising a sequence of any one of SEQ ID NOS: 2420 to 2436. Provided herein are methods for treatment of a metabolic disorder, wherein the metabolic disorder is Type II diabetes, or obesity. Provided herein are nucleic acids encoding for a protein comprising a sequence of any one of SEQ ID NOS: 2420 to 2436.
Provided herein are nucleic acid libraries comprising a plurality of nucleic acids, wherein each nucleic acid encodes for a sequence that when translated encodes for an immunoglobulin scaffold, wherein the immunoglobulin scaffold comprises a CDR-H3 loop that comprises a GPCR binding domain, and wherein each nucleic acid comprises a sequence encoding for a sequence variant of the GPCR binding domain. Provided herein are nucleic acid libraries, wherein a length of the CDR-H3 loop is about 20 to about 80 amino acids. Provided herein are nucleic acid libraries, wherein a length of the CDR-H3 loop is about 80 to about 230 base pairs. Provided herein are nucleic acid libraries, wherein the immunoglobulin scaffold further comprises one or more domains selected from variable domain, light chain (VL), variable domain, heavy chain (VH), constant domain, light chain (CL), and constant domain, heavy chain (CH). Provided herein are nucleic acid libraries, wherein the VH domain is IGHV1-18, IGHV1-69, IGHV1-8 IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV3-74, IGHV4-39, or IGHV4-59/61. Provided herein are nucleic acid libraries, wherein the VL domain is IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, or IGLV2-14. Provided herein are nucleic acid libraries, wherein a length of the VH domain is about 90 to about 100 amino acids. Provided herein are nucleic acid libraries, wherein a length of the VL domain is about 90 to about 120 amino acids. Provided herein are nucleic acid libraries, wherein a length of the VH domain is about 280 to about 300 base pairs. Provided herein are nucleic acid libraries, wherein a length of the VL domain is about 300 to about 350 base pairs. Provided herein are nucleic acid libraries, wherein the library comprises at least 105 non-identical nucleic acids. Provided herein are nucleic acid libraries, wherein the immunoglobulin scaffold comprises a single immunoglobulin domain. Provided herein are nucleic acid libraries, wherein the immunoglobulin scaffold comprises a peptide of at most 100 amino acids. Provided herein are vector libraries comprising nucleic acid libraries as described herein. Provided herein are cell libraries comprising nucleic acid libraries as described herein.
Provided herein are nucleic acid libraries comprising a plurality of nucleic acids, wherein each nucleic acid encodes for a sequence that when translated encodes a GPCR binding domain, and wherein each nucleic acid comprises sequence encoding for a different GPCR binding domain about 20 to about 80 amino acids. Provided herein are nucleic acid libraries, wherein a length of the GPCR binding domain is about 80 to about 230 base pairs. Provided herein are nucleic acid libraries, wherein the GPCR binding domain is designed based on conformational ligand interactions, peptide ligand interactions, small molecule ligand interactions, extracellular domains of GPCRs, or antibodies that target GPCRs. Provided herein are vector libraries comprising nucleic acid libraries as described herein. Provided herein are cell libraries comprising nucleic acid libraries as described herein.
Provided herein are protein libraries comprising a plurality of proteins, wherein each of the proteins of the plurality of proteins comprise an immunoglobulin scaffold, wherein the immunoglobulin scaffold comprises a CDR-H3 loop that comprises a sequence variant of a GPCR binding domain. Provided herein are protein libraries, wherein a length of the CDR-H3 loop is about 20 to about 80 amino acids. Provided herein are protein libraries, wherein the immunoglobulin scaffold further comprises one or more domains selected from variable domain, light chain (VL), variable domain, heavy chain (VH), constant domain, light chain (CL), and constant domain, heavy chain (CH). Provided herein are protein libraries, wherein the VH domain is IGHV1-18, IGHV1-69, IGHV1-8 IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV3-74, IGHV4-39, or IGHV4-59/61. Provided herein are protein libraries, wherein the VL domain is IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, or IGLV2-14. Provided herein are protein libraries, wherein a length of the VH domain is about 90 to about 100 amino acids. Provided herein are protein libraries, wherein a length of the VL domain is about 90 to about 120 amino acids. Provided herein are protein libraries, wherein the plurality of proteins is used to generate a peptidomimetic library. Provided herein are protein libraries, wherein the protein library comprises peptides. Provided herein are protein libraries, wherein the protein library comprises immunoglobulins. Provided herein are protein libraries, wherein the protein library comprises antibodies. Provided herein are cell libraries comprising protein libraries as described herein.
Provided herein are protein libraries comprising a plurality of proteins, wherein the plurality of proteins comprises sequence encoding for different GPCR binding domains, and wherein the length of each GPCR binding domain is about 20 to about 80 amino acids. Provided herein are protein libraries, wherein the protein library comprises peptides. Provided herein are protein libraries, wherein the protein library comprises immunoglobulins. Provided herein are protein libraries, wherein the protein library comprises antibodies. Provided herein are protein libraries, wherein the plurality of proteins are used to generate a peptidomimetic library. Provided herein are cell libraries comprising protein libraries as described herein.
Provided herein are vector libraries comprising a nucleic acid library described herein. Provided herein are cell libraries comprising a nucleic acid library described herein. Provided herein are cell libraries comprising a protein library described herein.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 depicts a schematic of G protein-coupled receptor (GPCR) ligand interaction surfaces.
FIG. 2A depicts a first schematic of an immunoglobulin scaffold.
FIG. 2B depicts a second schematic of an immunoglobulin scaffold.
FIG. 3 depicts a schematic of a motif for placement in a scaffold.
FIG. 4 depicts a schematic of a GPCR.
FIG. 5 depicts schematics of segments for assembly of clonal fragments and non-clonal fragments.
FIG. 6 depicts schematics of segments for assembly of clonal fragments and non-clonal fragments.
FIG. 7 presents a diagram of steps demonstrating an exemplary process workflow for gene synthesis as disclosed herein.
FIG. 8 illustrates an example of a computer system.
FIG. 9 is a block diagram illustrating an architecture of a computer system.
FIG. 10 is a diagram demonstrating a network configured to incorporate a plurality of computer systems, a plurality of cell phones and personal data assistants, and Network Attached Storage (NAS).
FIG. 11 is a block diagram of a multiprocessor computer system using a shared virtual address memory space.
FIGS. 12A-12C depict sequences of immunoglobulin scaffolds. FIG. 12A discloses SEQ ID NOS 2437-2453, 2448, 2454-2464, 2448, 2465-2471, 2466, 2472-2483, 2462, 2484-2485, 2448, 2486-2496, 2491, 2497-2507, 2491, 2508-2518, 2513, 2519-2520, 2462, 2521-2522, 2491, 2523-2539, 2534, 2540-2544, 2534, 2545-2549, 2534, 2550-2554, 2491, 2555-2559, 2513, 2560, 2556, 2561-2562, 2496, 2563-2564, 2556, 2565-2567, 2491, 2568-2575, 2552, 2576-2577, 2563, 2578-2581, 2522, 2491, 2582-2585, 2567 and 2563, respectively, in order of appearance. FIG. 12B discloses SEQ ID NOS 2586-2620, 2615, 2621-2631, 2459, 2632-2654, 2448, 2655-2658, 2464, 2448, 2659-2661, 2658, 2662-2672, 2658, 2673-2718, 2657, 2719, 2715, 2720-2728, 2720, 2729-2745, 2734, 2746-2753, 2748-2749 and 2754-2755, respectively, in order of appearance. FIG. 12C discloses SEQ ID NOS 2756-2766, 2761, 2767-2785, 2461, 2786-2788, 2448, 2789-2793, 2459, 2794-2798, 2448, 2799-2803, 2448, 2804-2808, 2734, 2809-2831, 2814, 2832-2836, 2820, 2837, 2551, 2838-2843, 2817, 2844, 2522, 2491, 2845-2848, 2522, 2849-2854, 2491, 2855-2859, 2513, 2860-2864, 2448, 2865-2874, 2464, 2448, 2875-2879, 2459, 2880-2881, 2873-2874, 2464, 2448, 2882-2903, 2608 and 2904, respectively, in order of appearance.
FIG. 13 depicts sequences of G protein-coupled receptors scaffolds. FIG. 13 discloses SEQ ID NOS 2905-2911, 2911, 2911-2912, 2912, 2911, 2911, 2911, 2911, 2911-2912, 2912, 2912, 2911, 2911, 2911-2912, 2911-2912, 2912, 2911, 2911, 2913-2915, 2915-2918, 2918, 2918, 2918, 2918, 2918 and 2918, respectively, in order of appearance.
FIG. 14 is a graph of normalized reads for a library for variable domain, heavy chains.
FIG. 15 is a graph of normalized reads for a library for variable domain, light chains.
FIG. 16 is a graph of normalized reads for a library for heavy chain complementarity determining region 3.
FIG. 17A is a plot of light chain frameworks assayed for folding. FIG. 17A discloses SEQ ID NOS 2919-2924, 2712, 2925-2926, 2725, 2927-2932, 2461, 2933, 2455, 2934-2939, 2730, 2742, 2940-2941, 2556, 2942, 2851, 2498, 2943, 2843, 2944-2945, 2757, 2946-2947, 2774 and 2948, respectively, in order of appearance.
FIG. 17B is a plot of light chain frameworks assayed for thermostability. FIG. 17B discloses SEQ ID NOS 2919-2924, 2712, 2925-2926, 2725, 2927-2932, 2461, 2933, 2455, 2934-2939, 2730, 2742, 2940-2941, 2556, 2942, 2851, 2498, 2943, 2843, 2944-2945, 2757, 2946-2947, 2774 and 2948, respectively, in order of appearance.
FIG. 17C is a plot of light chain frameworks assayed for motif display using FLAG tag. FIG. 17C discloses SEQ ID NOS 2919-2924, 2712, 2925-2926, 2725, 2927-2932, 2461, 2933, 2455, 2934-2939, 2730, 2742, 2940-2941, 2556, 2942, 2851, 2498, 2943, 2843, 2944-2945, 2757, 2946-2947, 2774 and 2948, respectively, in order of appearance.
FIG. 17D is a plot of light chain frameworks assayed for motif display using His tag. FIG. 17D discloses SEQ ID NOS 2919-2924, 2712, 2925-2926, 2725, 2927-2932, 2461, 2933, 2455, 2934-2939, 2730, 2742, 2940-2941, 2556, 2942, 2851, 2498, 2943, 2843, 2944-2945, 2757, 2946-2947, 2774 and 2948, respectively, in order of appearance.
FIG. 18A is a plot of heavy chain frameworks assayed for folding.
FIG. 18B is a plot of heavy chain frameworks assayed for stability.
FIG. 18C is a plot of heavy chain frameworks assayed for motif display using FLAG tag.
FIG. 18D is a plot of heavy chain frameworks assayed for motif display using His tag.
FIG. 18E is a plot of heavy chain frameworks assayed for expression.
FIG. 18F is a plot of heavy chain frameworks assayed for selection specificity.
FIGS. 19A-19C depict images of G protein-coupled receptors visualized by fluorescent antibodies.
FIGS. 20A-20C depict images of G protein-coupled receptors visualized by auto-fluorescent proteins.
FIG. 21A depicts a schematic of an immunoglobulin scaffold comprising a VH domain attached to a VL domain using a linker.
FIG. 21B depicts a schematic of a full-domain architecture of an immunoglobulin scaffold comprising a VH domain attached to a VL domain using a linker, a leader sequence, and pIII sequence.
FIG. 21C depicts a schematic of four framework elements (FW1, FW2, FW3, FW4) and the variable 3 CDR (L1, L2, L3) elements for a VL or VH domain.
DETAILED DESCRIPTION The present disclosure employs, unless otherwise indicated, conventional molecular biology techniques, which are within the skill of the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art.
Definitions Throughout this disclosure, various embodiments are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of any embodiments. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range to the tenth of the unit of the lower limit unless the context clearly dictates otherwise. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual values within that range, for example, 1.1, 2, 2.3, 5, and 5.9. This applies regardless of the breadth of the range. The upper and lower limits of these intervening ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, unless the context clearly dictates otherwise.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of any embodiment. As used herein, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items.
Unless specifically stated or obvious from context, as used herein, the term “about” in reference to a number or range of numbers is understood to mean the stated number and numbers +/−10% thereof, or 10% below the lower listed limit and 10% above the higher listed limit for the values listed for a range.
Unless specifically stated, as used herein, the term “nucleic acid” encompasses double- or triple-stranded nucleic acids, as well as single-stranded molecules. In double- or triple-stranded nucleic acids, the nucleic acid strands need not be coextensive (i.e., a double-stranded nucleic acid need not be double-stranded along the entire length of both strands). Nucleic acid sequences, when provided, are listed in the 5′ to 3′ direction, unless stated otherwise. Methods described herein provide for the generation of isolated nucleic acids. Methods described herein additionally provide for the generation of isolated and purified nucleic acids. A “nucleic acid” as referred to herein can comprise at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, or more bases in length. Moreover, provided herein are methods for the synthesis of any number of polypeptide-segments encoding nucleotide sequences, including sequences encoding non-ribosomal peptides (NRPs), sequences encoding non-ribosomal peptide-synthetase (NRPS) modules and synthetic variants, polypeptide segments of other modular proteins, such as antibodies, polypeptide segments from other protein families, including non-coding DNA or RNA, such as regulatory sequences e.g. promoters, transcription factors, enhancers, siRNA, shRNA, RNAi, miRNA, small nucleolar RNA derived from microRNA, or any functional or structural DNA or RNA unit of interest. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, intergenic DNA, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), small nucleolar RNA, ribozymes, complementary DNA (cDNA), which is a DNA representation of mRNA, usually obtained by reverse transcription of messenger RNA (mRNA) or by amplification; DNA molecules produced synthetically or by amplification, genomic DNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. cDNA encoding for a gene or gene fragment referred herein may comprise at least one region encoding for exon sequences without an intervening intron sequence in the genomic equivalent sequence.
GPCR Libraries
Provided herein are methods and compositions relating to G protein-coupled receptor (GPCR) binding libraries comprising nucleic acids encoding for a scaffold comprising a GPCR binding domain. Scaffolds as described herein can stably support a GPCR binding domain. The GPCR binding domain may be designed based on surface interactions of a GPCR ligand and the GPCR. Libraries as described herein may be further variegated to provide for variant libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries that may be generated when the nucleic acid libraries are translated. In some instances, nucleic acid libraries as described herein are transferred into cells to generate a cell library. Also provided herein are downstream applications for the libraries synthesized using methods described herein. Downstream applications include identification of variant nucleic acids or protein sequences with enhanced biologically relevant functions, e.g., improved stability, affinity, binding, functional activity, and for the treatment or prevention of a disease state associated with GPCR signaling.
Scaffold Libraries
Provided herein are libraries comprising nucleic acids encoding for a scaffold, wherein sequences for GPCR binding domains are placed in the scaffold. Scaffold described herein allow for improved stability for a range of GPCR binding domain encoding sequences when inserted into the scaffold, as compared to an unmodified scaffold. Exemplary scaffolds include, but are not limited to, a protein, a peptide, an immunoglobulin, derivatives thereof, or combinations thereof. In some instances, the scaffold is an immunoglobulin. Scaffolds as described herein comprise improved functional activity, structural stability, expression, specificity, or a combination thereof. In some instances, scaffolds comprise long regions for supporting a GPCR binding domain.
Provided herein are libraries comprising nucleic acids encoding for a scaffold, wherein the scaffold is an immunoglobulin. In some instances, the immunoglobulin is an antibody. As used herein, the term antibody will be understood to include proteins having the characteristic two-armed, Y-shape of a typical antibody molecule as well as one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Exemplary antibodies include, but are not limited to, a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv) (including fragments in which the VL and VH are joined using recombinant methods by a synthetic or natural linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules, including single chain Fab and scFab), a single chain antibody, a Fab fragment (including monovalent fragments comprising the VL, VH, CL, and CH1 domains), a F(ab′)2 fragment (including bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region), a Fd fragment (including fragments comprising the VH and CH1 fragment), a Fv fragment (including fragments comprising the VL and VH domains of a single arm of an antibody), a single-domain antibody (dAb or sdAb) (including fragments comprising a VH domain), an isolated complementarity determining region (CDR), a diabody (including fragments comprising bivalent dimers such as two VL and VH domains bound to each other and recognizing two different antigens), a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. In some instances, the libraries disclosed herein comprise nucleic acids encoding for a scaffold, wherein the scaffold is a Fv antibody, including Fv antibodies comprised of the minimum antibody fragment which contains a complete antigen-recognition and antigen-binding site. In some embodiments, the Fv antibody consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association, and the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. In some embodiments, the six hypervariable regions confer antigen-binding specificity to the antibody. In some embodiments, a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen, including single domain antibodies isolated from camelid animals comprising one heavy chain variable domain such as VHH antibodies or nanobodies) has the ability to recognize and bind antigen. In some instances, the libraries disclosed herein comprise nucleic acids encoding for a scaffold, wherein the scaffold is a single-chain Fv or scFv, including antibody fragments comprising a VH, a VL, or both a VH and VL domain, wherein both domains are present in a single polypeptide chain. In some embodiments, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains allowing the scFv to form the desired structure for antigen binding. In some instances, a scFv is linked to the Fc fragment or a VHH is linked to the Fc fragment (including minibodies). In some instances, the antibody comprises immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, e.g., molecules that contain an antigen binding site. Immunoglobulin molecules are of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG 2, IgG 3, IgG 4, IgA 1 and IgA 2) or subclass.
Libraries described herein comprising nucleic acids encoding for a scaffold, wherein the scaffold is an immunoglobulin, comprise variations in at least one region of the immunoglobulin. Exemplary regions of the antibody for variation include, but are not limited to, a complementarity-determining region (CDR), a variable domain, or a constant domain. In some instances, the CDR is CDR1, CDR2, or CDR3. In some instances, the CDR is a heavy domain including, but not limited to, CDR-H1, CDR-H2, and CDR-H3. In some instances, the CDR is a light domain including, but not limited to, CDR-L1, CDR-L2, and CDR-L3. In some instances, the variable domain is variable domain, light chain (VL) or variable domain, heavy chain (VH). In some instances, the VL domain comprises kappa or lambda chains. In some instances, the constant domain is constant domain, light chain (CL) or constant domain, heavy chain (CH).
Methods described herein provide for synthesis of libraries comprising nucleic acids encoding for a scaffold, wherein each nucleic acid encodes for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the scaffold library comprises varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon of a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
In some instances, the at least one region of the immunoglobulin for variation is from heavy chain V-gene family, heavy chain D-gene family, heavy chain J-gene family, light chain V-gene family, or light chain J-gene family. In some instances, the light chain V-gene family comprises immunoglobulin kappa (IGK) gene or immunoglobulin lambda (IGL). Exemplary genes include, but are not limited to, IGHV1-18, IGHV1-69, IGHV1-8, IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV1-69, IGHV3-74, IGHV4-39, IGHV4-59/61, IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, and IGLV2-14.
Provided herein are libraries comprising nucleic acids encoding for immunoglobulin scaffolds, wherein the libraries are synthesized with various numbers of fragments. In some instances, the fragments comprise the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3, VL, or VH domain. In some instances, the fragments comprise framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, the scaffold libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments. The length of each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.
Libraries comprising nucleic acids encoding for immunoglobulin scaffolds as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 amino acids to about 75 amino acids. In some instances, the immunoglobulin scaffolds comprise at least or about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, or more than 5000 amino acids.
A number of variant sequences for the at least one region of the immunoglobulin for variation are de novo synthesized using methods as described herein. In some instances, a number of variant sequences is de novo synthesized for CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3, VL, VH, or combinations thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). The number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences. In some instances, the number of variant sequences is at least or about 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, or more than 8000 sequences. In some instances, the number of variant sequences is about 10 to 500, 25 to 475, 50 to 450, 75 to 425, 100 to 400, 125 to 375, 150 to 350, 175 to 325, 200 to 300, 225 to 375, 250 to 350, or 275 to 325 sequences.
Variant sequences for the at least one region of the immunoglobulin, in some instances, vary in length or sequence. In some instances, the at least one region that is de novo synthesized is for CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3, VL, VH, or combinations thereof. In some instances, the at least one region that is de novo synthesized is for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or more than 50 variant nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 additional nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 less nucleotides or amino acids as compared to wild-type. In some instances, the libraries comprise at least or about 101, 102, 103, 104, 105, 106, 107, 108, 109, 1010, or more than 1010 variants.
Following synthesis of scaffold libraries, scaffold libraries may be used for screening and analysis. For example, scaffold libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag. Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG. In some instances, scaffold libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.
In some instances, the scaffold libraries are assayed for functional activity, structural stability (e.g., thermal stable or pH stable), expression, specificity, or a combination thereof. In some instances, the scaffold libraries are assayed for scaffolds capable of folding. In some instances, a region of the antibody is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof. For example, a VH region or VL region is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof.
GPCR Libraries
Provided herein are G protein-coupled receptor (GPCR) binding libraries comprising nucleic acids encoding for scaffolds comprising sequences for GPCR binding domains. In some instances, the scaffolds are immunoglobulins. In some instances, the scaffolds comprising sequences for GPCR binding domains are determined by interactions between the GPCR binding domains and the GPCRs.
Provided herein are libraries comprising nucleic acids encoding scaffolds comprising GPCR binding domains, wherein the GPCR binding domains are designed based on surface interactions on the GPCRs. Exemplary GPCRs are seen in Table 1. In some instances, the GPCR binding domains interact with the amino- or carboxy-terminus of the GPCR. In some instances, the GPCR binding domains interact with at least one transmembrane domain including, but not limited to, transmembrane domain 1 (TM1), transmembrane domain 2 (TM2), transmembrane domain 3 (TM3), transmembrane domain 4 (TM4), transmembrane domain 5 (TM5), transmembrane domain 6 (TM6), and transmembrane domain 7 (TM7). In some instances, the GPCR binding domains interact with an intracellular surface of the GPCR. For example, the GPCR binding domains interact with at least one intracellular loop including, but not limited to, intracellular loop 1 (ICL1), intracellular loop 2 (ICL2), and intracellular loop 3 (ICL3). In some instances, the GPCR binding domains interact with an extracellular surface of the GPCR. See FIG. 1. For example, the GPCR binding domains interact with at least one extracellular domain (ECD) or extracellular loop (ECL) of the GPCR. The extracellular loops include, but are not limited to, extracellular loop 1 (ECL1), extracellular loop 2 (ECL2), and extracellular loop 3 (ECL3).
TABLE 1
List of GPCRs
Gene Accession
GPCR Name Number
5-hydroxytryptamine receptor 1A HTR1A P08908
5-hydroxytryptamine receptor 1B HTR1B P28222
5-hydroxytryptamine receptor 1D HTR1D P28221
5-hydroxytryptamine receptor 1E HTR1E P28566
5-hydroxytryptamine receptor 1F HTR1F P30939
5-hydroxytryptamine receptor 2A HTR2A P28223
5-hydroxytryptamine receptor 2B HTR2B P41595
5-hydroxytryptamine receptor 2C HTR2C P28335
5-hydroxytryptamine receptor 4 HTR4 Q13639
5-hydroxytryptamine receptor 5A HTR5A P47898
5-hydroxytryptamine receptor 6 HTR6 P50406
5-hydroxytryptamine receptor HTR7 P34969
Adenosine receptor A1 ADORA1 P30542
Adenosine receptor A2a ADORA2A P29274
Adenosine receptor A2b ADORA2B P29275
Adenosine A3 receptor ADORA3 P33765
Muscarinic acetylcholine receptor M1 CHRM1 P11229
Muscarinic acetylcholine receptor M2 CHRM2 P08172
Muscarinic acetylcholine receptor M3 CHRM3 P20309
Muscarinic acetylcholine receptor M4 CHRM4 P08173
Muscarinic acetylcholine receptor M5 CHRM5 P08912
Adrenocorticotropic hormone receptor MC2R Q01718
α-1A adrenergic receptor ADRA1A P35348
α-1B adrenergic receptor ADRA1B P35368
α-1D adrenergic receptor ADRA1D P25100
α-2A adrenergic receptor ADRA2A P08913
α-2B adrenergic receptor ADRA2B P18089
α-2C adrenergic receptor ADRA2C P18825
β-1 adrenergic receptor ADRB1 P08588
β-2 adrenergic receptor ADRB2 P07550
β-3 adrenergic receptor ADRB3 P13945
Type-1 angiotensin II receptor AGTR1 P30556
Duffy antigen/chemokine receptor DARC Q16570
Endothelin-1 receptor EDNRA P25101
Endothelin B receptor EDNRB P24530
N-formyl peptide receptor 2 FPR2 P25090
Follicle-stimulating hormone receptor FSHR P23945
Galanin receptor type 1 GALR1 P47211
Galanin receptor type 2 GALR2 O43603
Galanin receptor type 3 GALR3 O60755
Gastrin/cholecystokinin type B receptor CCKBR P32239
Gonadotropin-releasing hormone receptor GNRHR P30968
Putative gonadotropin-releasing hormone II GNRHR2 Q96P88
receptor
G-protein coupled oestrogen receptor 1 GPER Q99527
Uracil nucleotide/cysteinyl leukotriene GPR17 Q13304
receptor
Putative G-protein coupled receptor 44 GPR44 Q9Y5Y4
G-protein coupled receptor 55 GPR55 Q9Y2T6
Gastrin-releasing peptide receptor GRPR P30550
Histamine H1 receptor HRH1 P35367
Histamine H2 receptor HRH2 P25021
Histamine H3 receptor HRH3 Q9Y5N1
Histamine H4 receptor HRH4 Q9H3N8
KiSS-1 receptor KISS1R Q969F8
Lysophosphatidic acid receptor 1 LPAR1 Q92633
Lysophosphatidic acid receptor 2 LPAR2 Q9HBW0
Lysophosphatidic acid receptor 3 LPAR3 Q9UBY5
Lysophosphatidic acid receptor 4 LPAR4 Q99677
Lysophosphatidic acid receptor 6 LPAR6 P43657
Lutropin-choriogonadotropic hormone LHCGR P22888
receptor
Leukotriene B4 receptor 1 LTB4R Q15722
Leukotriene B4 receptor 2 LTB4R2 Q9NPC1
Melanocortin receptor 3 MC3R P41968
Melanocortin receptor 4 MC4R P32245
Melanocortin receptor 5 MC5R P33032
Olfactory receptor 10G9 OR10G9 Q8NGN4
Olfactory receptor 10H1 OR10H1 Q9Y4A9
Olfactory receptor 10H2 OR10H2 O60403
Olfactory receptor 10H3 OR10H3 O60404
Olfactory receptor 10H4 OR10H4 Q8NGA5
Olfactory receptor 10H5 OR10H5 Q8NGA6
Olfactory receptor 10J1 OR10J1 P30954
Olfactory receptor 10J3 OR10J3 Q5JRS4
Olfactory receptor 10J5 OR10J5 Q8NHC4
Olfactory receptor 10K1 OR10K1 Q8NGX5
Olfactory receptor 10K2 OR10K2 Q6IF99
Olfactory receptor 10P1 OR10P1 Q8NGE3
Olfactory receptor 10Q1 OR10Q1 Q8NGQ4
Olfactory receptor 10R2 OR10R2 Q8NGX6
Olfactory receptor 10S1 OR10S1 Q8NGN2
Olfactory receptor 10T2 OR10T2 Q8NGX3
Olfactory receptor 10V1 OR10V1 Q8NGI7
Olfactory receptor 10W1 OR10W1 Q8NGF6
Olfactory receptor 14A2 OR14A2 Q96R54
Olfactory receptor 14C36 OR14C36 Q8NHC7
Olfactory receptor 14I1 OR14I1 A6ND48
Olfactory receptor 14J1 OR14J1 Q9UGF5
Olfactory receptor 14K1 OR14K1 Q8NGZ2
Olfactory receptor 2A12 OR2A12 Q8NGT7
Olfactory receptor 2A14 OR2A14 Q96R47
Olfactory receptor 2A25 OR2A25 A4D2G3
Olfactory receptor 2AG1 OR2AG1 Q9H205
Olfactory receptor 2AG2 OR2AG2 A6NM03
Olfactory receptor 2AJ1 OR2AJ1 Q8NGZ0
Olfactory receptor 2AK2 OR2AK2 Q8NG84
Olfactory receptor 2AP1 OR2AP1 Q8NGE2
Olfactory receptor 2AT4 OR2AT4 A6NND4
Olfactory receptor 51I2 OR51I2 Q9H344
Olfactory receptor 51J1 OR51J1 Q9H342
Olfactory receptor 51L1 OR51L1 Q8NGJ5
Olfactory receptor 51M1 OR51M1 Q9H341
Olfactory receptor 51Q1 OR51Q1 Q8NH59
Olfactory receptor 51S1 OR51S1 Q8NGJ8
Olfactory receptor 51T1 OR51T1 Q8NGJ9
Olfactory receptor 51V1 OR51V1 Q9H2C8
Olfactory receptor 52A1 OR52A1 Q9UKL2
Olfactory receptor 52A5 OR52A5 Q9H2C5
Olfactory receptor 52B2 OR52B2 Q96RD2
Olfactory receptor 52B4 OR52B4 Q8NGK2
Olfactory receptor 52B6 OR52B6 Q8NGF0
Olfactory receptor 52D1 OR52D1 Q9H346
Olfactory receptor 52E2 OR52E2 Q8NGJ4
Olfactory receptor 52E4 OR52E4 Q8NGH9
Olfactory receptor 52E5 OR52E5 Q8NH55
Olfactory receptor 52E6 OR52E6 Q96RD3
Olfactory receptor 52E8 OR52E8 Q6IFG1
Olfactory receptor 52H1 OR52H1 Q8NGJ2
Olfactory receptor 52I1 OR52I1 Q8NGK6
Olfactory receptor 52I2 OR52I2 Q8NH67
Olfactory receptor 52K1 OR52K1 Q8NGK4
Olfactory receptor 52K2 OR52K2 Q8NGK3
Olfactory receptor 52L1 OR52L1 Q8NGH7
Olfactory receptor 52M1 OR52M1 Q8NGK5
Olfactory receptor 52N1 OR52N1 Q8NH53
Olfactory receptor 52N2 OR52N2 Q8NGI0
Olfactory receptor 52N4 OR52N4 Q8NGI2
Olfactory receptor 52N5 OR52N5 Q8NH56
Olfactory receptor 52R1 OR52R1 Q8NGF1
Olfactory receptor 52W1 OR52W1 Q6IF63
Red-sensitive opsin OPN1LW P04000
Visual pigment-like receptor peropsin RRH O14718
Olfactory receptor 1A1 OR1A1 Q9P1Q5
Olfactory receptor 1A2 OR1A2 Q9Y585
Olfactory receptor 1B1 OR1B1 Q8NGR6
Olfactory receptor 1C1 OR1C1 Q15619
Olfactory receptor 1D2 OR1D2 P34982
Olfactory receptor 1F1 OR1F1 O43749
Olfactory receptor 1F12 OR1F12 Q8NHA8
Olfactory receptor 1G1 OR1G1 P47890
Olfactory receptor 1I1 OR1I1 O60431
Olfactory receptor 1J1 OR1J1 Q8NGS3
Olfactory receptor 1J2 OR1J2 Q8NGS2
Olfactory receptor 1J4 OR1J4 Q8NGS1
Olfactory receptor 1K1 OR1K1 Q8NGR3
Olfactory receptor 1L1 OR1L1 Q8NH94
Olfactory receptor 1L3 OR1L3 Q8NH93
Olfactory receptor 1L4 OR1L4 Q8NGR5
Olfactory receptor 1L6 OR1L6 Q8NGR2
Olfactory receptor 1L8 OR1L8 Q8NGR8
Olfactory receptor 1M1 OR1M1 Q8NGA1
Olfactory receptor 1N1 OR1N1 Q8NGS0
Olfactory receptor 1N2 OR1N2 Q8NGR9
Olfactory receptor 1Q1 OR1Q1 Q15612
Olfactory receptor 1S1 OR1S1 Q8NH92
Olfactory receptor 1S2 OR1S2 Q8NGQ3
Olfactory receptor 2A2 OR2A2 Q6IF42
Olfactory receptor 2A4 OR2A4 O95047
Olfactory receptor 2B2 OR2B2 Q9GZK3
Putative olfactory receptor 2B3 OR2B3 O76000
Olfactory receptor 2B6 OR2B6 P58173
Putative olfactory receptor 2B8 OR2B8P P59922
Olfactory receptor 2T5 OR2T5 Q6IEZ7
Olfactory receptor 2T6 OR2T6 Q8NHC8
Olfactory receptor 2T8 OR2T8 A6NH00
Olfactory receptor 2V1 OR2V1 Q8NHB1
Olfactory receptor 2V2 OR2V2 Q96R30
Olfactory receptor 2W1 OR2W1 Q9Y3N9
Olfactory receptor 2W3 OR2W3 Q7Z3T1
Olfactory receptor 2Y1 OR2Y1 Q8NGV0
Olfactory receptor 2Z1 OR2Z1 Q8NG97
Olfactory receptor 3A1 OR3A1 P47881
Olfactory receptor 3A2 OR3A2 P47893
Olfactory receptor 3A3 OR3A3 P47888
Olfactory receptor 3A4 OR3A4 P47883
Putative olfactory receptor 4A4 OR4A4P Q8NGN8
Olfactory receptor 4A5 OR4A5 Q8NH83
Olfactory receptor 4A8 OR4A8P P0C604
Olfactory receptor 4B1 OR4B1 Q8NGF8
Olfactory receptor 4C3 OR4C3 Q8NH37
Olfactory receptor 4C5 OR4C5 Q8NGB2
Olfactory receptor 4C6 OR4C6 Q8NH72
Olfactory receptor 4C11 OR4C11 Q6IEV9
Olfactory receptor 4C12 OR4C12 Q96R67
Olfactory receptor 4C13 OR4C13 Q8NGP0
Olfactory receptor 4C15 OR4C15 Q8NGM1
Olfactory receptor 4C16 OR4C16 Q8NGL9
Olfactory receptor 4D1 OR4D1 Q15615
Olfactory receptor 4D2 OR4D2 P58180
Olfactory receptor 4D5 OR4D5 Q8NGN0
Olfactory receptor 4D6 OR4D6 Q8NGJ1
Olfactory receptor 4D9 OR4D9 Q8NGE8
Olfactory receptor 4D10 OR4D10 Q8NGI6
Olfactory receptor 4D11 OR4D11 Q8NGI4
Olfactory receptor 5B17 OR5B17 Q8NGF7
Olfactory receptor 5B21 OR5B21 A6NL26
Olfactory receptor 5C1 OR5C1 Q8NGR4
Olfactory receptor 5D13 OR5D13 Q8NGL4
Olfactory receptor 5D14 OR5D14 Q8NGL3
Olfactory receptor 5D16 OR5D16 Q8NGK9
Olfactory receptor 5D18 OR5D18 Q8NGL1
Olfactory receptor 5F1 OR5F1 O95221
Olfactory receptor 5H1 OR5H1 A6NKK0
Olfactory receptor 5H2 OR5H2 Q8NGV7
Olfactory receptor 5H6 OR5H6 Q8NGV6
Olfactory receptor 5I1 OR5I1 Q13606
Olfactory receptor 5J2 OR5J2 Q8NH18
Olfactory receptor 5K1 OR5K1 Q8NHB7
Olfactory receptor 5K2 OR5K2 Q8NHB8
Olfactory receptor 5K3 OR5K3 A6NET4
Olfactory receptor 5K4 OR5K4 A6NMS3
Olfactory receptor 5L1 OR5L1 Q8NGL2
Olfactory receptor 5L2 OR5L2 Q8NGL0
Olfactory receptor 5M1 OR5M1 Q8NGP8
Olfactory receptor 5M3 OR5M3 Q8NGP4
Olfactory receptor 5M8 OR5M8 Q8NGP6
Olfactory receptor 5M9 OR5M9 Q8NGP3
Olfactory receptor 5M10 OR5M10 Q6IEU7
Olfactory receptor 5M11 OR5M11 Q96RB7
Olfactory receptor 5P2 OR5P2 Q8WZ92
Olfactory receptor 5P3 OR5P3 Q8WZ94
Olfactory receptor 5R1 OR5R1 Q8NH85
Olfactory receptor 5T1 OR5T1 Q8NG75
Olfactory receptor 5T2 OR5T2 Q8NGG2
Olfactory receptor 5T3 OR5T3 Q8NGG3
Olfactory receptor 5W2 OR5W2 Q8NH69
Olfactory receptor 7G3 OR7G3 Q8NG95
Olfactory receptor 8A1 OR8A1 Q8NGG7
Olfactory receptor 8B3 OR8B3 Q8NGG8
Olfactory receptor 8B4 OR8B4 Q96RC9
Olfactory receptor 8B8 OR8B8 Q15620
Olfactory receptor 8B12 OR8B12 Q8NGG6
Olfactory receptor 8D1 OR8D1 Q8WZ84
Olfactory receptor 8D2 OR8D2 Q9GZM6
Olfactory receptor 8D4 OR8D4 Q8NGM9
Orexin receptor type 1 HCRTR1 O43613
Orexin receptor type 2 HCRTR2 O43614
Oxoeicosanoid receptor 1 OXER1 Q8TDS5
Oxytocin receptor OXTR P30559
P2Y purinoceptor 1 P2RY1 P47900
P2Y purinoceptor 2 P2RY2 P41231
P2Y purinoceptor 4 P2RY4 P51582
P2Y purinoceptor 6 P2RY6 Q15077
P2Y purinoceptor 8 P2RY8 Q86VZ1
Putative P2Y purinoceptor 10 P2RY10 O00398
P2Y purinoceptor 11 P2RY11 Q96G91
P2Y purinoceptor 12 P2RY12 Q9H244
P2Y purinoceptor 13 P2RY13 Q9BPV8
P2Y purinoceptor 14 P2RY14 Q15391
Proteinase-activated receptor 1 F2R P25116
Proteinase-activated receptor 2 F2RL1 P55085
Proteinase-activated receptor 3 F2RL2 O00254
Proteinase-activated receptor 4 F2RL3 Q96RI0
Prostaglandin D2 receptor PTGDR Q13258
Prostaglandin E2 receptor EP1 subtype PTGER1 P34995
Prostaglandin E2 receptor EP2 subtype PTGER2 P43116
Prostaglandin E2 receptor EP3 subtype PTGER3 P43115
Prostaglandin E2 receptor EP4 subtype PTGER4 P35408
Type-2 angiotensin II receptor (AT2) AGTR2 P50052
Apelin receptor APLNR P35414
B1 bradykinin receptor BDKRB1 P46663
B2 bradykinin receptor BDKRB2 P30411
C5a anaphylatoxin chemotactic receptor C5AR1 P21730
Cholecystokinin receptor type A CCKAR P32238
C-C chemokine receptor type 10 CCR10 P46092
C-C chemokine receptor type 1 CCR1 P32246
C-C chemokine receptor type 2 CCR2 P41597
C-C chemokine receptor type 3 CCR3 P51677
C-C chemokine receptor type 4 CCR4 P51679
C-C chemokine receptor type 5 CCR5 P51681
C-C chemokine receptor type 6 CCR6 P51684
C-C chemokine receptor type 7 CCR7 P32248
C-C chemokine receptor type 8 CCR8 P51685
C-C chemokine receptor type 9 CCR9 P51686
Cysteinyl leukotriene receptor 1 CYSLTR1 Q9Y271
Cysteinyl leukotriene receptor 2 CYSLTR2 Q9NS75
Cannabinoid receptor 1 CNR1 P21554
Cannabinoid receptor 2 CNR2 P34972
CX3C chemokine receptor 1 CX3CR1 P49238
High affinity interleukin-8 receptor A IL8RA P25024
High affinity interleukin-8 receptor B IL8RB P25025
C-X-C chemokine receptor type 3 CXCR3 P49682
C-X-C chemokine receptor type 4 CXCR4 P61073
C-X-C chemokine receptor type 6 CXCR6 O00574
C-X-C chemokine receptor type 7 CXCR7 P25106
D(1A) dopamine receptor DRD1 P21728
D(2) dopamine receptor DRD2 P14416
D(3) dopamine receptor DRD3 P35462
D(4) dopamine receptor DRD4 P21917
D(1B) dopamine receptor DRD5 P21918
Melanocyte-stimulating hormone receptor MC1R Q01726
Melatonin receptor type 1A MTNR1A P48039
Melatonin receptor type 1B MTNR1B P49286
Substance-P receptor TACR1 P25103
Substance-K receptor TACR2 P21452
Neuromedin-K receptor TACR3 P29371
Neuromedin-B receptor NMBR P28336
Neuropeptides B/W receptor type 1 NPBWR1 P48145
Neuropeptides B/W receptor type 2 NPBWR2 P48146
Neuropeptide FF receptor 1 NPFFR1 Q9GZQ6
Neuropeptide FF receptor 2 NPFFR2 Q9Y5X5
Neuropeptide Y receptor type 1 NPY1R P25929
Neuropeptide Y receptor type 2 NPY2R P49146
Neuropeptide Y receptor type 4 PPYR1 P50391
Neuropeptide Y receptor type 5 NPY5R Q15761
Neurotensin receptor type 1 NTSR1 P30989
Neurotensin receptor type 2 NTSR2 O95665
Olfactory receptor 10A2 OR10A2 Q9H208
Olfactory receptor 10A3 OR10A3 P58181
Olfactory receptor 10A4 OR10A4 Q9H209
Olfactory receptor 10A5 OR10A5 Q9H207
Olfactory receptor 10A6 OR10A6 Q8NH74
Olfactory receptor 10A7 OR10A7 Q8NGE5
Olfactory receptor 10AD1 OR10AD1 Q8NGE0
Olfactory receptor 10AG1 OR10AG1 Q8NH19
Olfactory receptor 10C1 OR10C1 Q96KK4
Olfactory receptor 10G2 OR10G2 Q8NGC3
Olfactory receptor 10G3 OR10G3 Q8NGC4
Olfactory receptor 10G4 OR10G4 Q8NGN3
Olfactory receptor 10G6 OR10G6 Q8NH81
Olfactory receptor 10G7 OR10G7 Q8NGN6
Olfactory receptor 10G8 OR10G8 Q8NGN5
Olfactory receptor 2T10 OR2T10 Q8NGZ9
Olfactory receptor 2T11 OR2T11 Q8NH01
Olfactory receptor 2T12 OR2T12 Q8NG77
Olfactory receptor 2T27 OR2T27 Q8NH04
Olfactory receptor 2T29 OR2T29 Q8NH02
Olfactory receptor 2T33 OR2T33 Q8NG76
Olfactory receptor 2T34 OR2T34 Q8NGX1
Olfactory receptor 2T35 OR2T35 Q8NGX2
Olfactory receptor 4A15 OR4A15 Q8NGL6
Olfactory receptor 4A16 OR4A16 Q8NH70
Olfactory receptor 4A47 OR4A47 Q6IF82
Olfactory receptor 4C45 OR4C45 A6NMZ5
Olfactory receptor 4C46 OR4C46 A6NHA9
Olfactory receptor 4F15 OR4F15 Q8NGB8
Olfactory receptor 4F17 OR4F17 Q8NGA8
Olfactory receptor 4F21 OR4F21 O95013
Olfactory receptor 51A2 OR51A2 Q8NGJ7
Olfactory receptor 51A4 OR51A4 Q8NGJ6
Olfactory receptor 51A7 OR51A7 Q8NH64
Olfactory receptor 51B2 OR51B2 Q9Y5P1
Olfactory receptor 51B4 OR51B4 Q9Y5P0
Olfactory receptor 51B5 OR51B5 Q9H339
Olfactory receptor 51B5 OR51B6 Q9H340
Olfactory receptor 51D1 OR51D1 Q8NGF3
Olfactory receptor 51E1 OR51E1 Q8TCB6
Olfactory receptor 51E2 OR51E2 Q9H255
Olfactory receptor 51F1 OR51F1 A6NGY5
Olfactory receptor 51F2 OR51F2 Q8NH61
Olfactory receptor 51G1 OR51G1 Q8NGK1
Olfactory receptor 51G2 OR51G2 Q8NGK0
Putative olfactory receptor 51H1 OR51H1P Q8NH63
Olfactory receptor 51I1 OR51I1 Q9H343
Olfactory receptor 56A1 OR56A1 Q8NGH5
Olfactory receptor 56A3 OR56A3 Q8NH54
Olfactory receptor 56A4 OR56A4 Q8NGH8
Olfactory receptor 56A5 OR56A5 P0C7T3
Olfactory receptor 56B1 OR56B1 Q8NGI3
Olfactory receptor 56B4 OR56B4 Q8NH76
Olfactory receptor 5AC2 OR5AC2 Q9NZP5
Olfactory receptor 5AK2 OR5AK2 Q8NH90
Olfactory receptor 5AN1 OR5AN1 Q8NGI8
Olfactory receptor 5AP2 OR5AP2 Q8NGF4
Olfactory receptor 5AR1 OR5AR1 Q8NGP9
Olfactory receptor 5AS1 OR5AS1 Q8N127
Olfactory receptor 5AU1 OR5AU1 Q8NGC0
Olfactory receptor 5H14 OR5H14 A6NHG9
Olfactory receptor 5H15 OR5H15 A6NDH6
Olfactory receptor 6C65 OR6C65 A6NJZ3
Olfactory receptor 6C68 OR6C68 A6NDL8
Olfactory receptor 6C70 OR6C70 A6NIJ9
Olfactory receptor 6C74 OR6C74 A6NCV1
Olfactory receptor 6C75 OR6C75 A6NL08
Olfactory receptor 6C76 OR6C76 A6NM76
Olfactory receptor 7E24 OR7E24 Q6IFN5
Opsin-3 OPN3 Q9H1Y3
Melanopsin OPN4 Q9UHM6
Opsin-5 OPN5 Q6U736
δ-type opioid receptor OPRD1 P41143
κ-type opioid receptor OPRK1 P41145
μ-type opioid receptor OPRM1 P35372
Nociceptin receptor OPRL1 P41146
Blue-sensitive opsin OPN1SW P03999
Rhodopsin RHO P08100
Green-sensitive opsin OPN1MW P04001
Olfactory receptor 2B11 OR2B11 Q5JQS5
Olfactory receptor 2C1 OR2C1 O95371
Olfactory receptor 2C3 OR2C3 Q8N628
Olfactory receptor 2D2 OR2D2 Q9H210
Olfactory receptor 2D3 OR2D3 Q8NGH3
Olfactory receptor 2F1 OR2F1 Q13607
Olfactory receptor 2F2 OR2F2 O95006
Olfactory receptor 2G2 OR2G2 Q8NGZ5
Olfactory receptor 2G3 OR2G3 Q8NGZ4
Olfactory receptor 2G6 OR2G6 Q5TZ20
Olfactory receptor 2H1 OR2H1 Q9GZK4
Olfactory receptor 2H2 OR2H2 O95918
Putative olfactory receptor 2I1 OR2I1P Q8NGU4
Olfactory receptor 2J1 OR2J1 Q9GZK6
Olfactory receptor 2J2 OR2J2 O76002
Olfactory receptor 2J3 OR2J3 O76001
Olfactory receptor 2K2 OR2K2 Q8NGT1
Olfactory receptor 2L2 OR2L2 Q8NH16
Olfactory receptor 2L3 OR2L3 Q8NG85
Olfactory receptor 2L5 OR2L5 Q8NG80
Olfactory receptor 2L8 OR2L8 Q8NGY9
Olfactory receptor 2L13 OR2L13 Q8N349
Olfactory receptor 2M2 OR2M2 Q96R28
Olfactory receptor 2M3 OR2M3 Q8NG83
Olfactory receptor 2M4 OR2M4 Q96R27
Olfactory receptor 2M5 OR2M5 A3KFT3
Olfactory receptor 2M7 OR2M7 Q8NG81
Olfactory receptor 2S2 OR2S2 Q9NQN1
Olfactory receptor 2T1 OR2T1 O43869
Olfactory receptor 2T2 OR2T2 Q6IF00
Olfactory receptor 2T3 OR2T3 Q8NH03
Olfactory receptor 2T4 OR2T4 Q8NH00
Olfactory receptor 4E1 OR4E1 P0C645
Olfactory receptor 4E2 OR4E2 Q8NGC2
Olfactory receptor 4F3/4F16/4F29 OR4F3 Q6IEY1
Olfactory receptor 4F4 OR4F4 Q96R69
Olfactory receptor 4F5 OR4F5 Q8NH21
Olfactory receptor 4F6 OR4F6 Q8NGB9
Olfactory receptor 4K1 OR4K1 Q8NGD4
Olfactory receptor 4K2 OR4K2 Q8NGD2
Olfactory receptor 4K3 OR4K3 Q96R72
Olfactory receptor 4K5 OR4K5 Q8NGD3
Olfactory receptor 4K13 OR4K13 Q8NH42
Olfactory receptor 4K14 OR4K14 Q8NGD5
Olfactory receptor 4K15 OR4K15 Q8NH41
Olfactory receptor 4K17 OR4K17 Q8NGC6
Olfactory receptor 4L1 OR4L1 Q8NH43
Olfactory receptor 4M1 OR4M1 Q8NGD0
Olfactory receptor 4M2 OR4M2 Q8NGB6
Olfactory receptor 4N2 OR4N2 Q8NGD1
Olfactory receptor 4N4 OR4N4 Q8N0Y3
Olfactory receptor 4N5 OR4N5 Q8IXE1
Olfactory receptor 4P4 OR4P4 Q8NGL7
Olfactory receptor 4Q2 OR4Q2 P0C623
Olfactory receptor 4Q3 OR4Q3 Q8NH05
Olfactory receptor 4S1 OR4S1 Q8NGB4
Olfactory receptor 4S2 OR4S2 Q8NH73
Olfactory receptor 4X1 OR4X1 Q8NH49
Olfactory receptor 4X2 OR4X2 Q8NGF9
Olfactory receptor 5A1 OR5A1 Q8NGJ0
Olfactory receptor 5A2 OR5A2 Q8NGI9
Olfactory receptor 5B2 OR5B2 Q96R09
Olfactory receptor 5B3 OR5B3 Q8NH48
Olfactory receptor 5B12 OR5B12 Q96R08
Olfactory receptor 6A2 OR6A2 O95222
Olfactory receptor 6B1 OR6B1 O95007
Olfactory receptor 6B2 OR6B2 Q6IFH4
Olfactory receptor 6B3 OR6B3 Q8NGW1
Olfactory receptor 6C1 OR6C1 Q96RD1
Olfactory receptor 6C2 OR6C2 Q9NZP2
Olfactory receptor 6C3 OR6C3 Q9NZP0
Olfactory receptor 6C4 OR6C4 Q8NGE1
Olfactory receptor 6C6 OR6C6 A6NF89
Olfactory receptor 6F1 OR6F1 Q8NGZ6
Olfactory receptor 6J1 OR6J1 Q8NGC5
Olfactory receptor 6K2 OR6K2 Q8NGY2
Olfactory receptor 6K3 OR6K3 Q8NGY3
Olfactory receptor 6K6 OR6K6 Q8NGW6
Olfactory receptor 6M1 OR6M1 Q8NGM8
Olfactory receptor 6N1 OR6N1 Q8NGY5
Olfactory receptor 6N2 OR6N2 Q8NGY6
Olfactory receptor 6P1 OR6P1 Q8NGX9
Olfactory receptor 6Q1 OR6Q1 Q8NGQ2
Olfactory receptor 6S1 OR6S1 Q8NH40
Olfactory receptor 6T1 OR6T1 Q8NGN1
Olfactory receptor 6V1 OR6V1 Q8N148
Olfactory receptor 6X1 OR6X1 Q8NH79
Olfactory receptor 6Y1 OR6Y1 Q8NGX8
Olfactory receptor 7A5 OR7A5 Q15622
Olfactory receptor 7A10 OR7A10 O76100
Olfactory receptor 7A17 OR7A17 O14581
Olfactory receptor 7C1 OR7C1 O76099
Olfactory receptor 7C2 OR7C2 O60412
Olfactory receptor 7D4 OR7D4 Q8NG98
Olfactory receptor 7G1 OR7G1 Q8NGA0
Olfactory receptor 7G2 OR7G2 Q8NG99
Prostaglandin F2-α receptor PTGFR P43088
Prostacyclin receptor PTGIR P43119
Prolactin-releasing peptide receptor PRLHR P49683
Platelet-activating factor receptor PTAFR P25105
Pyroglutamylated RFamide peptide receptor QRFPR Q96P65
RPE-retinal G protein-coupled receptor RGR P47804
Sphingosine 1-phosphate receptor 1 S1PR1 P21453
Sphingosine 1-phosphate receptor 2 S1PR2 O95136
Sphingosine 1-phosphate receptor 3 S1PR3 Q99500
Sphingosine 1-phosphate receptor 4 S1PR4 O95977
Sphingosine 1-phosphate receptor 5 S1PR5 Q9H228
Somatostatin receptor type 1 SSTR1 P30872
Somatostatin receptor type 2 SSTR2 P30874
Somatostatin receptor type 3 SSTR3 P32745
Somatostatin receptor type 4 SSTR4 P31391
Somatostatin receptor type 5 SSTR5 P35346
Thromboxane A2 receptor TBXA2R P21731
Trace amine-associated receptor 1 TAAR1 Q96RJ0
Trace amine-associated receptor 2 TAAR2 Q9P1P5
Putative trace amine-associated receptor 3 TAAR3 Q9P1P4
Trace amine-associated receptor 5 TAAR5 O14804
Trace amine-associated receptor 6 TAAR6 Q96RI8
Trace amine-associated receptor 8 TAAR8 Q969N4
Trace amine-associated receptor 9 TAAR9 Q96RI9
Thyrotropin receptor TSHR P16473
Vasopressin V1a receptor AVPR1A P37288
Vasopressin V1b receptor AVPR1B P47901
Vasopressin V2 receptor AVPR2 P30518
Chemokine XC receptor 1 XCR1 P46094
Brain-specific angiogenesis inhibitor 1 BAI1 O14514
Brain-specific angiogenesis inhibitor 2 BAI2 O60241
Brain-specific angiogenesis inhibitor 3 BAI3 O60242
Calcitonin receptor CALCR P30988
Calcitonin gene-related peptide type 1 CALCRL Q16602
receptor
Corticotropin-releasing factor receptor 1 CRHR1 P34998
Corticotropin-releasing factor receptor 2 CRHR2 Q13324
Growth hormone-releasing hormone receptor GHRHR Q02643
Gastric inhibitory polypeptide receptor GIPR P48546
Glucagon-like peptide 1 receptor GLP1R P43220
Glucagon-like peptide 2 receptor GLP2R O95838
Glucagon receptor GCGR P47871
Pituitary adenylate cyclase-activating ADCYAP1R1 P41586
polypeptide type I receptor
Taste receptor 1 member 2 TAS1R2 Q8TE23
Parathyroid hormone receptor 1 PTH1R Q03431
Parathyroid hormone 2 receptor PTH2R P49190
Secretin receptor SCTR P47872
Vasoactive intestinal polypeptide receptor 1 VIPR1 P32241
Vasoactive intestinal polypeptide receptor 2 VIPR2 P41587
Frizzled-10 FZD10 Q9ULW2
Frizzled-1 FZD1 Q9UP38
Frizzled-2 FZD2 Q14332
Frizzled-3 FZD3 Q9NPG1
Frizzled-4 FZD4 Q9ULV1
Frizzled-5 FZD5 Q13467
Frizzled-6 FZD6 O60353
Frizzled-7 FZD7 O75084
Frizzled-8 FZD8 Q9H461
Frizzled-9 FZD9 (FZD3) O00144
Smoothened homologue SMO (SMOH) Q99835
Extracellular calcium-sensing receptor CASR P41180
GABA type B receptor 1subunit 1 GABBR1 Q9UBS5
GABA type B receptor subunit 2 GABBR2 O75899
GPCR family C group 6 member A GPRC6A Q5T6X5
Metabotropic glutamate receptor 1 GRM1 Q13255
Metabotropic glutamate receptor 2 GRM2 Q14416
Metabotropic glutamate receptor 3 GRM3 Q14832
Metabotropic glutamate receptor 4 GRM4 Q14833
Metabotropic glutamate receptor 5 GRM5 P41594
Metabotropic glutamate receptor 6 GRM6 O15303
Metabotropic glutamate receptor 7 GRM7 Q14831
Metabotropic glutamate receptor 8 GRM8 O00222
Taste receptor 1 member 1 TAS1R1 Q7RTX1
Taste receptor 1 member 2 TAS1R2 Q8TE23
Taste receptor 1 member 3 TAS1R3 Q7RTX0
Described herein are GPCR binding domains, wherein the GPCR binding domains are designed based on surface interactions between a GPCR ligand and the GPCR. In some instances, the ligand is a subatomic particle (e.g., a photon), an ion, an organic molecule, a peptide, and a protein. Non-limiting examples of ligands which can be bound by a GPCR include (−)-adrenaline, (−)-noradrenaline, (lyso)phospholipid mediators, [des-Arg10]kallidin, [des-Arg9]bradykinin, [des-Gln14]ghrelin, [Hyp3]bradykinin, [Leu]enkephalin, [Met]enkephalin, 12-hydroxyheptadecatrienoic acid, 12R-HETE, 12S-HETE, 12S-HPETE, 15S-HETE, 17β-estradiol, 20-hydroxy-LTB4, 2-arachidonoylglycerol, 2-oleoyl-LPA, 3-hydroxyoctanoic acid, 5-hydroxytryptamine, 5-oxo-15-HETE, 5-oxo-ETE, 5-oxo-ETrE, 5-oxo-ODE, 5S-HETE, 5S-HPETE, 7α,25-dihydroxycholesterol, acetylcholine, ACTH, adenosine diphosphate, adenosine, adrenomedullin 2/intermedin, adrenomedullin, amylin, anandamide, angiotensin II, angiotensin III, annexin I, apelin receptor early endogenous ligand, apelin-13, apelin-17, apelin-36, aspirin triggered lipoxin A4, aspirin-triggered resolvin D1, ATP, beta-defensin 4A, big dynorphin, bovine adrenal medulla peptide 8-22, bradykinin, C3a, C5a, Ca2+, calcitonin gene related peptide, calcitonin, cathepsin G, CCK-33, CCK-4, CCK-8, CCL1, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL7, CCL8, chemerin, chenodeoxycholic acid, cholic acid, corticotrophin-releasing hormone, CST-17, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12α, CXCL12β, CXCL13, CXCL16, CXCL2, CXCL3, CXCL4, CXCL6, CXCL7, CXCL8, CXCL9, cysteinyl-leukotrienes (CysLTs), uracil nucleotides, deoxycholic acid, dihydrosphingosine-1-phosphate, dioleoylphosphatidic acid, dopamine, dynorphin A, dynorphin A-(1-13), dynorphin A-(1-8), dynorphin B, endomorphin-1, endothelin-1, endothelin-2, endothelin-3, F2L, Free fatty acids, FSH, GABA, galanin, galanin-like peptide, gastric inhibitory polypeptide, gastrin-17, gastrin-releasing peptide, ghrelin, GHRH, glucagon, glucagon-like peptide 1-(7-36) amide, glucagon-like peptide 1-(7-37), glucagon-like peptide 2, glucagon-like peptide 2-(3-33), GnRH I, GnRH II, GRP-(18-27), hCG, histamine, humanin, INSL3, INSL5, kallidin, kisspeptin-10, kisspeptin-13, kisspeptin-14, kisspeptin-54, kynurenic acid, large neuromedin N, large neurotensin, L-glutamic acid, LH, lithocholic acid, L-lactic acid, long chain carboxylic acids, LPA, LTB4, LTC4, LTD4, LTE4, LXA4, Lys-[Hyp3]-bradykinin, lysophosphatidylinositol, lysophosphatidylserine, Medium-chain-length fatty acids, melanin-concentrating hormone, melatonin, methylcarbamyl PAF, Mg2+, motilin, N-arachidonoylglycine, neurokinin A, neurokinin B, neuromedin B, neuromedin N, neuromedin S-33, neuromedin U-25, neuronostatin, neuropeptide AF, neuropeptide B-23, neuropeptide B-29, neuropeptide FF, neuropeptide S, neuropeptide SF, neuropeptide W-23, neuropeptide W-30, neuropeptide Y, neuropeptide Y-(3-36), neurotensin, nociceptin/orphanin FQ, N-oleoylethanolamide, obestatin, octopamine, orexin-A, orexin-B, Oxysterols, oxytocin, PACAP-27, PACAP-38, PAF, pancreatic polypeptide, peptide YY, PGD2, PGE2, PGF2a, PGI2, PGJ2, PHM, phosphatidylserine, PHV, prokineticin-1, prokineticin-2, prokineticin-2β, prosaposin, PrRP-20, PrRP-31, PTH, PTHrP, PTHrP-(1-36), QRFP43, relaxin, relaxin-1, relaxin-3, resolvin D1, resolvin E1, RFRP-1, RFRP-3, R-spondins, secretin, serine proteases, sphingosine 1-phosphate, sphingosylphosphorylcholine, SRIF-14, SRIF-28, substance P, succinic acid, thrombin, thromboxane A2, TIP39, T-kinin, TRH, TSH, tyramine, UDP-glucose, uridine diphosphate, urocortin 1, urocortin 2, urocortin 3, urotensin II-related peptide, urotensin-II, vasopressin, VIP, Wnt, Wnt-1, Wnt-10a, Wnt-10b, Wnt-11, Wnt-16, Wnt-2, Wnt-2b, Wnt-3, Wnt-3a, Wnt-4, Wnt-5a, Wnt-5b, Wnt-6, Wnt-7a, Wnt-7b, Wnt-8a, Wnt-8b, Wnt-9a, Wnt-9b, XCL1, XCL2, Zn2+, α-CGRP, α-ketoglutaric acid, α-MSH, α-neoendorphin, β-alanine, β-CGRP, β-D-hydroxybutyric acid, β-endorphin, β-MSH, β-neoendorphin, β-phenylethylamine, and γ-MSH.
Sequences of GPCR binding domains based on surface interactions between a GPCR ligand and the GPCR are analyzed using various methods. For example, multispecies computational analysis is performed. In some instances, a structure analysis is performed. In some instances, a sequence analysis is performed. Sequence analysis can be performed using a database known in the art. Non-limiting examples of databases include, but are not limited to, NCBI BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi), UCSC Genome Browser (genome.ucsc.edu/), UniProt (www.uniprot.org/), and IUPHAR/BPS Guide to PHARMACOLOGY (guidetopharmacology.org/).
Described herein are GPCR binding domains designed based on sequence analysis among various organisms. For example, sequence analysis is performed to identify homologous sequences in different organisms. Exemplary organisms include, but are not limited to, mouse, rat, equine, sheep, cow, primate (e.g., chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, fish, fly, and human.
Following identification of GPCR binding domains, libraries comprising nucleic acids encoding for the GPCR binding domains may be generated. In some instances, libraries of GPCR binding domains comprise sequences of GPCR binding domains designed based on conformational ligand interactions, peptide ligand interactions, small molecule ligand interactions, extracellular domains of GPCRs, or antibodies that target GPCRs. Libraries of GPCR binding domains may be translated to generate protein libraries. In some instances, libraries of GPCR binding domains are translated to generate peptide libraries, immunoglobulin libraries, derivatives thereof, or combinations thereof. In some instances, libraries of GPCR binding domains are translated to generate protein libraries that are further modified to generate peptidomimetic libraries. In some instances, libraries of GPCR binding domains are translated to generate protein libraries that are used to generate small molecules.
Methods described herein provide for synthesis of libraries of GPCR binding domains comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the libraries of GPCR binding domains comprise varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a GPCR binding domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a GPCR binding domain. An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
Methods described herein provide for synthesis of libraries comprising nucleic acids encoding for the GPCR binding domains, wherein the libraries comprise sequences encoding for variation of length of the GPCR binding domains. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.
Following identification of GPCR binding domains, the GPCR binding domains may be placed in scaffolds as described herein. In some instances, the scaffolds are immunoglobulins. In some instances, the GPCR binding domains are placed in the CDR-H3 region. GPCR binding domains that may be placed in scaffolds can also be referred to as a motif. Scaffolds comprising GPCR binding domains may be designed based on binding, specificity, stability, expression, folding, or downstream activity. In some instances, the scaffolds comprising GPCR binding domains enable contact with the GPCRs. In some instances, the scaffolds comprising GPCR binding domains enables high affinity binding with the GPCRs. Exemplary amino acid sequences of GPCR binding domains are described in Table 2.
TABLE 2
GPCR amino acid sequences
SEQ
ID
NO GPCR Amino Acid Sequence
1 CXCR4 MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENAN
FNKIFLPTIYSIIFLTGIVGNGLVILVMGYQKKLR
SMTDKYRLHLSVADLLFVITLPFWAVDAVANWYFG
NFLCKAVHVIYTVNLYSSVLILAFISLDRYLAIVH
ATNSQRPRKLLAEKVVYVGVWIPALLLTIPDFIFA
NVSEADDRYICDRFYPNDLWWVFQFQHIMVGLILP
GIVILSCYCIIISKLSHSKGHQKRKALKTTVILIL
AFFACWLPYYIGISIDSFILLEIIKQGCEFENTVH
KWISITEALAFFHCCLNPILYAFLGAKFKTSAQHA
LTSVSRGSSLKILSKGKRGGHSSVSTESESSSFHS
S
2 CCR4 MNPTDIADTTLDESIYSNYYLYESIPKPCTKEGIK
AFGELFLPPLYSLVFVFGLLGNSVVVLVLFKYKRL
RSMTDVYLLNLAISDLLFVFSLPFWGYYAADQWVF
GLGLCKMISWMYLVGFYSGIFFVMLMSIDRYLAIV
HAVFSLRARTLTYGVITSLATWSVAVFASLPGFLF
STCYTERNHTYCRTKYSLNSTTWKVLSSLEINILG
LVIPLGIMLFCYSMIIRTLQHCKNEKKNKAVKMIF
AVVVLFLGFWTPYNIVLFLETLVELEVLQDCTFER
YLDYAIQATETLAFVHCCLNPIIYFFLGEKFRKYI
LQLFKTCRGLFVLCQYCGLLQIYSADTPSSSYTQS
TMDHDLHDAL
3 GCGR MPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEK
WKLYGDQCHHNLSLLPPPTELVCNRTFDKYSCWPD
TPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQ
WVRGPRGQPWRDASQCQMDGEEIEVQKEVAKMYSS
FQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNA
IHANLFASFVLKASSVLVIDGLLRTRYSQKIGDDL
SVSTWLSDGAVAGCRVAAVFMQYGIVANYCWLLVE
GLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVV
PWAVVKCLFENVQCWTSNDNMGFWWILRFPVFLAI
LINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKS
TLTLIPLLGVHEVVFAFVTDEHAQGTLRSAKLFFD
LFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRL
GKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGG
SQDSSAETPLAGGLPRLAESPF
4 mGluR5 MVLLLILSVLLLKEDVRGSAQSSERRVVAHMPGDI
IIGALFSVHHQPTVDKVHERKCGAVREQYGIQRVE
AMLHTLERINSDPTLLPNITLGCEIRDSCWHSAVA
LEQSIEFIRDSLISSEEEEGLVRCVDGSSSSFRSK
KPIVGVIGPGSSSVAIQVQNLLQLFNIPQIAYSAT
SMDLSDKTLFKYFMRVVPSDAQQARAMVDIVKRYN
WTYVSAVHTEGNYGESGMEAFKDMSAKEGI
CIAHSYKIYSNAGEQSFDKLLKKLTSHLPKARVVA
CFCEGMTVRGLLMAMRRLGLAGEFLLLGSDGWADR
YDVTDGYQREAVGGITIKLQSPDVKWFDDYYLKLR
PETNHRNPWFQEFWQHRFQCRLEGFPQENSKYNKT
CNSSLTLKTHHVQDSKMGFVINAIYSMAYGLHNMQ
MSLCPGYAGLCDAMKPIDGRKLLESLMKTNFTGVS
GDTILFDENGDSPGRYEIMNFKEMGKDYFDYINVG
SWDNGELKMDDDEVWSKKSNIIRSVCSEPCEKGQI
KVIRKGEVSCCWTCTPCKENEYVFDEYTCKACQLG
SWPTDDLTGCDLIPVQYLRWGDPEPIAAVVFACLG
LLATLFVTVVFIIYRDTPVVKSSSRELCYIILAGI
CLGYLCTFCLIAKPKQIYCYLQRIGIGLSPAMSYS
ALVTKTNRIARILAGSKKKICTKKPRFMSACAQLV
IAFILICIQLGIIVALFIMEPPDIMHDYPSIREVY
LICNTTNLGVVTPLGYNGLLILSCTFYAFKTRNVP
ANFNEAKYIAFTMYTTCIIWLAFVPIYFGSNYKII
TMCFSVSLSATVALGCMFVPKVYIILAKPERNVRS
AFTTSTVVRMHVGDGKSSSAASRSSSLVNLWKRRG
SSGETLRYKDRRLAQHKSEIECFTPKGSMGNGGRA
TMSSSNGKSVTWAQNEKSSRGQHLWQRLSIHINKK
ENPNQTAVIKPFPKSTESRGLGAGAGAGGSAGGVG
ATGGAGCAGAGPGGPESPDAGPKALYDVAEAEEHF
PAPARPRSPSPISTLSHRAGSASRTDDDVPSLHSE
PVARSSSSQGSLMEQISSVVTRFTANISELNSMML
STAAPSPGVGAPLCSSYLIPKEIQLPTTMTTFAEI
QPLPAIEVTGGAQPAAGAQAAGDAARESPAAGPEA
AAAKPDLEELVALTPPSPFRDSVDSGSTTPNSPVS
ESALCIPSSPKYDTLIIRDYTQSSSSL
5 GLP-1R RPQGATVSLWETVQKWREYRRQCQRSLTEDPPPAT
DLFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWAS
SVPQGHVYRFCTAEGLWLQKDNSSLPWRDLSECEE
SKRGERSSPEEQLLFLYIIYTVGYALSFSALVIAS
AILLGFRHLHCTRNYIHLNLFASFILRALSVFIKD
AALKWMYSTAAQQHQWDGLLSYQDSLSCRLVFLLM
QYCVAANYYWLLVEGVYLYTLLAFSVLSEQWIFRL
YVSIGWGVPLLFVVPWGIVKYLYEDEGCWTRNSNM
NYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKAN
LMCKTDIKCRLAKSTLTLIPLLGTHEVIFAFVMDE
HARGTLRFIKLFTELSFTSFQGLMVAILYCFVNNE
VQLEFRKSWERWRLEHLHIQRDSSMKPLKCPTSSL
SSGATAGSSMYTATCQASCS
6 GABAB MLLLLLLAPLFLRPPGAGGAQTPNATSEGCQIIHP
PWEGGIRYRGLTRDQVKAINFLPVDYEIEYVCRGE
REVVGPKVRKCLANGSWTDMDTPSRCVRICSKSYL
TLENGKVFLTGGDLPALDGARVDFRCDPDFHLVGS
SRSICSQGQWSTPKPHCQVNRTPHSERRAVYIGAL
FPMSGGWPGGQACQPAVEMALEDVNSRRDILPDYE
LKLIHHDSKCDPGQATKYLYELLYNDPIKIILMPG
CSSVSTLVAEAARMWNLIVLSYGSSSPALSNRQRF
PTFFRTHPSATLHNPTRVKLFEKWGWKKIATIQQT
TEVFTSTLDDLEERVKEAGIEITFRQSFFSDPAVP
VKNLKRQDARIIVGLFYETEARKVFCEVYKERLFG
KKYVWFLIGWYADNWFKIYDPSINCTVDEMTEAVE
GHITTEIVMLNPANTRSISNMTSQEFVEKLTKRLK
RHPEETGGFQEAPLAYDAIWALALALNKTSGGGGR
SGVRLEDFNYNNQTITDQIYRAMNSSSFEGVSGHV
VFDASGSRMAWTLIEQLQGGSYKKIGYYDSTKDDL
SWSKTDKWIGGSPPADQTLVIKTFRFLSQKLFISV
SVLSSLGIVLAVVCLSFNIYNSHVRYIQNSQPNLN
NLTAVGCSLALAAVFPLGLDGYHIGRNQFPFVCQA
RLWLLGLGFSLGYGSMFTKIWWVHTVFTKKEEKKE
WRKTLEPWKLYATVGLLVGMDVLTLAIWQIVDPLH
RTIETFAKEEPKEDIDVSILPQLEHCSSRKMNTWL
GIFYGYKGLLLLLGIFLAYETKSVSTEKINDHRAV
GMAIYNVAVLCLITAPVTMILSSQQDAAFAFASLA
IVFSSYITLVVLFVPKMRRLITRGEWQSEAQDTMK
TGSSTNNNEEEKSRLLEKENRELEKIIAEKEERVS
ELRHQLQSRQQLRSRRHPPTPPEPSGGLPRGPPEP
PDRLSCDGSRVHLLYK
7 OPRM1 MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLS
HLDGNLSDPCGPNRTDLGGRDSLCPPTGSPSMITA
ITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTAT
NIYIFNLALADALATSTLPFQSVNYLMGTWPFGTI
LCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPV
KALDFRTPRNAKIINVCNWILSSAIGLPVMFMATT
KYRQGSIDCTLTFSHPTWYWENLLKICVFIFAFIM
PVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRI
TRMVLVVVAVFIVCWTPIHIYVIIKALVTIPETTF
QTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFR
EFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRT
NHQLENLEAETAPLP
8 OPRK1 MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAE
PDSNGSAGSEDAQLEPAHISPAIPVIITAVYSVVF
VVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALAD
ALVTTTMPFQSTVYLMNSWPFGDVLCKIVISIDYY
NMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKA
KIINICIWLLSSSVGISAIVLGGTKVREDVDVIEC
SLQFPDDDYSWWDLFMKICVFIFAFVIPVLIIIVC
YTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVV
AVFVVCWTPIHIFILVEALGSTSHSTAALSSYYFC
IALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKM
RMERQSTSRVRNTVQDPAYLRDIDGMNKPV
9 C5aR MDSFNYTTPDYGHYDDKDTLDLNTPVDKTSNTLRV
PDILALVIFAVVFLVGVLGNALVVWVTAFEAKRTI
NAIWFLNLAVADFLSCLALPILFTSIVQHHHWPFG
GAACSILPSLILLNMYASILLLATISADRFLLVFK
PIWCQNFRGAGLAWIACAVAWGLALLLTIPSFLYR
VVREEYFPPKVLCGVDYSHDKRRERAVAIVRLVLG
FLWPLLTLTICYTFILLRTWSRRATRSTKTLKVVV
AVVASFFIFWLPYQVTGIMMSFLEPSSPTFLLLKK
LDSLCVSFAYINCCINPIIYVVAGQGFQGRLRKSL
PSLLRNVLTEESVVRESKSFTRSTVDTMAQKTQAV
10 CGRP ELEESPEDSIQLGVTRNKIMTAQYECYQKIMQDPI
QQAEGVYCNRTWDGWLCWNDVAAGTESMQLCPDYF
QDFDPSEKVTKICDQDGNWFRHPASNRTWTNYTQC
NVNTHEKVKTALNLFYLTIIGHGLSIASLLISLGI
FFYFKSLSCQRITLHKNLFFSFVCNSVVTIIHLTA
VANNQALVATNPVSCKVSQFIHLYLMGCNYFWMLC
EGIYLHTLIVVAVFAEKQHLMWYYFLGWGFPLIPA
CIHAIARSLYYNDNCWISSDTHLLYIIHGPICAAL
LVNLFFLLNIVRVLITKLKVTHQAESNLYMKAVRA
TLILVPLLGIEFVLIPWRPEGKIAEEVYDYIMHIL
MHFQGLLVSTIFCFFNGEVQAILRRNWNQYKIQFG
NSFSNSEALRSASYTVSTISDGPGYSHDCPSEHLN
GKSIHDIENVLLKPENLYN
11 M1 MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLL
muscarinic SLATVTGNLLVLISFKVNTELKTVNNYFLLSLACA
DLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALD
YVASNASVMNLLLISFDRYFSVTRPLSYRAKRTPR
RAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLA
GQCYIQFLSQPIITFGTAMAAFYLPVTVMCTLYWR
IYRETENRARELAALQGSETPGKGGGSSSSSERSQ
PGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEE
DEGSMESLTSSEGEEPGSEVVIKMPMVDPEAQAPT
KQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLA
KRKTFSLVKEKKAARTLSAILLAFILTWTPYNIMV
LVSTFCKDCVPETLWELGYWLCYVNSTINPMCYAL
CNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRT
PSRQC
12 M4 MANFTPVNGSSGNQSVRLVTSSSHNRYETVEMVFI
muscarinic ATVTGSLSLVTVVGNILVMLSIKVNRQLQTVNNYF
LFSLACADLIIGAFSMNLYTVYIIKGYWPLGAVVC
DLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTY
PARRTTKMAGLMIAAAWVLSFVLWAPAILFWQFVV
GKRTVPDNQCFIQFLSNPAVTFGTAIAAFYLPVVI
MTVLYIHISLASRSRVHKHRPEGPKEKKAKTLAFL
KSPLMKQSVKKPPPGEAAREELRNGKLEEAPPPAL
PPPPRPVADKDTSNESSSGSATQNTKERPATELST
TEATTPAMPAPPLQPRALNPASRWSKIQIVTKQTG
NECVTAIEIVPATPAGMRPAANVARKFASIARNQV
RKKRQMAARERKVTRTIFAILLAFILTWTPYNVMV
LVNTFCQSCIPDTVWSIGYWLCYVNSTINPACYAL
CNATFKKTFRHLLLCQYRNIGTAR
13 CCR2 MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKF
DVKQIGAQLLPPLYSLVFIFGFVGNMLVVLILINC
KKLKCLTDIYLLNLAISDLLFLITLPLWAHSAANE
WVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYL
AIVHAVFALKARTVTFGVVTSVITWLVAVFASVPG
IIFTKCQKEDSVYVCGPYFPRGWNNFHTIMRNILG
LVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVI
FTIMIVYFLFWTPYNIVILLNTFQEFFGLSNCEST
SQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSL
FHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGL
LDGRGKGKSIGRAPEASLQDKEGA
14 CCR9 MTPTDFTSPIPNMADDYGSESTSSMEDYVNFNFTD
FYCEKNNVRQFASHFLPPLYWLVFIVGALGNSLVI
LVYWYCTRVKTMTDMFLLNLAIADLLFLVTLPFWA
IAAADQWKFQTFMCKVVNSMYKMNFYSCVLLIMCI
SVDRYIAIAQAMRAHTWREKRLLYSKMVCFTIWVL
AAALCIPEILYSQIKEESGIAICTMVYPSDESTKL
KSAVLTLKVILGFFLPFVVMACCYTIIIHTLIQAK
KSSKHKALKVTITVLTVFVLSQFPYNCILLVQTID
AYAMFISNCAVSTNIDICFQVTQTIAFFHSCLNPV
LYVFVGERFRRDLVKTLKNLGCISQAQWVSFTRRE
GSLKLSSMLLETTSGALSL
15 GPR174 MPANYTCTRPDGDNTDFRYFIYAVTYTVILVPGLI
GNILALWVFYGYMKETKRAVIFMINLAIADLLQVL
SLPLRIFYYLNHDWPFGPGLCMFCFYLKYVNMYAS
IYFLVCISVRRFWFLMYPFRFHDCKQKYDLYISIA
GWLIICLACVLFPLLRTSDDTSGNRTKCFVDLPTR
NVNLAQSVVMMTIGELIGFVTPLLIVLYCTWKTVL
SLQDKYPMAQDLGEKQKALKMILTCAGVFLICFAP
YHFSFPLDFLVKSNEIKSCLARRVILIFHSVALCL
ASLNSCLDPVIYYFSTNEFRRRLSRQDLHDSIQLH
AKSFVSNHTASTMTPELC
16 MASP-2 TPLGPKWPEPVFGRLASPGFPGEYANDQERRWTLT
APPGYRLRLYFTHFDLELSHLCEYDFVKLSSGAKV
LATLCGQESTDTERAPGKDTFYSLGSSLDITFRSD
YSNEKPFTGFEAFYAAEDIDECQVAPGEAPTCDHH
CHNHLGGFYCSCRAGYVLHRNKRTCSALCSGQVFT
QRSGELSSPEYPRPYPKLSSCTYSISLEEGFSVIL
DFVESFDVETHPETLCPYDFLKIQTDREEHGPFCG
KTLPHRIETKSNTVTITFVTDESGDHTGWKIHYTS
TAQPCPYPMAPPNGHVSPVQAKYILKDSFSIFCET
GYELLQGHLPLKSFTAVCQKDGSWDRPMPACSIVD
CGPPDDLPSGRVEYITGPGVTTYKAVIQYSCEETF
YTMKVNDGKYVCEADGFWTSSKGEKSLPVCEPVCG
LSARTTGGRIYGGQKAKPGDFPWQVLILGGTTAAG
ALLYDNWVLTAAHAVYEQKHDASALDIRMGTLKRL
SPHYTQAWSEAVFIHEGYTHDAGFDNDIALIKLNN
KVVINSNITPICLPRKEAESFMRTDDIGTASGWGL
TQRGFLARNLMYVDIPIVDHQKCTAAYEKPPYPRG
SVTANMLCAGLESGGKDSCRGDSGGALVFLDSETE
RWFVGGIVSWGSMNCGEAGQYGVYTKVINYIPWIE
NIISDF
17 CCR5 MDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPP
LYSLVFIFGFVGNMLVILILINCKRLKSMTDIYLL
NLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLT
GLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKAR
TVTFGVVTSVITWVVAVFASLPGIIFTRSQKEGLH
YTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVM
VICYSGILKTLLRCRNEKKRHRAVRLIFTIMIVYF
LFWAPYNIVLLLNTFQEFFGLNNCSSSNRLDQAMQ
VTETLGMTHCCINPIIYAFVGEKFRNYLLVFFQKH
IAKRFCKCCSIFQQEAPERASSVYTRSTGEQEISV
GL
18 FSHR CHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELR
FVLTKLRVIQKGAFSGFGDLEKIEISQNDVLEVIE
ADVFSNLPKLHEIRIEKANNLLYINPEAFQNLPNL
QYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINI
HTIERNSFVGLSFESVILWLNKNGIQEIHNCAFNG
TQLDELNLSDNNNLEELPNDVFHGASGPVILDISR
TRIHSLPSYGLENLKKLRARSTYNLKKLPTLEKLV
ALMEASLTYPSHCCAFANWRRQISELHPICNKSIL
RQEVDYMTQARGQRSSLAEDNESSYSRGFDMTYTE
FDYDLCNEVVDVTCSPKPDAFNPCEDIMGYNILRV
LIWFISILAITGNIIVLVILTTSQYKLTVPRFLMC
NLAFADLCIGIYLLLIASVDIHTKSQYHNYAIDWQ
TGAGCDAAGFFTVFASELSVYTLTAITLERWHTIT
HAMQLDCKVQLRHAASVMVMGWIFAFAAALFPIFG
ISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVLAF
VVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAML
IFTDFLCMAPISFFAISASLKVPLITVSKAKILLV
LFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCY
EMQAQIYRTETSSTVHNTHPRNGHCSSAPRVTNGS
TYILVPLSHLAQN
19 mGluR2 EGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPV
PAM NEHRGIQRLEAMLFALDRINRDPHLLPGVRLGAHI
LDSCSKDTHALEQALDFVRASLSRGADGSRHICPD
GSYATHGDAPTAITGVIGGSYSDVSIQVANLLRLF
QIPQISYASTSAKLSDKSRYDYFARTVPPDFFQAK
AMAEILRFFNWTYVSTVASEGDYGETGIEAFELEA
RARNICVATSEKVGRAMSRAAFEGVVRALLQKPSA
RVAVLFTRSEDARELLAASQRLNASFTWVASDGWG
ALESVVAGSEGAAEGAITIELASYPISDFASYFQS
LDPWNNSRNPWFREFWEQRFRCSFRQRDCAAHSLR
AVPFEQESKIMFVVNAVYAMAHALHNMHRALCPNT
TRLCDAMRPVNGRRLYKDFVLNVKFDAPFRPADTH
NEVRFDRFGDGIGRYNIFTYLRAGSGRYRYQKVGY
WAEGLTLDTSLIPWASPSAGPLPASRCSEPCLQNE
VKSVQPGEVCCWLCIPCQPYEYRLDEFTCADCGLG
YWPNASLTGCFELPQEYIRWGDAWAVGPVTIACLG
ALATLFVLGVFVRHNATPVVKASGRELCYILLGGV
FLCYCMTFIFIAKPSTAVCTLRRLGLGTAFSVCYS
ALLTKTNRIARIFGGAREGAQRPRFISPASQVAIC
LALISGQLLIVVAWLVVEAPGTGKETAPERREVVT
LRCNHRDASMLGSLAYNVLLIALCTLYAFKTRKCP
ENFNEAKFIGFTMYTTCIIWLAFLPIFYVTSSDYR
VQTTTMCVSVSLSGSVVLGCLFAPKLHIILFQPQK
NVVSHRAPTSRFGSAAARASSSLGQGSGSQFVPTV
CNGREVVDSTTSSL
20 mGluR3 LGDHNFLRREIKIEGDLVLGGLFPINEKGTGTEEC
GRINEDRGIQRLEAMLFAIDEINKDDYLLPGVKLG
VHILDTCSRDTYALEQSLEFVRASLTKVDEAEYMC
PDGSYAIQENIPLLIAGVIGGSYSSVSIQVANLLR
LFQIPQISYASTSAKLSDKSRYDYFARTVPPDFYQ
AKAMAEILRFFNWTYVSTVASEGDYGETGIEAFEQ
EARLRNICIATAEKVGRSNIRKSYDSVIRELLQKP
NARVVVLFMRSDDSRELIAAASRANASFTWVASDG
WGAQESIIKGSEHVAYGAITLELASQPVRQFDRYF
QSLNPYNNHRNPWFRDFWEQKFQCSLQNKRNHRRV
CDKHLAIDSSNYEQESKIMFVVNAVYAMAHALHKM
QRTLCPNTTKLCDAMKILDGKKLYKDYLLKINFTA
PFNPNKDADSIVKFDTFGDGMGRYNVFNFQNVGGK
YSYLKVGHWAETLSLDVNSIHWSRNSVPTSQCSDP
CAPNEMKNMQPGDVCCWICIPCEPYEYLADEFTCM
DCGSGQWPTADLTGCYDLPEDYIRWEDAWAIGPVT
IACLGFMCTCMVVTVFIKHNNTPLVKASGRELCYI
LLFGVGLSYCMTFFFIAKPSPVICALRRLGLGSSF
AICYSALLTKTNCIARIFDGVKNGAQRPKFISPSS
QVFICLGLILVQIVMVSVWLILEAPGTRRYTLAEK
RETVILKCNVKDSSMLISLTYDVILVILCTVYAFK
TRKCPENFNEAKFIGFTMYTTCIIWLAFLPIFYVT
SSDYRVQTTTMCISVSLSGFVVLGCLFAPKVHIIL
FQPQKNVVTHRLHLNRFSVSGTGTTYSQSSASTYV
PTVCNGREVLDSTTSSL
21 mGluR4 KPKGHPHMNSIRIDGDITLGGLFPVHGRGSEGKPC
GELKKEKGIHRLEAMLFALDRINNDPDLLPNITLG
ARILDTCSRDTHALEQSLTFVQALIEKDGTEVRCG
SGGPPIITKPERVVGVIGASGSSVSIMVANILRLF
KIPQISYASTAPDLSDNSRYDFFSRVVPSDTYQAQ
AMVDIVRALKWNYVSTVASEGSYGESGVEAFIQKS
REDGGVCIAQSVKIPREPKAGEFDKIIRRLLETSN
ARAVIIFANEDDIRRVLEAARRANQTGHFFWMGSD
SWGSKIAPVLHLEEVAEGAVTILPKRMSVRGFDRY
FSSRTLDNNRRNIWFAEFWEDNFHCKLSRHALKKG
SHVKKCTNRERIGQDSAYEQEGKVQFVIDAVYAMG
HALHAMHRDLCPGRVGLCPRMDPVDGTQLLKYIRN
VNFSGIAGNPVTFNENGDAPGRYDIYQYQLRNDSA
EYKVIGSWTDHLHLRIERMHWPGSGQQLPRSICSL
PCQPGERKKTVKGMPCCWHCEPCTGYQYQVDRYTC
KTCPYDMRPTENRTGCRPIPIIKLEWGSPWAVLPL
FLAVVGIAATLFVVITFVRYNDTPIVKASGRELSY
VLLAGIFLCYATTFLMIAEPDLGTCSLRRIFLGLG
MSISYAALLTKTNRIYRIFEQGKRSVSAPRFISPA
SQLAITFSLISLQLLGICVWFVVDPSHSVVDFQDQ
RTLDPRFARGVLKCDISDLSLICLLGYSMLLMVTC
TVYAIKTRGVPETFNEAKPIGFTMYTTCIVWLAFI
PIFFGTSQSADKLYIQTTTLTVSVSLSASVSLGML
YMPKVYIILFHPEQNVPKRKRSLKAVVTAATMSNK
FTQKGNFRPNGEAKSELCENLEAPALATKQTYVTY
TNHAI
22 mGluR7 QEMYAPHSIRIEGDVTLGGLFPVHAKGPSGVPCGD
IKRENGIHRLEAMLYALDQINSDPNLLPNVTLGAR
ILDTCSRDTYALEQSLTFVQALIQKDTSDVRCTNG
EPPVFVKPEKVVGVIGASGSSVSIMVANILRLFQI
PQISYASTAPELSDDRRYDFFSRVVPPDSFQAQAM
VDIVKALGWNYVSTLASEGSYGEKGVESFTQISKE
AGGLCIAQSVRIPQERKDRTIDFDRIIKQLLDTPN
SRAVVIFANDEDIKQILAAAKRADQVGHFLWVGSD
SWGSKINPLHQHEDIAEGAITIQPKRATVEGFDAY
FTSRTLENNRRNVWFAEYWEENFNCKLTISGSKKE
DTDRKCTGQERIGKDSNYEQEGKVQFVIDAVYAMA
HALHHMNKDLCADYRGVCPEMEQAGGKKLLKYIRN
VNFNGSAGTPVMFNKNGDAPGRYDIFQYQTTNTSN
PGYRLIGQWTDELQLNIEDMQWGKGVREIPASVCT
LPCKPGQRKKTQKGTPCCWTCEPCDGYQYQFDEMT
CQHCPYDQRPNENRTGCQDIPIIKLEWHSPWAVIP
VFLAMLGIIATIFVMATFIRYNDTPIVRASGRELS
YVLLTGIFLCYIITFLMIAKPDVAVCSFRRVFLGL
GMCISYAALLTKTNRIYRIFEQGKKSVTAPRLISP
TSQLAITSSLISVQLLGVFIWFGVDPPNIIIDYDE
HKTMNPEQARGVLKCDITDLQIICSLGYSILLMVT
CTVYAIKTRGVPENFNEAKPIGFTMYTTCIVWLAF
IPIFFGTAQSAEKLYIQTTTLTISMNLSASVALGM
LYMPKVYIIIFHPELNVQKRKRSFKAVVTAATMSS
RLSHKPSDRPNGEAKTELCENVDPNSPAAKKKYVS
YNNLVI
23 CXCR3 MVLEVSDHQVLNDAEVAALLENFSSSYDYGENESD
SCCTSPPCPQDFSLNFDRAFLPALYSLLFLLGLLG
NGAVAAVLLSRRTALSSTDTFLLHLAVADTLLVLT
LPLWAVDAAVQWVFGSGLCKVAGALFNINFYAGAL
LLACISFDRYLNIVHATQLYRRGPPARVTLTCLAV
WGLCLLFALPDFIFLSAHHDERLNATHCQYNFPQV
GRTALRVLQLVAGFLLPLLVMAYCYAHILAVLLVS
RGQRRLRAMRLVVWVVAFALCWTPYHLVVLVDILM
DLGALARNCGRESRVDVAKSVTSGLGYMHCCLNPL
LYAFVGVKFRERMWMLLLRLGCPNQRGLQRQPSSS
RRDSSWSETSEASYSGL
24 CCR8 MDYTLDLSVTTVTDYYYPDIFSSPCDAELIQTNGK
LLLAVFYCLLFVFSLLGNSLVILVLVVCKKLRSIT
DVYLLNLALSDLLFVFSFPFQTYYLLDQWVFGTVM
CKVVSGFYYIGFYSSMFFITLMSVDRYLAVVHAVY
ALKVRTIRMGTTLCLAVWLTAIMATIPLLVFYQVA
SEDGVLQCYSFYNQQTLKWKIFTNFKMNILGLLIP
FTIFMFCYIKILHQLKRCQNHNKTKAIRLVLIVVI
ASLLFWVPFNVVLFLTSLHSMHILDGCSISQQLTY
ATHVTEIISFTHCCVNPVIYAFVGEKFKKHLSEIF
QKSCSQIFNYLGRQMPRESCEKSSSCQQHSSRSSS
VDYIL
25 Adenosine MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNS
A2a NLQNVTNYFVVSLAAADIAVGVLAIPFAITISTGF
CAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIA
IRIPLRYNGLVTGTRAKGIIAICWVLSFAIGLTPM
LGWNNCGQPKEGKNHSQGCGEGQVACLFEDVVPMN
YMVYFNFFACVLVPLLLMLGVYLRIFLAARRQLKQ
MESQPLPGERARSTLQKEVHAAKSLAIIVGLFALC
WLPLHIINCFTFFCPDCSHAPLWLMYLAIVLSHTN
SVVNPFIYAYRIREFRQTFRKIIRSHVLRQQEPFK
AAGTSARVLAAHGSDGEQVSLRLNGHPPGVWANGS
APHPERRPNGYALGLVSGGSAQESQGNTGLPDVEL
LSHELKGVCPEPPGLDDPLAQDGAGVS
26 Orexin MEPSATPGAQMGVPPGSREPSPVPPDYEDEFLRYL
OX1 WRDYLYPKQYEWVLIAAYVAVFVVALVGNTLVCLA
VWRNHHMRTVTNYFIVNLSLADVLVTAICLPASLL
VDITESWLFGHALCKVIPYLQAVSVSVAVLTLSFI
ALDRWYAICHPLLFKSTARRARGSILGIWAVSLAI
MVPQAAVMECSSVLPELANRTRLFSVCDERWADDL
YPKIYHSCFFIVTYLAPLGLMAMAYFQIFRKLWGR
QIPGTTSALVRNWKRPSDQLGDLEQGLSGEPQPRA
RAFLAEVKQMRARRKTAKMLMVVLLVFALCYLPIS
VLNVLKRVFGMFRQASDREAVYACFTFSHWLVYAN
SAANPIIYNFLSGKFREQFKAAFSCCLPGLGPCGS
LKAPSPRSSASHKSLSLQSRCSISKISEHVVLTSV
TTVLP
27 Orexin MSGTKILEDSPPCRNWSSASELNETQEPFLNPTDY
OX2 DDEEFLRYLWREYLHPKEYEWVLIAGYIIVFVVAL
IGNYLVCVAVWKNHHMRTVTNYFIVNLSLADVLVT
ITCLPATLVVDITETWFFGQSLCKVIPYLQTVSVS
VSVLTLSCIALDRWYAICHPLMFKSTAKRARNSIV
IIWIVSCIIMIPQAIVMECSTVFPGLANKTTLFTV
CDERWGGEIYPKMYHICFFLVTYMAPLCLMVLAYL
QIFRKLWCRQIPGTSSVVQRKWKPLQPVSQPRGPG
QPTKSRMSAVAAEIKQIRARRKTARMLMIVLLVFA
ICYLPISILNVLKRVFGMFAHTEDRETVYAWFTFS
HWLVYANSAANPIIYNFLSGKFREEFKAAFSCCCL
GVHHRQEDRLTRGRTSTESRKSLTTQISNFDNISK
LSEQVVLTSISTLPAANGAGPLQNW
28 PAR-2 IQGTNRSSKGRSLIGKVDGTSHVTGKGVTVETVFS
VDEFSASVLTGKLTTVFLPIVYTIVFVVGLPSNGM
ALWVFLFRTKKKHPAVIYMANLALADLLSVIWFPL
KIAYHIHGNNWIYGEALCNVLIGFFYGNMYCSILF
MTCLSVQRYWVIVNPMGHSRKKANIAIGISLAIWL
LILLVTIPLYVVKQTIFIPALNITTCHDVLPEQLL
VGDMFNYFLSLAIGVFLFPAFLTASAYVLMIRMLR
SSAMDENSEKKRKRAIKLIVTVLAMYLICFTPSNL
LLVVHYFLIKSQGQSHVYALYIVALCLSTLNSCID
PFVYYFVSHDFRDHAKNALLCRSVRTVKQMQVSLT
SKKHSRKSSSYSSSSTTVKTSY
29 C3aR MASFSAETNSTDLLSQPWNEPPVILSMVILSLTFL
LGLPGNGLVLWVAGLKMQRTVNTIWFLHLTLADLL
CCLSLPFSLAHLALQGQWPYGRFLCKLIPSIIVLN
MFASVFLLTAISLDRCLVVFKPIWCQNHRNVGMAC
SICGCIWVVAFVMCIPVFVYREIFTTDNHNRCGYK
FGLSSSLDYPDFYGDPLENRSLENIVQPPGEMNDR
LDPSSFQTNDHPWTVPTVFQPQTFQRPSADSLPRG
SARLTSQNLYSNVFKPADVVSPKIPSGFPIEDHET
SPLDNSDAFLSTHLKLFPSASSNSFYESELPQGFQ
DYYNLGQFTDDDQVPTPLVAITITRLVVGFLLPSV
IMIACYSFIVFRMQRGRFAKSQSKTFRVAWVVAVF
LVCWTPYHIFGVLSLLTDPETPLGKTLMSWDHVCI
ALASANSCFNPFLYALLGKDFRKKARQSIQGILEA
AFSEELTRSTHCPSNNVISERNSTTV
30 LGR5 GSSPRSGVLLRGCPTHCHCEPDGRMLLRVDCSDLG
LSELPSNLSVFTSYLDLSMNNISQLLPNPLPSLRF
LEELRLAGNALTYIPKGAFTGLYSLKV
LMLQNNQLRHVPTEALQNLRSLQSLRLDANHISYV
PPSCFSGLHSLRHLWLDDNALTEIPVQAFRSLSAL
QAMTLALNKIHHIPDYAFGNLSSLVVLHLHNNRIH
SLGKKCFDGLHSLETLDLNYNNLDEFPTAIRTLSN
LKELGFHSNNIRSIPEKAFVGNPSLITIHFYDNPI
QFVGRSAFQHLPELRTLTLNGASQITEFPDLTGTA
NLESLTLTGAQISSLPQTVCNQLPNLQVLDLSYNL
LEDLPSFSVCQKLQKIDLRHNEIYEIKVDTFQQLL
SLRSLNLAWNKIAIIHPNAFSTLPSLIKLDLSSNL
LSSFPITGLHGLTHLKLTGNHALQSLISSENFPEL
KVIEMPYAYQCCAFGVCENAYKISNQWNKGDNSSM
DDLHKKDAGMFQAQDERDLEDFLLDFEEDLKAL
HSVQCSPSPGPFKPCEHLLDGWLIRIGVWTIAVLA
LTCNALVTSTVFRSPLYISPIKLLIGVIAAVNMLT
GVSSAVLAGVDAFTFGSFARHGAWWENGVGCHVIG
FLSIFASESSVFLLTLAALERGFSVKYSAKFETKA
PFSSLKVIILLCALLALTMAAVPLLGGSKYGASPL
CLPLPFGEPSTMGYMVALILLNSLCFLMMTIAYTK
LYCNLDKGDLENIWDCSMVKHIALLLFTNCILNCP
VAFLSFSSLINLTFISPEVIKFILLVVVPLPACLN
PLLYILFNPHFKEDLVSLRKQTYVWTRSKHPSLMS
INSDDVEKQSCDSTQALVTFTSSSITYDLPPSSVP
SPAYPVTESCHLSSVAFVPCL
31 GPR101 MTSTCTNSTRESNSSHTCMPLSKMPISLAHGIIRS
TVLVIFLAASFVGNIVLALVLQRKPQLLQVTNRFI
FNLLVTDLLQISLVAPWVVATSVPLFWPLNSHFCT
ALVSLTHLFAFASVNTIVVVSVDRYLSIIHPLSYP
SKMTQRRGYLLLYGTWIVAILQSTPPLYGWGQAAF
DERNALCSMIWGASPSYTILSVVSFIVIPLIVMIA
CYSVVFCAARRQHALLYNVKRHSLEVRVKDCVENE
DEEGAEKKEEFQDESEFRRQHEGEVKAKEGRMEAK
DGSLKAKEGSTGTSESSVEARGSEEVRESSTVASD
GSMEGKEGSTKVEENSMKADKGRTEVNQCSIDLGE
DDMEFGEDDINFSEDDVEAVNIPESLPPSRRNSNS
NPPLPRCYQCKAAKVIFIIIFSYVLSLGPYCFLAV
LAVWVDVETQVPQWVITIIIWLFFLQCCIHPYVYG
YMHKTIKKEIQDMLKKFFCKEKPPKEDSHPDLPGT
EGGTEGKIVPSYDSATFP
32 GPR151 MLAAAFADSNSSSMNVSFAHLHFAGGYLPSDSQDW
RTIIPALLVAVCLVGFVGNLCVIGILLHNAWKGKP
SMIHSLILNLSLADLSLLLFSAPIRATAYSKSVW
DLGWFVCKSSDWFIHTCMAAKSLTIVVVAKVCFMY
ASDPAKQVSIHNYTIWSVLVAIWTVASLLPLPEW
FFSTIRHHEGVEMCLVDVPAVAEEFM
SMFGKLYPLLAFGLPLFFASFYFWRAYDQCKKRGT
KTQNLRNQIRSKQVTVMLLSIAIISALLWLPEWVA
WLWVWHLKAAGPAPPQGFIALSQVLMFSISSANPL
IFLVMSEEFREGLKGVWKWMITKKPPTVSESQETP
AGNSEGLPDKVPSPESPASIPEKEKPSSPSSGKGK
TEKAEIPILPDVEQFWHERDTVPSVQDNDPIPWEF
IEDQETGEGVK
33 GPR161 MSLNSSLSCRKELSNLTEEEGGEGGVIITQFIAII
VITIFVCLGNLVIVVTLYKKSYLLTLSNKFVFSLT
LSNFLLSVLVLPFVVTSSIRREWIFGVVWCNFSAL
LYLLISSASMLTLGVIAIDRYYAVLYPMVYPMKIT
GNRAVMALVYIWLHSLIGCLPPLFGWSSVEFDEFK
WMCVAAWHREPGYTAFWQIWCALFPFLVMLVCYGF
IFRVARVKARKVHCGTVVIVEEDAQRTGRKNSSTS
TSSSGSRRNAFQGVVYSANQCKALITILVVLGAFM
VTWGPYMVVIASEALWGKSSVSPSLETWATWLSFA
SAVCHPLIYGLWNKTVRKELLGMCFGDRYYREPFV
QRQRTSRLFSISNRITDLGLSPHLTALMAGGQPLG
HSSSTGDTGFSCSQDSGTDMMLLEDYTSDDNPPSH
CTCPPKRRSSVTFEDEVEQIKEAAKNSILHVKAEV
HKSLDSYAASLAKAIEAEAKINLFGEEALPGVLVT
ARTVPGGGFGGRRGSRTLVSQRLQLQSIEEGDVLA
AEQR
34 GPR17 MSKRSWWAGSRKPPREMLKLSGSDSSQSMNGLEVA
PPGLITNFSLATAEQCGQETPLENMLFASFYLLDF
ILALVGNTLALWLFIRDHKSGTPANLMLQNNQLRH
VPTEALQNLRSLQSLRLDANHISYVPPSCFSGLHS
LRHLWLDDNALTEIPVQAFRSLSALQAMTLALNKI
HHIPDYAFGNLSSLVVLHLHNNRIHSLGKKCFDGL
HSLETLDLNYNNLDEFPTAIRTLSNLKELGFHSNN
IRSIPEKAFVGNPSLITIHFYDNPIQFVGRSAFQH
LPELRTLTLNGASQITEFPDLTGTANLESLTLTGA
QISSLPQTVCNQLPNLQVLDLSYNLLEDLPSFSVC
QKLQKIDLRHNEIYEIKVDTFQQLLSLRSLNLAWN
KIAIIHPNAFSTLPSLIKLDLSSNLLSSFPITGLH
GLTHLKLTGNHALQSLISSENFPELKVIEMPYAYQ
CCAFGVCENAYKISNQWNKGDNSSMDDLHKKDAGM
FQAQDERDLEDFLLDFEEDLKAL
HSVQCSPSPGPFKPCEHLLDGWLIRIGVWTIAVLA
LTCNALVTSTVFRSPLYISPIKLLIGVIAAVNMLT
GVSSAVLAGVDAFTFGSFARHGAWWENGVGCHVIG
FLSIFASESSVFLLTLAALERGFSVKYSAKFETKA
PFSSLKVIILLCALLALTMAAVPLLGGSKYGASPL
CLPLPFGEPSTMGYMVALILLNSLCFLMMTIAYTK
LYCNLDKGDLENIWDCSMVKHIALLLFTNCILNCP
VAFLSFSSLINLTFISPEVIKFILLVVVPLPACLN
PLLYILFNPHFKEDLVSLRKQTYVWTRSKHPSLMS
INSDDVEKQSCDSTQALVTFTSSSITYDLPPSSVP
SPAYPVTESCHLSSVAFVPCL
35 GPR183 MDIQMANNFTPPSATPQGNDCDLYAHHSTARIVMP
LHYSLVFIIGLVGNLLALVVIVQNRKKINSTTLYS
TNLVISDILFTTALPTRIAYYAMGFDWRIGDALCR
ITALVFYINTYAGVNFMTCLSIDRFIAVVHPLRYN
KIKRIEHAKGVCIFVWILVFAQTLPLLINPMSKQE
AERITCMEYPNFEETKSLPWILLGACFIGYVLPLI
IILICYSQICCKLFRTAKQNPLTEKSGVNKKALNT
IILIIVVFVLCFTPYHVAIIQHMIKKLRFSNFLEC
SQRHSFQISLHFTVCLMNFNCCMDPFIYFFACKGY
KRKVMRMLKRQVSVSISSAVKSAPEENSREMTETQ
MMIHSKSSNGK
36 CRTH2 MSANATLKPLCPILEQMSRLQSHSNTSIRYIDHAA
VLLHGLASLLGLVENGVILFVVGCRMRQTVVTTWV
LHLALSDLLASASLPFFTYFLAVGHSWELGTTFCK
LHSSIFFLNMFASGFLLSAISLDRCLQVVRPVWAQ
NHRTVAAAHKVCLVLWALAVLNTVPYFVFRDTISR
LDGRIMCYYNVLLLNPGPDRDATCNSRQVALAVSK
FLLAFLVPLAIIASSHAAVSLRLQHRGRRRPGRFV
RLVAAVVAAFALCWGPYHVFSLLEARAHANPGLRP
LVWRGLPFVTSLAFFNSVANPVLYVLTCPDMLRKL
RRSLRTVLESVLVDDSELGGAGSSRRRRTSSTARS
ASPLALCSRPEEPRGPARLLGWLLGSCAASPQTGP
LNRALSSTSS
37 5-HT4 MDKLDANVSSEEGFGSVEKVVLLTFLSTVILMAIL
GNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVS
VLVMPFGAIELVQDIWIYGEVFCLVRTSLDVLLTT
ASIFHLCCISLDRYYAICCQPLVYRNKMTPLRIAL
MLGGCWVIPTFISFLPIMQGWNNIGIIDLIEKRKF
NQNSNSTYCVFMVNKPYAITCSVVAFYIPFLLMVL
AYYRIYVTAKEHAHQIQMLQRAGASSESRPQSADQ
HSTHRMRTETKAAKTLCIIMGCFCLCWAPFFVTNI
VDPFIDYTVPGQVWTAFLWLGYINSGLNPFLYAFL
NKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTT
INGSTHVLRDAVECGGQWESQCHPPATSPLVAAQP
SDT
38 5-HT6 MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCV
VIALTAAANSLLIALICTQPALRNTSNFFLVSLFT
SDLMVGLVVMPPAMLNALYGRWVLARGLCLLWTAF
DVMCCSASILNLCLISLDRYLLILSPLRYKLRMTP
LRALALVLGAWSLAALASFLPLLLGWHELGHARPP
VPGQCRLLASLPFVLVASGLTFFLPSGAICFTYCR
ILLAARKQAVQVASLTTGMASQASETLQVPRTPRP
GVESADSRRLATKHSRKALKASLTLGILLGMFFVT
WLPFFVANIVQAVCDCISPGLFDVLTWLGYCNSTM
NPIIYPLFMRDFKRALGRFLPCPRCPRERQASLAS
PSLRTSHSGPRPGLSLQQVLPLPLPPDSDSDSDAG
SGGSSGLRLTAQLLLPGEATQDPPLPTRAAAAVNF
FNIDPAEPELRPHPLGIPTN
39 CB2 MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTA
VAVLCTLLGLLSALENVAVLYLILSSHQLRRKPSY
LFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAV
FLLKIGSVTMTFTASVGSLLLTAIDRYLCLRYPPS
YKALLTRGRALVTLGIMWVLSALVSYLPLMGWTCC
PRPCSELFPLIPNDYLLSWLLFIAFLFSGIIYTYG
HVLWKAHQHVASLSGHQDRQVPGMARMRLDVRLAK
TLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKA
FAFCSMLCLINSMVNPVIYALRSGEIRSSAHHCLA
HWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWP
DSRDLDLSDC
40 Histamine- MERAPPDGPLNASGALAGEAAAAGGARGFSAAWTA
3 VLAALMALLIVATVLGNALVMLAFVADSSLRTQNN
FFLLNLAISDFLVGAFCIPLYVPYVLTGRWTFGRG
LCKLWLVVDYLLCTSSAFNIVLISYDRFLSVTRAV
SYRAQQGDTRRAVRKMLLVWVLAFLLYGPAILSWE
YLSGGSSIPEGHCYAEFFYNWYFLITASTLEFFTP
FLSVTFFNLSIYLNIQRRTRLRLDGAREAAGPEPP
PEAQPSPPPPPGCWGCWQKGHGEAMPLHRYGVGE
AAVGAEAGEATLGGGGGGGSVASPTSSSGSSSRG
TERP
RSLKRGSKPSASSASLEKRMKMVSQSFTQRFRLSR
DRKVAKSLAVIVSIFGLCWAPYTLLMIIRAACHGH
CVPDYWYETSFWLLWANSAVNPVLYPLCHHSFRRA
FTKLLCPQKLKIQPHSSLEHCWK
41 VPAC-1 or ARLQEECDYVQMIEVQHKQCLEEAQLENETIGCSK
VIPR1 MWDNLTCWPATPRGQVVVLACPLIFKLFSSIQGRN
VSRSCTDEGWTHLEPGPYPIACGLDDKAASLDEQQ
TMFYGSVKTGYTIGYGLSLATLLVATAILSLFRKL
HCTRNYIHMHLFISFILRAAAVFIKDLALFDSGES
DQCSEGSVGCKAAMVFFQYCVMANFFWLLVEGLYL
YTLLAVSFFSERKYFWGYILIGWGVPSTFTMVWTI
ARIHFEDYGCWDT
INSSLWWIIKGPILTSILVNFILFICIIRILLQKL
RPPDIRKSDSSPYSRLARSTLLLIPLFGVHYIMFA
FFPDNFKPEVKMVFELVVGSFQGFVVAILYCFLNG
EVQAELRRKWRRWHLQGVLGWNPKYRHPSGGSNGA
TCSTQVSMLTRVSPGARRSSSFQAEVSLV
42 GIPR RAETGSKGQTAGELYQRWERYRRECQETLAAAEPP
SGLACNGSFDMYVCWDYAAPNATARASCPWYLPWH
HHVAAGFVLRQCGSDGQWGLWRDHTQCENPEKNEA
FLDQRLILERLQVMYTVGYSLSLATLLLALLILSL
FRRLHCTRNYIHINLFTSFMLRAAAILSRDRLLPR
PGPYLGDQALALWNQALAACRTAQIVTQYCVGANY
TWLLVEGVYLHSLLVLVGGSEEGHFRYYLLLGWGA
PALFVIPWVIVRYLYEN
TQCWERNEVKAIWWIIRTPILMTILINFLIFIRIL
GILLSKLRTRQMRCRDYRLRLARSTLTLVPLLGVH
EVVFAPVTEEQARGALRFAKLGFEIFLSSFQGFLV
SVLYCFINKEVQSEIRRGWHHCRLRRSLGEEQRQL
PERAFRALPSGSGPGEVPTSRGLSSGTLPGPGNEA
SRELESYC
43 5-HT1B MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSA
GPCR KDYIYQDSISLPWKVLLVMLLALITLATTLSNAFV
IATVYRTRKLHTPANYLIASLAVTDLLVSILVMPI
STMYTVTGRWTLGQVVCDFWLSSDITCCTASILHL
CVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWV
FSISISLPPFFWRQAKAEEEVSECVVNTDHILYTV
YSTVGAFYFPTLLLIALYGRIYVEARSRILKQTPN
RTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSE
SGSPVYVNQVKVRVSDALLEKKKLMAARERKATKT
LGIILGAFIVCWLPFFIISLVMPICKDACWFHLAI
FDFFTWLGYLNSLINPIIYTMSNEDFKQAFHKLIR
FKCTS
44 CCR7 QDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAW
FLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTD
TYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFC
KLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSA
HRHRARVLLISKLSCVGIWILATVLSIPELLYSDL
QRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLV
PLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVV
VVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQL
NIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFK
LFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTT
TFSP
45 CXCR5 MNYPLTLEMDLENLEDLFWELDRLDNYNDTSLVEN
HLCPATEGPLMASFKAVFVPVAYSLIFLLGVIGNV
LVLVILERHRQTRSSTETFLFHLAVADLLLVFILP
FAVAEGSVGWVLGTFLCKTVIALHKVNFYCSSLLL
ACIAVDRYLAIVHAVHAYRHRRLLSIHITCGTIWL
VGFLLALPEILFAKVSQGHHNNSLPRCTFSQENQA
ETHAWFTSRFLYHVAGFLLPMLVMGWCYVGVVHRL
RQAQRRPQRQKAVRVAILVTSIFFLCWSPYHIVIF
LDTLARLKAVDNTCKLNGSLPVAITMCEFLGLAHC
CLNPMLYTFAGVKFRSDLSRLLTKLGCTGPASLCQ
LFPSWRRSSLSESENATSLTTF
46 GPR119 MESSFSFGVILAVLASLIIATNTLVAVAVLLLIHK
NDGVSLCFTLNLAVADTLIGVAISGLLTDQLSSPS
RPTQKTLCSLRMAFVTSSAAASVLTVMLITFDRYL
AIKQPFRYLKIMSGFVAGACIAGLWLVSYLIGFLP
LGIPMFQQTAYKGQCSFFAVFHPHFVLTLSCVGFF
PAMLLFVFFYCDMLKIASMHSQQIRKMEHAGAMAG
GYRSPRTPSDFKALRTVSVLIGSFALSWTPFLITG
IVQVACQECHLYLVLERYLWLLGVGNSLLNPLIYA
YWQKEVRLQLYHMALGVKKVLTSFLLFLSARNCGP
ERPRESSCHIVTISSSEFDG
47 GPR55 MSQQNTSGDCLFDGVNELMKTLQFAVHIPTFVLGL
LLNLLAIHGFSTFLKNRWPDYAATSIYMINLAVFD
LLLVLSLPFKMVLSQVQSPFPSLCTLVECLYFVSM
YGSVFTICFISMDRFLAIRYPLLVSHLRSPRKIFG
ICCTIWVLVWTGSIPIYSFHGKVEKYMCFHNMSDD
TWSAKVFFPLEVFGFLLPMGIMGFCCSRSIHILLG
RRDHTQDWVQQKACIYSIAASLAVFVVSFLPVHLG
FFLQFLVRNSFIVECRAKQSISFFLQLSMCFSNVN
CCLDVFCYYFVIKEFRMNIRAHRPSRVQLVLQDTT
ISRG
Provided herein are scaffolds comprising GPCR binding domains, wherein the sequences of the GPCR binding domains support interaction with at least one GPCR. The sequence may be homologous or identical to a sequence of a GPCR ligand. In some instances, the GPCR binding domain sequence comprises at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47. In some instances, the GPCR binding domain sequence comprises at least or about 95% homology to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47. In some instances, the GPCR binding domain sequence comprises at least or about 97% homology to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47. In some instances, the GPCR binding domain sequence comprises at least or about 99% homology to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47. In some instances, the GPCR binding domain sequence comprises at least or about 100% homology to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47. In some instances, the GPCR binding domain sequence comprises at least a portion having at least or about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, or more than 400 amino acids of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47.
Libraries comprising nucleic acids encoding for scaffolds comprising GPCR binding domains may bind to one or more GPCRs. In some instances, the scaffolds comprising GPCR binding domains binds to a single GPCR. In some instances, the scaffolds comprising GPCR binding domains binds to GPCRs in a same family or class. In some instances, the scaffolds comprising GPCR binding domains bind to multiple GPCRs. For example, the scaffolds are multimeric and comprise at least 2 scaffolds. In some instances, the multimeric scaffolds comprise at least or about 3, 4, 5, 6, 7, 8, or more than 8 scaffolds. In some instances, the multimeric scaffolds comprise at least 2 scaffolds linked by, for example, a dimerization domain, an amino acid linker, a disulfide bond, a chemical crosslink, or any other linker known in the art. In some instances, the multimeric scaffolds bind to the same GPCRs or different GPCRs.
Provided herein are GPCR binding libraries comprising nucleic acids encoding for scaffolds comprising GPCR binding domains comprise variation in domain type, domain length, or residue variation. In some instances, the domain is a region in the scaffold comprising the GPCR binding domains. For example, the region is the VH, CDR-H3, or VL domain. In some instances, the domain is the GPCR binding domain.
Methods described herein provide for synthesis of a GPCR binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the GPCR binding library comprises varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon of a VH, CDR-H3, or VL domain. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a GPCR binding domain. For example, at least one single codon of a GPCR binding domain as listed in Table 2 is varied. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a VH, CDR-H3, or VL domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a GPCR binding domain. An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
Methods described herein provide for synthesis of a GPCR binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence, wherein the GPCR binding library comprises sequences encoding for variation of length of a domain. In some instances, the domain is VH, CDR-H3, or VL domain. In some instances, the domain is the GPCR binding domain. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.
Provided herein are GPCR binding libraries comprising nucleic acids encoding for scaffolds comprising GPCR binding domains, wherein the GPCR binding libraries are synthesized with various numbers of fragments. In some instances, the fragments comprise the VH, CDR-H3, or VL domain. In some instances, the GPCR binding libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments. The length of each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.
GPCR binding libraries comprising nucleic acids encoding for scaffolds comprising GPCR binding domains as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 to about 75 amino acids.
GPCR binding libraries comprising de novo synthesized variant sequences encoding for scaffolds comprising GPCR binding domains comprise a number of variant sequences. In some instances, a number of variant sequences is de novo synthesized for a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3, VL, VH, or a combination thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, a number of variant sequences is de novo synthesized for a GPCR binding domain. For example, the number of variant sequences is about 1 to about 10 sequences for the VH domain, about 108 sequences for the GPCR binding domain, and about 1 to about 44 sequences for the VK domain. See FIG. 2. The number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences. In some instances, the number of variant sequences is about 10 to 300, 25 to 275, 50 to 250, 75 to 225, 100 to 200, or 125 to 150 sequences.
GPCR binding libraries comprising de novo synthesized variant sequences encoding for scaffolds comprising GPCR binding domains comprise improved diversity. For example, variants are generated by placing GPCR binding domain variants in immunoglobulin scaffold variants comprising N-terminal CDR-H3 variations and C-terminal CDR-H3 variations. In some instances, variants include affinity maturation variants. Alternatively or in combination, variants include variants in other regions of the immunoglobulin including, but not limited to, CDR-H1, CDR-H2, CDR-L1, CDR-L2, and CDR-L3. In some instances, the number of variants of the GPCR binding libraries is least or about 104, 105, 106, 107, 108, 109, 1010, or more than 1010 non-identical sequences. For example, a library comprising about 10 variant sequences for a VH region, about 237 variant sequences for a CDR-H3 region, and about 43 variant sequences for a VL and CDR-L3 region comprises 105 non-identical sequences (10×237×43). See FIGS. 4A-4B.
Following synthesis of GPCR binding libraries comprising nucleic acids encoding scaffolds comprising GPCR binding domains, libraries may be used for screening and analysis. For example, libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag. Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG. For example as seen in FIG. 3, the GPCR binding libraries comprises nucleic acids encoding scaffolds comprising GPCR binding domains with multiple tags such as GFP, FLAG, and Lucy as well as a DNA barcode. In some instances, libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.
Expression Systems
Provided herein are libraries comprising nucleic acids encoding for scaffolds comprising GPCR binding domains, wherein the libraries have improved specificity, stability, expression, folding, or downstream activity. In some instances, libraries described herein are used for screening and analysis.
Provided herein are libraries comprising nucleic acids encoding for scaffolds comprising GPCR binding domains, wherein the nucleic acid libraries are used for screening and analysis. In some instances, screening and analysis comprises in vitro, in vivo, or ex vivo assays. Cells for screening include primary cells taken from living subjects or cell lines. Cells may be from prokaryotes (e.g., bacteria and fungi) or eukaryotes (e.g., animals and plants). Exemplary animal cells include, without limitation, those from a mouse, rabbit, primate, and insect. In some instances, cells for screening include a cell line including, but not limited to, Chinese Hamster Ovary (CHO) cell line, human embryonic kidney (HEK) cell line, or baby hamster kidney (BHK) cell line. In some instances, nucleic acid libraries described herein may also be delivered to a multicellular organism. Exemplary multicellular organisms include, without limitation, a plant, a mouse, rabbit, primate, and insect.
Nucleic acid libraries described herein may be screened for various pharmacological or pharmacokinetic properties. In some instances, the libraries are screened using in vitro assays, in vivo assays, or ex vivo assays. For example, in vitro pharmacological or pharmacokinetic properties that are screened include, but are not limited to, binding affinity, binding specificity, and binding avidity. Exemplary in vivo pharmacological or pharmacokinetic properties of libraries described herein that are screened include, but are not limited to, therapeutic efficacy, activity, preclinical toxicity properties, clinical efficacy properties, clinical toxicity properties, immunogenicity, potency, and clinical safety properties.
Provided herein are nucleic acid libraries, wherein the nucleic acid libraries may be expressed in a vector. Expression vectors for inserting nucleic acid libraries disclosed herein may comprise eukaryotic or prokaryotic expression vectors. Exemplary expression vectors include, without limitation, mammalian expression vectors: pSF-CMV-NEO-NH2-PPT-3XFLAG, pSF-CMV-NEO—COOH-3XFLAG, pSF-CMV—PURO-NH2-GST-TEV, pSF-OXB20-COOH-TEV-FLAG(R)-6His, pCEP4 pDEST27, pSF-CMV-Ub-KrYFP, pSF-CMV-FMDV-daGFP, pEF1a-mCherry-N1 Vector, pEF1a-tdTomato Vector, pSF-CMV-FMDV-Hygro, pSF-CMV-PGK-Puro, pMCP-tag(m), and pSF-CMV—PURO-NH2-CMYC; bacterial expression vectors: pSF-OXB20-BetaGal,pSF-OXB20-Fluc, pSF-OXB20, and pSF-Tac; plant expression vectors: pRI 101-AN DNA and pCambia2301; and yeast expression vectors: pTYB21 and pKLAC2, and insect vectors: pAc5.1N5-His A and pDEST8. In some instances, the vector is pcDNA3 or pcDNA3.1.
Described herein are nucleic acid libraries that are expressed in a vector to generate a construct comprising a scaffold comprising sequences of GPCR binding domains. In some instances, a size of the construct varies. In some instances, the construct comprises at least or about 500, 600, 700, 800, 900, 1000, 1100, 1300, 1400, 1500, 1600, 1700, 1800, 2000, 2400, 2600, 2800, 3000, 3200, 3400, 3600, 3800, 4000, 4200, 4400, 4600, 4800, 5000, 6000, 7000, 8000, 9000, 10000, or more than 10000 bases. In some instances, a the construct comprises a range of about 300 to 1,000, 300 to 2,000, 300 to 3,000, 300 to 4,000, 300 to 5,000, 300 to 6,000, 300 to 7,000, 300 to 8,000, 300 to 9,000, 300 to 10,000, 1,000 to 2,000, 1,000 to 3,000, 1,000 to 4,000, 1,000 to 5,000, 1,000 to 6,000, 1,000 to 7,000, 1,000 to 8,000, 1,000 to 9,000, 1,000 to 10,000, 2,000 to 3,000, 2,000 to 4,000, 2,000 to 5,000, 2,000 to 6,000, 2,000 to 7,000, 2,000 to 8,000, 2,000 to 9,000, 2,000 to 10,000, 3,000 to 4,000, 3,000 to 5,000, 3,000 to 6,000, 3,000 to 7,000, 3,000 to 8,000, 3,000 to 9,000, 3,000 to 10,000, 4,000 to 5,000, 4,000 to 6,000, 4,000 to 7,000, 4,000 to 8,000, 4,000 to 9,000, 4,000 to 10,000, 5,000 to 6,000, 5,000 to 7,000, 5,000 to 8,000, 5,000 to 9,000, 5,000 to 10,000, 6,000 to 7,000, 6,000 to 8,000, 6,000 to 9,000, 6,000 to 10,000, 7,000 to 8,000, 7,000 to 9,000, 7,000 to 10,000, 8,000 to 9,000, 8,000 to 10,000, or 9,000 to 10,000 bases.
Provided herein are libraries comprising nucleic acids encoding for scaffolds comprising GPCR binding domains, wherein the nucleic acid libraries are expressed in a cell. In some instances, the libraries are synthesized to express a reporter gene. Exemplary reporter genes include, but are not limited to, acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucoronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), cerulean fluorescent protein, citrine fluorescent protein, orange fluorescent protein, cherry fluorescent protein, turquoise fluorescent protein, blue fluorescent protein, horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), luciferase, and derivatives thereof. Methods to determine modulation of a reporter gene are well known in the art, and include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), and antibiotic resistance determination.
Diseases and Disorders
Provided herein are GPCR binding libraries comprising nucleic acids encoding for scaffolds comprising GPCR binding domains may have therapeutic effects. In some instances, the GPCR binding libraries result in protein when translated that is used to treat a disease or disorder. In some instances, the protein is an immunoglobulin. In some instances, the protein is a peptidomimetic. Exemplary diseases include, but are not limited to, cancer, inflammatory diseases or disorders, a metabolic disease or disorder, a cardiovascular disease or disorder, a respiratory disease or disorder, pain, a digestive disease or disorder, a reproductive disease or disorder, an endocrine disease or disorder, or a neurological disease or disorder. In some instances, the cancer is a solid cancer or a hematologic cancer. In some instances, an inhibitor of GPCR glucagon like peptide 1 receptor (GLP1R) as described herein is used for treatment of a metabolic disorder. In some instances, an inhibitor of GPCR GLP1R as described herein is used for treatment of weight gain (or for inducing weight loss), treatment of obesity, or treatment of Type II diabetes. In some instances, the subject is a mammal. In some instances, the subject is a mouse, rabbit, dog, or human. Subjects treated by methods described herein may be infants, adults, or children. Pharmaceutical compositions comprising antibodies or antibody fragments as described herein may be administered intravenously or subcutaneously. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDR-H3 comprising a sequence of any one of SEQ ID NOS: 2420 to 2436. In further instances, the pharmaceutical composition is used for treatment of a metabolic disorder.
Variant Libraries
Codon variation.
Variant nucleic acid libraries described herein may comprise a plurality of nucleic acids, wherein each nucleic acid encodes for a variant codon sequence compared to a reference nucleic acid sequence. In some instances, each nucleic acid of a first nucleic acid population contains a variant at a single variant site. In some instances, the first nucleic acid population contains a plurality of variants at a single variant site such that the first nucleic acid population contains more than one variant at the same variant site. The first nucleic acid population may comprise nucleic acids collectively encoding multiple codon variants at the same variant site. The first nucleic acid population may comprise nucleic acids collectively encoding up to 19 or more codons at the same position. The first nucleic acid population may comprise nucleic acids collectively encoding up to 60 variant triplets at the same position, or the first nucleic acid population may comprise nucleic acids collectively encoding up to 61 different triplets of codons at the same position. Each variant may encode for a codon that results in a different amino acid during translation. Table 3 provides a listing of each codon possible (and the representative amino acid) for a variant site.
TABLE 3
List of codons and amino acids
One Three
letter letter
Amino Acids code code Codons
Alanine A Ala GCA GCC GCG GCT
Cysteine C Cys TGC TGT
Aspartic acid D Asp GAC GAT
Glutamic acid E Glu GAA GAG
Phenylalanine F Phe TTC TTT
Glycine G Gly GGA GGC GGG GGT
Histidine H His CAC CAT
Isoleucine I Iso ATA ATC ATT
Lysine K Lys AAA AAG
Leucine L Leu TTA TTG CTA CTC CTG CTT
Methionine M Met ATG
Asparagine N Asn AAC AAT
Proline P Pro CCA CCC CCG CCT
Glutamine Q Gln CAA CAG
Arginine R Arg AGA AGG CGA CGC CGG CGT
Serine S Ser AGC AGT TCA TCC TCG TCT
Threonine T Thr ACA ACC ACG ACT
Valine V Val GTA GTC GTG GTT
Tryptophan W Trp TGG
Tyrosine Y Tyr TAC TAT
A nucleic acid population may comprise varied nucleic acids collectively encoding up to 20 codon variations at multiple positions. In such cases, each nucleic acid in the population comprises variation for codons at more than one position in the same nucleic acid. In some instances, each nucleic acid in the population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more codons in a single nucleic acid. In some instances, each variant long nucleic acid comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single long nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons in at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more codons in a single long nucleic acid.
Highly Parallel Nucleic Acid Synthesis
Provided herein is a platform approach utilizing miniaturization, parallelization, and vertical integration of the end-to-end process from polynucleotide synthesis to gene assembly within nanowells on silicon to create a revolutionary synthesis platform. Devices described herein provide, with the same footprint as a 96-well plate, a silicon synthesis platform is capable of increasing throughput by a factor of up to 1,000 or more compared to traditional synthesis methods, with production of up to approximately 1,000,000 or more polynucleotides, or 10,000 or more genes in a single highly-parallelized run.
With the advent of next-generation sequencing, high resolution genomic data has become an important factor for studies that delve into the biological roles of various genes in both normal biology and disease pathogenesis. At the core of this research is the central dogma of molecular biology and the concept of “residue-by-residue transfer of sequential information.” Genomic information encoded in the DNA is transcribed into a message that is then translated into the protein that is the active product within a given biological pathway.
Another exciting area of study is on the discovery, development and manufacturing of therapeutic molecules focused on a highly-specific cellular target. High diversity DNA sequence libraries are at the core of development pipelines for targeted therapeutics. Gene mutants are used to express proteins in a design, build, and test protein engineering cycle that ideally culminates in an optimized gene for high expression of a protein with high affinity for its therapeutic target. As an example, consider the binding pocket of a receptor. The ability to test all sequence permutations of all residues within the binding pocket simultaneously will allow for a thorough exploration, increasing chances of success. Saturation mutagenesis, in which a researcher attempts to generate all possible mutations at a specific site within the receptor, represents one approach to this development challenge. Though costly and time and labor-intensive, it enables each variant to be introduced into each position. In contrast, combinatorial mutagenesis, where a few selected positions or short stretch of DNA may be modified extensively, generates an incomplete repertoire of variants with biased representation.
To accelerate the drug development pipeline, a library with the desired variants available at the intended frequency in the right position available for testing—in other words, a precision library, enables reduced costs as well as turnaround time for screening. Provided herein are methods for synthesizing nucleic acid synthetic variant libraries which provide for precise introduction of each intended variant at the desired frequency. To the end user, this translates to the ability to not only thoroughly sample sequence space but also be able to query these hypotheses in an efficient manner, reducing cost and screening time. Genome-wide editing can elucidate important pathways, libraries where each variant and sequence permutation can be tested for optimal functionality, and thousands of genes can be used to reconstruct entire pathways and genomes to re-engineer biological systems for drug discovery.
In a first example, a drug itself can be optimized using methods described herein. For example, to improve a specified function of an antibody, a variant polynucleotide library encoding for a portion of the antibody is designed and synthesized. A variant nucleic acid library for the antibody can then be generated by processes described herein (e.g., PCR mutagenesis followed by insertion into a vector). The antibody is then expressed in a production cell line and screened for enhanced activity. Example screens include examining modulation in binding affinity to an antigen, stability, or effector function (e.g., ADCC, complement, or apoptosis). Exemplary regions to optimize the antibody include, without limitation, the Fc region, Fab region, variable region of the Fab region, constant region of the Fab region, variable domain of the heavy chain or light chain (VH or VL), and specific complementarity-determining regions (CDRs) of VH or VL.
Nucleic acid libraries synthesized by methods described herein may be expressed in various cells associated with a disease state. Cells associated with a disease state include cell lines, tissue samples, primary cells from a subject, cultured cells expanded from a subject, or cells in a model system. Exemplary model systems include, without limitation, plant and animal models of a disease state.
To identify a variant molecule associated with prevention, reduction or treatment of a disease state, a variant nucleic acid library described herein is expressed in a cell associated with a disease state, or one in which a cell a disease state can be induced. In some instances, an agent is used to induce a disease state in cells. Exemplary tools for disease state induction include, without limitation, a Cre/Lox recombination system, LPS inflammation induction, and streptozotocin to induce hypoglycemia. The cells associated with a disease state may be cells from a model system or cultured cells, as well as cells from a subject having a particular disease condition. Exemplary disease conditions include a bacterial, fungal, viral, autoimmune, or proliferative disorder (e.g., cancer). In some instances, the variant nucleic acid library is expressed in the model system, cell line, or primary cells derived from a subject, and screened for changes in at least one cellular activity. Exemplary cellular activities include, without limitation, proliferation, cycle progression, cell death, adhesion, migration, reproduction, cell signaling, energy production, oxygen utilization, metabolic activity, and aging, response to free radical damage, or any combination thereof
Substrates
Devices used as a surface for polynucleotide synthesis may be in the form of substrates which include, without limitation, homogenous array surfaces, patterned array surfaces, channels, beads, gels, and the like. Provided herein are substrates comprising a plurality of clusters, wherein each cluster comprises a plurality of loci that support the attachment and synthesis of polynucleotides. In some instances, substrates comprise a homogenous array surface. For example, the homogenous array surface is a homogenous plate. The term “locus” as used herein refers to a discrete region on a structure which provides support for polynucleotides encoding for a single predetermined sequence to extend from the surface. In some instances, a locus is on a two dimensional surface, e.g., a substantially planar surface. In some instances, a locus is on a three-dimensional surface, e.g., a well, microwell, channel, or post. In some instances, a surface of a locus comprises a material that is actively functionalized to attach to at least one nucleotide for polynucleotide synthesis, or preferably, a population of identical nucleotides for synthesis of a population of polynucleotides. In some instances, polynucleotide refers to a population of polynucleotides encoding for the same nucleic acid sequence. In some cases, a surface of a substrate is inclusive of one or a plurality of surfaces of a substrate. The average error rates for polynucleotides synthesized within a library described here using the systems and methods provided are often less than 1 in 1000, less than about 1 in 2000, less than about 1 in 3000 or less often without error correction.
Provided herein are surfaces that support the parallel synthesis of a plurality of polynucleotides having different predetermined sequences at addressable locations on a common support. In some instances, a substrate provides support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more non-identical polynucleotides. In some cases, the surfaces provide support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more polynucleotides encoding for distinct sequences. In some instances, at least a portion of the polynucleotides have an identical sequence or are configured to be synthesized with an identical sequence. In some instances, the substrate provides a surface environment for the growth of polynucleotides having at least 80, 90, 100, 120, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 bases or more.
Provided herein are methods for polynucleotide synthesis on distinct loci of a substrate, wherein each locus supports the synthesis of a population of polynucleotides. In some cases, each locus supports the synthesis of a population of polynucleotides having a different sequence than a population of polynucleotides grown on another locus. In some instances, each polynucleotide sequence is synthesized with 1, 2, 3, 4, 5, 6, 7, 8, 9 or more redundancy across different loci within the same cluster of loci on a surface for polynucleotide synthesis. In some instances, the loci of a substrate are located within a plurality of clusters. In some instances, a substrate comprises at least 10, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 20000, 30000, 40000, 50000 or more clusters. In some instances, a substrate comprises more than 2,000; 5,000; 10,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,100,000; 1,200,000; 1,300,000; 1,400,000; 1,500,000; 1,600,000; 1,700,000; 1,800,000; 1,900,000; 2,000,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; or 10,000,000 or more distinct loci. In some instances, a substrate comprises about 10,000 distinct loci. The amount of loci within a single cluster is varied in different instances. In some cases, each cluster includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 150, 200, 300, 400, 500 or more loci. In some instances, each cluster includes about 50-500 loci. In some instances, each cluster includes about 100-200 loci. In some instances, each cluster includes about 100-150 loci. In some instances, each cluster includes about 109, 121, 130 or 137 loci. In some instances, each cluster includes about 19, 20, 61, 64 or more loci. Alternatively or in combination, polynucleotide synthesis occurs on a homogenous array surface.
In some instances, the number of distinct polynucleotides synthesized on a substrate is dependent on the number of distinct loci available in the substrate. In some instances, the density of loci within a cluster or surface of a substrate is at least or about 1, 10, 25, 50, 65, 75, 100, 130, 150, 175, 200, 300, 400, 500, 1,000 or more loci per mm2. In some cases, a substrate comprises 10-500, 25-400, 50-500, 100-500, 150-500, 10-250, 50-250, 10-200, or 50-200 mm2. In some instances, the distance between the centers of two adjacent loci within a cluster or surface is from about 10-500, from about 10-200, or from about 10-100 um. In some instances, the distance between two centers of adjacent loci is greater than about 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some instances, the distance between the centers of two adjacent loci is less than about 200, 150, 100, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, each locus has a width of about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some cases, each locus is has a width of about 0.5-100, 0.5-50, 10-75, or 0.5-50 um.
In some instances, the density of clusters within a substrate is at least or about 1 cluster per 100 mm2, 1 cluster per 10 mm2, 1 cluster per 5 mm2, 1 cluster per 4 mm2, 1 cluster per 3 mm2, 1 cluster per 2 mm2, 1 cluster per 1 mm2, 2 clusters per 1 mm2, 3 clusters per 1 mm2, 4 clusters per 1 mm2, 5 clusters per 1 mm2, 10 clusters per 1 mm2, 50 clusters per 1 mm2 or more. In some instances, a substrate comprises from about 1 cluster per 10 mm2 to about 10 clusters per 1 mm2. In some instances, the distance between the centers of two adjacent clusters is at least or about 50, 100, 200, 500, 1000, 2000, or 5000 um. In some cases, the distance between the centers of two adjacent clusters is between about 50-100, 50-200, 50-300, 50-500, and 100-2000 um. In some cases, the distance between the centers of two adjacent clusters is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some cases, each cluster has a cross section of about 0.5 to about 2, about 0.5 to about 1, or about 1 to about 2 mm. In some cases, each cluster has a cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm. In some cases, each cluster has an interior cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm.
In some instances, a substrate is about the size of a standard 96 well plate, for example between about 100 and about 200 mm by between about 50 and about 150 mm. In some instances, a substrate has a diameter less than or equal to about 1000, 500, 450, 400, 300, 250, 200, 150, 100 or 50 mm. In some instances, the diameter of a substrate is between about 25-1000, 25-800, 25-600, 25-500, 25-400, 25-300, or 25-200 mm. In some instances, a substrate has a planar surface area of at least about 100; 200; 500; 1,000; 2,000; 5,000; 10,000; 12,000; 15,000; 20,000; 30,000; 40,000; 50,000 mm2 or more. In some instances, the thickness of a substrate is between about 50-2000, 50-1000, 100-1000, 200-1000, or 250-1000 mm.
Surface Materials
Substrates, devices, and reactors provided herein are fabricated from any variety of materials suitable for the methods, compositions, and systems described herein. In certain instances, substrate materials are fabricated to exhibit a low level of nucleotide binding. In some instances, substrate materials are modified to generate distinct surfaces that exhibit a high level of nucleotide binding. In some instances, substrate materials are transparent to visible and/or UV light. In some instances, substrate materials are sufficiently conductive, e.g., are able to form uniform electric fields across all or a portion of a substrate. In some instances, conductive materials are connected to an electric ground. In some instances, the substrate is heat conductive or insulated. In some instances, the materials are chemical resistant and heat resistant to support chemical or biochemical reactions, for example polynucleotide synthesis reaction processes. In some instances, a substrate comprises flexible materials. For flexible materials, materials can include, without limitation: nylon, both modified and unmodified, nitrocellulose, polypropylene, and the like. In some instances, a substrate comprises rigid materials. For rigid materials, materials can include, without limitation: glass; fuse silica; silicon, plastics (for example polytetraflouroethylene, polypropylene, polystyrene, polycarbonate, and blends thereof, and the like); metals (for example, gold, platinum, and the like). The substrate, solid support or reactors can be fabricated from a material selected from the group consisting of silicon, polystyrene, agarose, dextran, cellulosic polymers, polyacrylamides, polydimethylsiloxane (PDMS), and glass. The substrates/solid supports or the microstructures, reactors therein may be manufactured with a combination of materials listed herein or any other suitable material known in the art.
Surface Architecture
Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates have a surface architecture suitable for the methods, compositions, and systems described herein. In some instances, a substrate comprises raised and/or lowered features. One benefit of having such features is an increase in surface area to support polynucleotide synthesis. In some instances, a substrate having raised and/or lowered features is referred to as a three-dimensional substrate. In some cases, a three-dimensional substrate comprises one or more channels. In some cases, one or more loci comprise a channel. In some cases, the channels are accessible to reagent deposition via a deposition device such as a material deposition device. In some cases, reagents and/or fluids collect in a larger well in fluid communication one or more channels. For example, a substrate comprises a plurality of channels corresponding to a plurality of loci with a cluster, and the plurality of channels are in fluid communication with one well of the cluster. In some methods, a library of polynucleotides is synthesized in a plurality of loci of a cluster.
Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates are configured for polynucleotide synthesis. In some instances, the structure is configured to allow for controlled flow and mass transfer paths for polynucleotide synthesis on a surface. In some instances, the configuration of a substrate allows for the controlled and even distribution of mass transfer paths, chemical exposure times, and/or wash efficacy during polynucleotide synthesis. In some instances, the configuration of a substrate allows for increased sweep efficiency, for example by providing sufficient volume for a growing polynucleotide such that the excluded volume by the growing polynucleotide does not take up more than 50, 45, 40, 35, 30, 25, 20, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1%, or less of the initially available volume that is available or suitable for growing the polynucleotide. In some instances, a three-dimensional structure allows for managed flow of fluid to allow for the rapid exchange of chemical exposure.
Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates comprise structures suitable for the methods, compositions, and systems described herein. In some instances, segregation is achieved by physical structure. In some instances, segregation is achieved by differential functionalization of the surface generating active and passive regions for polynucleotide synthesis. In some instances, differential functionalization is achieved by alternating the hydrophobicity across the substrate surface, thereby creating water contact angle effects that cause beading or wetting of the deposited reagents. Employing larger structures can decrease splashing and cross-contamination of distinct polynucleotide synthesis locations with reagents of the neighboring spots. In some cases, a device, such as a material deposition device, is used to deposit reagents to distinct polynucleotide synthesis locations. Substrates having three-dimensional features are configured in a manner that allows for the synthesis of a large number of polynucleotides (e.g., more than about 10,000) with a low error rate (e.g., less than about 1:500, 1:1000, 1:1500, 1:2,000, 1:3,000, 1:5,000, or 1:10,000). In some cases, a substrate comprises features with a density of about or greater than about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400 or 500 features per mm2.
A well of a substrate may have the same or different width, height, and/or volume as another well of the substrate. A channel of a substrate may have the same or different width, height, and/or volume as another channel of the substrate. In some instances, the diameter of a cluster or the diameter of a well comprising a cluster, or both, is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.05-1, 0.05-0.5, 0.05-0.1, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some instances, the diameter of a cluster or well or both is less than or about 5, 4, 3, 2, 1, 0.5, 0.1, 0.09, 0.08, 0.07, 0.06, or 0.05 mm. In some instances, the diameter of a cluster or well or both is between about 1.0 and 1.3 mm. In some instances, the diameter of a cluster or well, or both is about 1.150 mm. In some instances, the diameter of a cluster or well, or both is about 0.08 mm. The diameter of a cluster refers to clusters within a two-dimensional or three-dimensional substrate.
In some instances, the height of a well is from about 20-1000, 50-1000, 100-1000, 200-1000, 300-1000, 400-1000, or 500-1000 um. In some cases, the height of a well is less than about 1000, 900, 800, 700, or 600 um.
In some instances, a substrate comprises a plurality of channels corresponding to a plurality of loci within a cluster, wherein the height or depth of a channel is 5-500, 5-400, 5-300, 5-200, 5-100, 5-50, or 10-50 um. In some cases, the height of a channel is less than 100, 80, 60, 40, or 20 um.
In some instances, the diameter of a channel, locus (e.g., in a substantially planar substrate) or both channel and locus (e.g., in a three-dimensional substrate wherein a locus corresponds to a channel) is from about 1-1000, 1-500, 1-200, 1-100, 5-100, or 10-100 um, for example, about 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the diameter of a channel, locus, or both channel and locus is less than about 100, 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the distance between the center of two adjacent channels, loci, or channels and loci is from about 1-500, 1-200, 1-100, 5-200, 5-100, 5-50, or 5-30, for example, about 20 um.
Surface Modifications
Provided herein are methods for polynucleotide synthesis on a surface, wherein the surface comprises various surface modifications. In some instances, the surface modifications are employed for the chemical and/or physical alteration of a surface by an additive or subtractive process to change one or more chemical and/or physical properties of a substrate surface or a selected site or region of a substrate surface. For example, surface modifications include, without limitation, (1) changing the wetting properties of a surface, (2) functionalizing a surface, i.e., providing, modifying or substituting surface functional groups, (3) defunctionalizing a surface, i.e., removing surface functional groups, (4) otherwise altering the chemical composition of a surface, e.g., through etching, (5) increasing or decreasing surface roughness, (6) providing a coating on a surface, e.g., a coating that exhibits wetting properties that are different from the wetting properties of the surface, and/or (7) depositing particulates on a surface.
In some cases, the addition of a chemical layer on top of a surface (referred to as adhesion promoter) facilitates structured patterning of loci on a surface of a substrate. Exemplary surfaces for application of adhesion promotion include, without limitation, glass, silicon, silicon dioxide and silicon nitride. In some cases, the adhesion promoter is a chemical with a high surface energy. In some instances, a second chemical layer is deposited on a surface of a substrate. In some cases, the second chemical layer has a low surface energy. In some cases, surface energy of a chemical layer coated on a surface supports localization of droplets on the surface. Depending on the patterning arrangement selected, the proximity of loci and/or area of fluid contact at the loci are alterable.
In some instances, a substrate surface, or resolved loci, onto which nucleic acids or other moieties are deposited, e.g., for polynucleotide synthesis, are smooth or substantially planar (e.g., two-dimensional) or have irregularities, such as raised or lowered features (e.g., three-dimensional features). In some instances, a substrate surface is modified with one or more different layers of compounds. Such modification layers of interest include, without limitation, inorganic and organic layers such as metals, metal oxides, polymers, small organic molecules and the like.
In some instances, resolved loci of a substrate are functionalized with one or more moieties that increase and/or decrease surface energy. In some cases, a moiety is chemically inert. In some cases, a moiety is configured to support a desired chemical reaction, for example, one or more processes in a polynucleotide synthesis reaction. The surface energy, or hydrophobicity, of a surface is a factor for determining the affinity of a nucleotide to attach onto the surface. In some instances, a method for substrate functionalization comprises: (a) providing a substrate having a surface that comprises silicon dioxide; and (b) silanizing the surface using, a suitable silanizing agent described herein or otherwise known in the art, for example, an organofunctional alkoxysilane molecule. Methods and functionalizing agents are described in U.S. Pat. No. 5,474,796, which is herein incorporated by reference in its entirety.
In some instances, a substrate surface is functionalized by contact with a derivatizing composition that contains a mixture of silanes, under reaction conditions effective to couple the silanes to the substrate surface, typically via reactive hydrophilic moieties present on the substrate surface. Silanization generally covers a surface through self-assembly with organofunctional alkoxysilane molecules. A variety of siloxane functionalizing reagents can further be used as currently known in the art, e.g., for lowering or increasing surface energy. The organofunctional alkoxysilanes are classified according to their organic functions.
Polynucleotide Synthesis
Methods of the current disclosure for polynucleotide synthesis may include processes involving phosphoramidite chemistry. In some instances, polynucleotide synthesis comprises coupling a base with phosphoramidite. Polynucleotide synthesis may comprise coupling a base by deposition of phosphoramidite under coupling conditions, wherein the same base is optionally deposited with phosphoramidite more than once, i.e., double coupling. Polynucleotide synthesis may comprise capping of unreacted sites. In some instances, capping is optional. Polynucleotide synthesis may also comprise oxidation or an oxidation step or oxidation steps. Polynucleotide synthesis may comprise deblocking, detritylation, and sulfurization. In some instances, polynucleotide synthesis comprises either oxidation or sulfurization. In some instances, between one or each step during a polynucleotide synthesis reaction, the device is washed, for example, using tetrazole or acetonitrile. Time frames for any one step in a phosphoramidite synthesis method may be less than about 2 min, 1 min, 50 sec, 40 sec, 30 sec, 20 sec and 10 sec.
Polynucleotide synthesis using a phosphoramidite method may comprise a subsequent addition of a phosphoramidite building block (e.g., nucleoside phosphoramidite) to a growing polynucleotide chain for the formation of a phosphite triester linkage. Phosphoramidite polynucleotide synthesis proceeds in the 3′ to 5′ direction. Phosphoramidite polynucleotide synthesis allows for the controlled addition of one nucleotide to a growing nucleic acid chain per synthesis cycle. In some instances, each synthesis cycle comprises a coupling step. Phosphoramidite coupling involves the formation of a phosphite triester linkage between an activated nucleoside phosphoramidite and a nucleoside bound to the substrate, for example, via a linker. In some instances, the nucleoside phosphoramidite is provided to the device activated. In some instances, the nucleoside phosphoramidite is provided to the device with an activator. In some instances, nucleoside phosphoramidites are provided to the device in a 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100-fold excess or more over the substrate-bound nucleosides. In some instances, the addition of nucleoside phosphoramidite is performed in an anhydrous environment, for example, in anhydrous acetonitrile. Following addition of a nucleoside phosphoramidite, the device is optionally washed. In some instances, the coupling step is repeated one or more additional times, optionally with a wash step between nucleoside phosphoramidite additions to the substrate. In some instances, a polynucleotide synthesis method used herein comprises 1, 2, 3 or more sequential coupling steps. Prior to coupling, in many cases, the nucleoside bound to the device is de-protected by removal of a protecting group, where the protecting group functions to prevent polymerization. A common protecting group is 4,4′-dimethoxytrityl (DMT).
Following coupling, phosphoramidite polynucleotide synthesis methods optionally comprise a capping step. In a capping step, the growing polynucleotide is treated with a capping agent. A capping step is useful to block unreacted substrate-bound 5′—OH groups after coupling from further chain elongation, preventing the formation of polynucleotides with internal base deletions. Further, phosphoramidites activated with 1H-tetrazole may react, to a small extent, with the O6 position of guanosine. Without being bound by theory, upon oxidation with I2/water, this side product, possibly via O6-N7 migration, may undergo depurination. The apurinic sites may end up being cleaved in the course of the final deprotection of the polynucleotide thus reducing the yield of the full-length product. The O6 modifications may be removed by treatment with the capping reagent prior to oxidation with I2/water. In some instances, inclusion of a capping step during polynucleotide synthesis decreases the error rate as compared to synthesis without capping. As an example, the capping step comprises treating the substrate-bound polynucleotide with a mixture of acetic anhydride and 1-methylimidazole. Following a capping step, the device is optionally washed.
In some instances, following addition of a nucleoside phosphoramidite, and optionally after capping and one or more wash steps, the device bound growing nucleic acid is oxidized. The oxidation step comprises the phosphite triester is oxidized into a tetracoordinated phosphate triester, a protected precursor of the naturally occurring phosphate diester internucleoside linkage. In some instances, oxidation of the growing polynucleotide is achieved by treatment with iodine and water, optionally in the presence of a weak base (e.g., pyridine, lutidine, collidine). Oxidation may be carried out under anhydrous conditions using, e.g. tert-Butyl hydroperoxide or (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (CSO). In some methods, a capping step is performed following oxidation. A second capping step allows for device drying, as residual water from oxidation that may persist can inhibit subsequent coupling. Following oxidation, the device and growing polynucleotide is optionally washed. In some instances, the step of oxidation is substituted with a sulfurization step to obtain polynucleotide phosphorothioates, wherein any capping steps can be performed after the sulfurization. Many reagents are capable of the efficient sulfur transfer, including but not limited to 3-(Dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-3-thione, DDTT, 3H-1,2-benzodithiol-3-one 1,1-dioxide, also known as Beaucage reagent, and N,N,N′N′-Tetraethylthiuram disulfide (TETD).
In order for a subsequent cycle of nucleoside incorporation to occur through coupling, the protected 5′ end of the device bound growing polynucleotide is removed so that the primary hydroxyl group is reactive with a next nucleoside phosphoramidite. In some instances, the protecting group is DMT and deblocking occurs with trichloroacetic acid in dichloromethane. Conducting detritylation for an extended time or with stronger than recommended solutions of acids may lead to increased depurination of solid support-bound polynucleotide and thus reduces the yield of the desired full-length product. Methods and compositions of the disclosure described herein provide for controlled deblocking conditions limiting undesired depurination reactions. In some instances, the device bound polynucleotide is washed after deblocking. In some instances, efficient washing after deblocking contributes to synthesized polynucleotides having a low error rate.
Methods for the synthesis of polynucleotides typically involve an iterating sequence of the following steps: application of a protected monomer to an actively functionalized surface (e.g., locus) to link with either the activated surface, a linker or with a previously deprotected monomer; deprotection of the applied monomer so that it is reactive with a subsequently applied protected monomer; and application of another protected monomer for linking. One or more intermediate steps include oxidation or sulfurization. In some instances, one or more wash steps precede or follow one or all of the steps.
Methods for phosphoramidite-based polynucleotide synthesis comprise a series of chemical steps. In some instances, one or more steps of a synthesis method involve reagent cycling, where one or more steps of the method comprise application to the device of a reagent useful for the step. For example, reagents are cycled by a series of liquid deposition and vacuum drying steps. For substrates comprising three-dimensional features such as wells, microwells, channels and the like, reagents are optionally passed through one or more regions of the device via the wells and/or channels.
Methods and systems described herein relate to polynucleotide synthesis devices for the synthesis of polynucleotides. The synthesis may be in parallel. For example, at least or about at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 10000, 50000, 75000, 100000 or more polynucleotides can be synthesized in parallel. The total number polynucleotides that may be synthesized in parallel may be from 2-100000, 3-50000, 4-10000, 5-1000, 6-900, 7-850, 8-800, 9-750, 10-700, 11-650, 12-600, 13-550, 14-500, 15-450, 16-400, 17-350, 18-300, 19-250, 20-200, 21-150,22-100, 23-50, 24-45, 25-40, 30-35. Those of skill in the art appreciate that the total number of polynucleotides synthesized in parallel may fall within any range bound by any of these values, for example 25-100. The total number of polynucleotides synthesized in parallel may fall within any range defined by any of the values serving as endpoints of the range. Total molar mass of polynucleotides synthesized within the device or the molar mass of each of the polynucleotides may be at least or at least about 10, 20, 30, 40, 50, 100, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 25000, 50000, 75000, 100000 picomoles, or more. The length of each of the polynucleotides or average length of the polynucleotides within the device may be at least or about at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 400, 500 nucleotides, or more. The length of each of the polynucleotides or average length of the polynucleotides within the device may be at most or about at most 500, 400, 300, 200, 150, 100, 50, 45, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 nucleotides, or less. The length of each of the polynucleotides or average length of the polynucleotides within the device may fall from 10-500, 9-400, 11-300, 12-200, 13-150, 14-100, 15-50, 16-45, 17-40, 18-35, 19-25. Those of skill in the art appreciate that the length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range bound by any of these values, for example 100-300. The length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range defined by any of the values serving as endpoints of the range.
Methods for polynucleotide synthesis on a surface provided herein allow for synthesis at a fast rate. As an example, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 125, 150, 175, 200 nucleotides per hour, or more are synthesized. Nucleotides include adenine, guanine, thymine, cytosine, uridine building blocks, or analogs/modified versions thereof. In some instances, libraries of polynucleotides are synthesized in parallel on substrate. For example, a device comprising about or at least about 100; 1,000; 10,000; 30,000; 75,000; 100,000; 1,000,000; 2,000,000; 3,000,000; 4,000,000; or 5,000,000 resolved loci is able to support the synthesis of at least the same number of distinct polynucleotides, wherein polynucleotide encoding a distinct sequence is synthesized on a resolved locus. In some instances, a library of polynucleotides is synthesized on a device with low error rates described herein in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours or less. In some instances, larger nucleic acids assembled from a polynucleotide library synthesized with low error rate using the substrates and methods described herein are prepared in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours or less.
In some instances, methods described herein provide for generation of a library of nucleic acids comprising variant nucleic acids differing at a plurality of codon sites. In some instances, a nucleic acid may have 1 site, 2 sites, 3 sites, 4 sites, 5 sites, 6 sites, 7 sites, 8 sites, 9 sites, 10 sites, 11 sites, 12 sites, 13 sites, 14 sites, 15 sites, 16 sites, 17 sites 18 sites, 19 sites, 20 sites, 30 sites, 40 sites, 50 sites, or more of variant codon sites.
In some instances, the one or more sites of variant codon sites may be adjacent. In some instances, the one or more sites of variant codon sites may not be adjacent and separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more codons.
In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein all the variant codon sites are adjacent to one another, forming a stretch of variant codon sites. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein none the variant codon sites are adjacent to one another. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein some the variant codon sites are adjacent to one another, forming a stretch of variant codon sites, and some of the variant codon sites are not adjacent to one another.
Referring to the Figures, FIG. 7 illustrates an exemplary process workflow for synthesis of nucleic acids (e.g., genes) from shorter nucleic acids. The workflow is divided generally into phases: (1) de novo synthesis of a single stranded nucleic acid library, (2) joining nucleic acids to form larger fragments, (3) error correction, (4) quality control, and (5) shipment. Prior to de novo synthesis, an intended nucleic acid sequence or group of nucleic acid sequences is preselected. For example, a group of genes is preselected for generation.
Once large nucleic acids for generation are selected, a predetermined library of nucleic acids is designed for de novo synthesis. Various suitable methods are known for generating high density polynucleotide arrays. In the workflow example, a device surface layer is provided. In the example, chemistry of the surface is altered in order to improve the polynucleotide synthesis process. Areas of low surface energy are generated to repel liquid while areas of high surface energy are generated to attract liquids. The surface itself may be in the form of a planar surface or contain variations in shape, such as protrusions or microwells which increase surface area. In the workflow example, high surface energy molecules selected serve a dual function of supporting DNA chemistry, as disclosed in International Patent Application Publication WO/2015/021080, which is herein incorporated by reference in its entirety.
In situ preparation of polynucleotide arrays is generated on a solid support and utilizes single nucleotide extension process to extend multiple oligomers in parallel. A deposition device, such as a material deposition device, is designed to release reagents in a step wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 702. In some instances, polynucleotides are cleaved from the surface at this stage. Cleavage includes gas cleavage, e.g., with ammonia or methylamine.
The generated polynucleotide libraries are placed in a reaction chamber. In this exemplary workflow, the reaction chamber (also referred to as “nanoreactor”) is a silicon coated well, containing PCR reagents and lowered onto the polynucleotide library 703. Prior to or after the sealing 704 of the polynucleotides, a reagent is added to release the polynucleotides from the substrate. In the exemplary workflow, the polynucleotides are released subsequent to sealing of the nanoreactor 705. Once released, fragments of single stranded polynucleotides hybridize in order to span an entire long range sequence of DNA. Partial hybridization 705 is possible because each synthesized polynucleotide is designed to have a small portion overlapping with at least one other polynucleotide in the pool.
After hybridization, a PCA reaction is commenced. During the polymerase cycles, the polynucleotides anneal to complementary fragments and gaps are filled in by a polymerase. Each cycle increases the length of various fragments randomly depending on which polynucleotides find each other. Complementarity amongst the fragments allows for forming a complete large span of double stranded DNA 706.
After PCA is complete, the nanoreactor is separated from the device 707 and positioned for interaction with a device having primers for PCR 708. After sealing, the nanoreactor is subject to PCR 709 and the larger nucleic acids are amplified. After PCR 710, the nanochamber is opened 711, error correction reagents are added 712, the chamber is sealed 713 and an error correction reaction occurs to remove mismatched base pairs and/or strands with poor complementarity from the double stranded PCR amplification products 714. The nanoreactor is opened and separated 715. Error corrected product is next subject to additional processing steps, such as PCR and molecular bar coding, and then packaged 722 for shipment 723.
In some instances, quality control measures are taken. After error correction, quality control steps include for example interaction with a wafer having sequencing primers for amplification of the error corrected product 716, sealing the wafer to a chamber containing error corrected amplification product 717, and performing an additional round of amplification 718. The nanoreactor is opened 719 and the products are pooled 720 and sequenced 721. After an acceptable quality control determination is made, the packaged product 722 is approved for shipment 723.
In some instances, a nucleic acid generate by a workflow such as that in FIG. 7 is subject to mutagenesis using overlapping primers disclosed herein. In some instances, a library of primers are generated by in situ preparation on a solid support and utilize single nucleotide extension process to extend multiple oligomers in parallel. A deposition device, such as a material deposition device, is designed to release reagents in a step wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 702.
Computer Systems
Any of the systems described herein, may be operably linked to a computer and may be automated through a computer either locally or remotely. In various instances, the methods and systems of the disclosure may further comprise software programs on computer systems and use thereof. Accordingly, computerized control for the synchronization of the dispense/vacuum/refill functions such as orchestrating and synchronizing the material deposition device movement, dispense action and vacuum actuation are within the bounds of the disclosure. The computer systems may be programmed to interface between the user specified base sequence and the position of a material deposition device to deliver the correct reagents to specified regions of the substrate.
The computer system 800 illustrated in FIG. 8 may be understood as a logical apparatus that can read instructions from media 811 and/or a network port 805, which can optionally be connected to server 809 having fixed media 812. The system, such as shown in FIG. 8 can include a CPU 801, disk drives 803, optional input devices such as keyboard 815 and/or mouse 816 and optional monitor 807. Data communication can be achieved through the indicated communication medium to a server at a local or a remote location. The communication medium can include any means of transmitting and/or receiving data. For example, the communication medium can be a network connection, a wireless connection or an internet connection. Such a connection can provide for communication over the World Wide Web. It is envisioned that data relating to the present disclosure can be transmitted over such networks or connections for reception and/or review by a party 822 as illustrated in FIG. 8.
FIG. 14 is a block diagram illustrating a first example architecture of a computer system 1400 that can be used in connection with example instances of the present disclosure. As depicted in FIG. 14, the example computer system can include a processor 1402 for processing instructions. Non-limiting examples of processors include: Intel Xeon™ processor, AMD Opteron™ processor, Samsung 32-bit RISC ARM 1176JZ(F)-S v1.0TM processor, ARM Cortex-A8 Samsung S5PC100TM processor, ARM Cortex-A8 Apple A4TM processor, Marvell PXA 930TM processor, or a functionally-equivalent processor. Multiple threads of execution can be used for parallel processing. In some instances, multiple processors or processors with multiple cores can also be used, whether in a single computer system, in a cluster, or distributed across systems over a network comprising a plurality of computers, cell phones, and/or personal data assistant devices.
As illustrated in FIG. 9, a high speed cache 904 can be connected to, or incorporated in, the processor 902 to provide a high speed memory for instructions or data that have been recently, or are frequently, used by processor 902. The processor 902 is connected to a north bridge 906 by a processor bus 908. The north bridge 906 is connected to random access memory (RAM) 910 by a memory bus 912 and manages access to the RAM 910 by the processor 902. The north bridge 906 is also connected to a south bridge 914 by a chipset bus 916. The south bridge 914 is, in turn, connected to a peripheral bus 918. The peripheral bus can be, for example, PCI, PCI-X, PCI Express, or other peripheral bus. The north bridge and south bridge are often referred to as a processor chipset and manage data transfer between the processor, RAM, and peripheral components on the peripheral bus 918. In some alternative architectures, the functionality of the north bridge can be incorporated into the processor instead of using a separate north bridge chip. In some instances, system 900 can include an accelerator card 922 attached to the peripheral bus 918. The accelerator can include field programmable gate arrays (FPGAs) or other hardware for accelerating certain processing. For example, an accelerator can be used for adaptive data restructuring or to evaluate algebraic expressions used in extended set processing.
Software and data are stored in external storage 924 and can be loaded into RAM 910 and/or cache 904 for use by the processor. The system 900 includes an operating system for managing system resources; non-limiting examples of operating systems include: Linux, Windows™, MACOS™, BlackBerry OS™, iOS™, and other functionally-equivalent operating systems, as well as application software running on top of the operating system for managing data storage and optimization in accordance with example instances of the present disclosure. In this example, system 900 also includes network interface cards (NICs) 920 and 921 connected to the peripheral bus for providing network interfaces to external storage, such as Network Attached Storage (NAS) and other computer systems that can be used for distributed parallel processing.
FIG. 10 is a diagram showing a network 1000 with a plurality of computer systems 1002a, and 1002b, a plurality of cell phones and personal data assistants 1002c, and Network Attached Storage (NAS) 1004a, and 1004b. In example instances, systems 1002a, 1002b, and 1002c can manage data storage and optimize data access for data stored in Network Attached Storage (NAS) 1004a and 1004b. A mathematical model can be used for the data and be evaluated using distributed parallel processing across computer systems 1002a, and 1002b, and cell phone and personal data assistant systems 1002c. Computer systems 1002a, and 1002b, and cell phone and personal data assistant systems 1002c can also provide parallel processing for adaptive data restructuring of the data stored in Network Attached Storage (NAS) 1004a and 1004b. FIG. 10 illustrates an example only, and a wide variety of other computer architectures and systems can be used in conjunction with the various instances of the present disclosure. For example, a blade server can be used to provide parallel processing. Processor blades can be connected through a back plane to provide parallel processing. Storage can also be connected to the back plane or as Network Attached Storage (NAS) through a separate network interface. In some example instances, processors can maintain separate memory spaces and transmit data through network interfaces, back plane or other connectors for parallel processing by other processors. In other instances, some or all of the processors can use a shared virtual address memory space.
FIG. 11 is a block diagram of a multiprocessor computer system 1100 using a shared virtual address memory space in accordance with an example instance. The system includes a plurality of processors 1102a-f that can access a shared memory subsystem 1104. The system incorporates a plurality of programmable hardware memory algorithm processors (MAPs) 1106a-f in the memory subsystem 1104. Each MAP 1106a-f can comprise a memory 1108a-f and one or more field programmable gate arrays (FPGAs) 1110a-f. The MAP provides a configurable functional unit and particular algorithms or portions of algorithms can be provided to the FPGAs 1110a-f for processing in close coordination with a respective processor. For example, the MAPs can be used to evaluate algebraic expressions regarding the data model and to perform adaptive data restructuring in example instances. In this example, each MAP is globally accessible by all of the processors for these purposes. In one configuration, each MAP can use Direct Memory Access (DMA) to access an associated memory 1108a-f, allowing it to execute tasks independently of, and asynchronously from the respective microprocessor 1102a-f In this configuration, a MAP can feed results directly to another MAP for pipelining and parallel execution of algorithms.
The above computer architectures and systems are examples only, and a wide variety of other computer, cell phone, and personal data assistant architectures and systems can be used in connection with example instances, including systems using any combination of general processors, co-processors, FPGAs and other programmable logic devices, system on chips (SOCs), application specific integrated circuits (ASICs), and other processing and logic elements. In some instances, all or part of the computer system can be implemented in software or hardware. Any variety of data storage media can be used in connection with example instances, including random access memory, hard drives, flash memory, tape drives, disk arrays, Network Attached Storage (NAS) and other local or distributed data storage devices and systems.
In example instances, the computer system can be implemented using software modules executing on any of the above or other computer architectures and systems. In other instances, the functions of the system can be implemented partially or completely in firmware, programmable logic devices such as field programmable gate arrays (FPGAs) as referenced in FIG. 9, system on chips (SOCs), application specific integrated circuits (ASICs), or other processing and logic elements. For example, the Set Processor and Optimizer can be implemented with hardware acceleration through the use of a hardware accelerator card, such as accelerator card 922 illustrated in FIG. 9.
The following examples are set forth to illustrate more clearly the principle and practice of embodiments disclosed herein to those skilled in the art and are not to be construed as limiting the scope of any claimed embodiments. Unless otherwise stated, all parts and percentages are on a weight basis.
EXAMPLES The following examples are given for the purpose of illustrating various embodiments of the disclosure and are not meant to limit the present disclosure in any fashion. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the disclosure. Changes therein and other uses which are encompassed within the spirit of the disclosure as defined by the scope of the claims will occur to those skilled in the art.
Example 1: Functionalization of a Device Surface A device was functionalized to support the attachment and synthesis of a library of polynucleotides. The device surface was first wet cleaned using a piranha solution comprising 90% H2SO4 and 10% H2O2 for 20 minutes. The device was rinsed in several beakers with DI water, held under a DI water gooseneck faucet for 5 min, and dried with N2. The device was subsequently soaked in NH4OH (1:100; 3 mL:300 mL) for 5 min, rinsed with DI water using a handgun, soaked in three successive beakers with DI water for 1 min each, and then rinsed again with DI water using the handgun. The device was then plasma cleaned by exposing the device surface to O2. A SAMCO PC-300 instrument was used to plasma etch O2 at 250 watts for 1 min in downstream mode.
The cleaned device surface was actively functionalized with a solution comprising N-(3-triethoxysilylpropyl)-4-hydroxybutyramide using a YES-1224P vapor deposition oven system with the following parameters: 0.5 to 1 torr, 60 min, 70° C., 135° C. vaporizer. The device surface was resist coated using a Brewer Science 200X spin coater. SPR™ 3612 photoresist was spin coated on the device at 2500 rpm for 40 sec. The device was pre-baked for 30 min at 90° C. on a Brewer hot plate. The device was subjected to photolithography using a Karl Suss MA6 mask aligner instrument. The device was exposed for 2.2 sec and developed for 1 min in MSF 26A. Remaining developer was rinsed with the handgun and the device soaked in water for 5 min. The device was baked for 30 min at 100° C. in the oven, followed by visual inspection for lithography defects using a Nikon L200. A descum process was used to remove residual resist using the SAMCO PC-300 instrument to O2 plasma etch at 250 watts for 1 min.
The device surface was passively functionalized with a 100 μL solution of perfluorooctyltrichlorosilane mixed with 10 μL light mineral oil. The device was placed in a chamber, pumped for 10 min, and then the valve was closed to the pump and left to stand for 10 min. The chamber was vented to air. The device was resist stripped by performing two soaks for 5 min in 500 mL NMP at 70° C. with ultrasonication at maximum power (9 on Crest system). The device was then soaked for 5 min in 500 mL isopropanol at room temperature with ultrasonication at maximum power. The device was dipped in 300 mL of 200 proof ethanol and blown dry with N2. The functionalized surface was activated to serve as a support for polynucleotide synthesis.
Example 2: Synthesis of a 50-Mer Sequence on an Oligonucleotide Synthesis Device A two dimensional oligonucleotide synthesis device was assembled into a flowcell, which was connected to a flowcell (Applied Biosystems (ABI394 DNA Synthesizer”). The two-dimensional oligonucleotide synthesis device was uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4-HYDROXYBUTYRAMIDE (Gelest) was used to synthesize an exemplary polynucleotide of 50 bp (“50-mer polynucleotide”) using polynucleotide synthesis methods described herein.
The sequence of the 50-mer was as described in SEQ ID NO.: 48. 5′AGACAATCAACCATTTGGGGTGGACAGCCTTGACCTCTAGACTTCGGCAT⊥⊥TTTTTTT TTT3′ (SEQ ID NO.: 48), where # denotes Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes), which is a cleavable linker enabling the release of oligos from the surface during deprotection.
The synthesis was done using standard DNA synthesis chemistry (coupling, capping, oxidation, and deblocking) according to the protocol in Table 4 and an ABI synthesizer.
TABLE 4
Synthesis protocols
General DNA Synthesis Time
Process Name Process Step (sec)
WASH (Acetonitrile Wash Acetonitrile System Flush 4
Flow) Acetonitrile to Flowcell 23
N2 System Flush 4
Acetonitrile System Flush 4
DNA BASE ADDITION Activator Manifold Flush 2
(Phosphoramidite + Activator to Flowcell 6
Activator Flow) Activator + 6
Phosphoramidite to
Flowcell
Activator to Flowcell 0.5
Activator + 5
Phosphoramidite to
Flowcell
Activator to Flowcell 0.5
Activator + 5
Phosphoramidite to
Flowcell
Activator to Flowcell 0.5
Activator + 5
Phosphoramidite to
Flowcell
Incubate for 25 sec 25
WASH (Acetonitrile Wash Acetonitrile System Flush 4
Flow) Acetonitrile to Flowcell 15
N2 System Flush 4
Acetonitrile System Flush 4
DNA BASE ADDITION Activator Manifold Flush 2
(Phosphoramidite + Activator to Flowcell 5
Activator Flow) Activator + 18
Phosphoramidite to
Flowcell
Incubate for 25 sec 25
WASH (Acetonitrile Wash Acetonitrile System Flush 4
Flow) Acetonitrile to Flowcell 15
N2 System Flush 4
Acetonitrile System Flush 4
CAPPING (CapA + B, 1:1, CapA + B to Flowcell 15
Flow)
WASH (Acetonitrile Wash Acetonitrile System Flush 4
Flow) Acetonitrile to Flowcell 15
Acetonitrile System Flush 4
OXIDATION (Oxidizer Oxidizer to Flowcell 18
Flow)
WASH (Acetonitrile Wash Acetonitrile System Flush 4
Flow) N2 System Flush 4
Acetonitrile System Flush 4
Acetonitrile to Flowcell 15
Acetonitrile System Flush 4
Acetonitrile to Flowcell 15
N2 System Flush 4
Acetonitrile System Flush 4
Acetonitrile to Flowcell 23
N2 System Flush 4
Acetonitrile System Flush 4
DEBLOCKING (Deblock Deblock to Flowcell 36
Flow)
WASH (Acetonitrile Wash Acetonitrile System Flush 4
Flow) N2 System Flush 4
Acetonitrile System Flush 4
Acetonitrile to Flowcell 18
N2 System Flush 4.13
Acetonitrile System Flush 4.13
Acetonitrile to Flowcell 15
The phosphoramidite/activator combination was delivered similar to the delivery of bulk reagents through the flowcell. No drying steps were performed as the environment stays “wet” with reagent the entire time.
The flow restrictor was removed from the ABI 394 synthesizer to enable faster flow. Without flow restrictor, flow rates for amidites (0.1M in ACN), Activator, (0.25M Benzoylthiotetrazole (“BTT”; 30-3070-xx from GlenResearch) in ACN), and Ox (0.02M 12 in 20% pyridine, 10% water, and 70% THF) were roughly ˜100 uL/sec, for acetonitrile (“ACN”) and capping reagents (1:1 mix of CapA and CapB, wherein CapA is acetic anhydride in THF/Pyridine and CapB is 16% 1-methylimidizole in THF), roughly ˜200 uL/sec, and for Deblock (3% dichloroacetic acid in toluene), roughly ˜300 uL/sec (compared to ˜50 uL/sec for all reagents with flow restrictor). The time to completely push out Oxidizer was observed, the timing for chemical flow times was adjusted accordingly and an extra ACN wash was introduced between different chemicals. After polynucleotide synthesis, the chip was deprotected in gaseous ammonia overnight at 75 psi. Five drops of water were applied to the surface to recover polynucleotides. The recovered polynucleotides were then analyzed on a BioAnalyzer small RNA chip.
Example 3: Synthesis of a 100-Mer Sequence on an Oligonucleotide Synthesis Device The same process as described in Example 2 for the synthesis of the 50-mer sequence was used for the synthesis of a 100-mer polynucleotide (“100-mer polynucleotide”; 5′ CGGGATCCTTATCGTCATCGTCGTACAGATCCCGACCCATTTGCTGTCCACCAGTCATG CTAGCCATACCATGATGATGATGATGATGAGAACCCCGCAT ##TTTTTTTTTT3′, where # denotes Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes); SEQ ID NO.: 49) on two different silicon chips, the first one uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4-HYDROXYBUTYRAMIDE and the second one functionalized with 5/95 mix of 11-acetoxyundecyltriethoxysilane and n-decyltriethoxysilane, and the polynucleotides extracted from the surface were analyzed on a BioAnalyzer instrument.
All ten samples from the two chips were further PCR amplified using a forward (5′ATGCGGGGTTCTCATCATC3′; SEQ ID NO.: 50) and a reverse (5′CGGGATCCTTATCGTCATCG3′; SEQ ID NO.: 51) primer in a 50 uL PCR mix (25 uL NEB Q5 mastermix, 2.5 uL 10 uM Forward primer, 2.5 uL 10 uM Reverse primer, 1 uL polynucleotide extracted from the surface, and water up to 50 uL) using the following thermalcycling program:
98° C., 30 sec
98° C., 10 sec; 63° C., 10 sec; 72° C., 10 sec; repeat 12 cycles
72° C., 2 min
The PCR products were also run on a BioAnalyzer, demonstrating sharp peaks at the 100-mer position. Next, the PCR amplified samples were cloned, and Sanger sequenced. Table 5 summarizes the results from the Sanger sequencing for samples taken from spots 1-5 from chip 1 and for samples taken from spots 6-10 from chip 2.
TABLE 5
Sequencing results
Spot Error rate Cycle efficiency
1 1/763 bp 99.87%
2 1/824 bp 99.88%
3 1/780 bp 99.87%
4 1/429 bp 99.77%
5 1/1525 bp 99.93%
6 1/1615 bp 99.94%
7 1/531 bp 99.81%
8 1/1769 bp 99.94%
9 1/854 bp 99.88%
10 1/1451 bp 99.93%
Thus, the high quality and uniformity of the synthesized polynucleotides were repeated on two chips with different surface chemistries. Overall, 89% of the 100-mers that were sequenced were perfect sequences with no errors, corresponding to 233 out of 262.
Table 6 summarizes error characteristics for the sequences obtained from the polynucleotides samples from spots 1-10.
TABLE 6
Error characteristics
Sample ID/Spot no.
OSA_0046/1 OSA_0047/2 OSA_0048/3 OSA_0049/4 OSA_0050/5 OSA_0051/6
Total 32 32 32 32 32 32
Sequences
Sequencing 25 of 28 27 of 27 26 of 30 21 of 23 25 of 26 29 of 30
Quality
Oligo 23 of 25 25 of 27 22 of 26 18 of 21 24 of 25 25 of 29
Quality
ROI 2500 2698 2561 2122 2499 2666
Match
Count
ROI 2 2 1 3 1 0
Mutation
ROI Multi 0 0 0 0 0 0
Base
Deletion
ROI Small 1 0 0 0 0 0
Insertion
ROI 0 0 0 0 0 0
Single
Base
Deletion
Large 0 0 1 0 0 1
Deletion
Count
Mutation: 2 2 1 2 1 0
G > A
Mutation: 0 0 0 1 0 0
T > C
ROI Error 3 2 2 3 1 1
Count
ROI Error Err: ~1 Err: ~1 Err: ~1 Err: ~1 Err: ~1 Err: ~1
Rate in 834 in 1350 in 1282 in 708 in 2500 in 2667
ROI MP MP MP MP MP MP
Minus Err: ~1 Err: ~1 Err: ~1 Err: ~1 Err: ~1 Err: ~1
Primer in 763 in 824 in 780 in 429 in 1525 in 1615
Error Rate
Sample ID/Spot no.
OSA_0052/7 OSA_0053/8 OSA_0054/9 OSA_0055/10
Total 32 32 32 32
Sequences
Sequencing 27 of 31 29 of 31 28 of 29 25 of 28
Quality
Oligo 22 of 27 28 of 29 26 of 28 20 of 25
Quality
ROI 2625 2899 2798 2348
Match
Count
ROI 2 1 2 1
Mutation
ROI Multi 0 0 0 0
Base
Deletion
ROI Small 0 0 0 0
Insertion
ROI 0 0 0 0
Single
Base
Deletion
Large 1 0 0 0
Deletion
Count
Mutation: 2 1 2 1
G > A
Mutation: 0 0 0 0
T > C
ROI Error 3 1 2 1
Count
ROI Error Err: ~1 Err: ~1 Err: ~1 Err: ~1
Rate in 876 in 2900 in 1400 in 2349
ROI MP MP MP MP
Minus Err: ~1 Err: ~1 Err: ~1 Err: ~1
Primer in 531 in 1769 in 854 in 1451
Error Rate
Example 4: Design of G Protein-Coupled Receptor Binding Domains Based on Conformational Ligand Interactions G protein-coupled receptor (GPCR) binding domains were designed using interaction surfaces between conformational ligands that interact with GPCRs. Analysis of the interaction surfaces between chemokines and cytokines and the GPCRs indicated that the N-terminal peptide prior to the first conformational cysteine represents the activation peptide, and the core helical and beta-turn-beta topologies mediate interactions with the extracellular domain (ECD) of the GPCR.
An additional 254 GPCR ligands were designed based on cross-searching Uniprot and IUPHAR databases. The ligands represented 112 human, 71 rat, 4 pig, 1 sheep, and 1 cow derived interaction classes. The ligands were then collapsed to the following 101 cross-species ligand sequence annotations: ADM, ADM2, Agouti-related protein, Angiotensinogen, Annexin A1, Apelin, Apelin receptor early, Appetite regulating hormone, Beta-defensin 4A, C-C motif chemokine, C—X—C motif chemokine, Calcitonin, Calcitonin gene-related peptide, Cathepsin G, Cathepsin G (Fragment), Cholecystokinin, Complement C3, Complement C5, Complement C5 (Fragment), Corticoliberin, Cortistatin, Cytokine SCM-1 beta, Endothelin-2, Endothelin-3, Eotaxin, Fractalkine, Galanin peptides, Galanin-like peptide, Gastric inhibitory polypeptide, Gastrin, Gastrin-releasing peptide, Glucagon, Growth-regulated alpha protein, Heme-binding protein 1, Humanin, Insulin-like 3, Insulin-like peptide INSL5, Interleukin-8, Islet amyloid polypeptide, Kininogen-1, Lymphotactin, Metastasis-suppressor KiSS-1, Neurokinin-B, Neuromedin-B, Neuromedin-S, Neuromedin-U, Neuropeptide B, Neuropeptide S, Neuropeptide W, Neurotensin/neuromedin N, Orexigenic neuropeptide QRFP, Orexin, Oxytocin-neurophysin 1, Pancreatic prohormone, Parathyroid hormone, Parathyroid hormone-related protein, Peptide YY, Pituitary adenylate cyclase-activating, Platelet basic protein, Platelet factor 4, Prepronociceptin, Pro-FMRFamide-related neuropeptide FF, Pro-FMRFamide-related neuropeptide VF, Pro-MCH, Pro-neuropeptide Y, Pro-opiomelanocortin, Pro-thyrotropin releasing hormone, Proenkephalin-A, Proenkephalin-B, Progonadoliberin-1, Progonadoliberin-2, Prokineticin-1, Prokineticin-2, Prolactin-releasing peptide, Promotilin, Protachykinin-1, Protein Wnt-2, Protein Wnt-3 a, Protein Wnt-4, Protein Wnt-5a, Protein Wnt-7b, Prothrombin, Proto-oncogene Wnt-1, Protooncogene Wnt-3, Putative uncharacterized protein, RCG55748, Retinoic acid receptor, Secretin, Somatoliberin, Somatostatin, Stromal cell-derived factor, T-kininogen 2, Tuberoinfundibular peptide of, Urocortin, Urocortin-2, Urocortin-3, Urotensin-2, Urotensin-2B, VEGF coregulated chemokine, VIP peptides, and Vasopressin-neurophysin 2-copeptin.
Structural analysis of the ligands was performed and indicated that a majority of them comprised the N-terminal activation peptide of about 11 amino acids. Motif variants were then created by trimming back the N-terminal activation peptide. As seen in Table 7, an exemplary set of variants were created based on the N-terminal activation peptide for stromal derived factor-1. The motif variants were also placed combinatorially at multiple positions in the CDR-H3. A total of 1016 motifs were extracted for placement in the CDR-H3. In addition, the motif variants were provided with variably boundary placement and with 5-20 substring variants that were also placed in the CDR-H3.
TABLE 7
Variant amino acid sequences for
stromal derived factor-1
SEQ
ID
NO. Variant Amino Acid Sequence
53 1 ggggSDYKPVSLSYR
54 2 ggggDYKPVSLSYR
55 3 ggggYKPVSLSYR
56 4 ggggKPVSLSYR
57 5 ggggPVSLSYR
As seen in Table 8, an exemplary set of variants were created for interleukin-8 based on the following sequence:
(SEQ ID NO: 52)
MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTY
SKPFHPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDP
KENWVQRVVEKFLKRAENS.
TABLE 8
Variant amino acid sequences
for inteleukin-8
SEQ
ID
NO. Variant Amino Acid Sequence
58 1 ggggSAALCEGAVLPRSA
59 2 ggggAALCEGAVLPRSA
60 3 ggggALCEGAVLPRSA
61 4 ggggLCEGAVLPRSA
62 5 ggggCEGAVLPRSA
63 6 ggggSAALCEGAVLPRSAKE
64 7 ggggAALCEGAVLPRSAKE
65 8 ggggALCEGAVLPRSAKE
66 9 ggggLCEGAVLPRSAKE
67 10 ggggCEGAVLPRSAKE
68 11 ggggSAALCEGAVLPRSAKELR
69 12 ggggAALCEGAVLPRSAKELR
70 13 ggggALCEGAVLPRSAKELR
71 14 ggggLCEGAVLPRSAKELR
72 15 ggggCEGAVLPRSAKELR
Example 5: Design of G Protein-Coupled Receptor Binding Domains Based on Peptide Ligand Interactions GPCR binding domains were designed based on interaction surfaces between peptide ligands that interact with class B GPCRs. About 66 different ligands were used and include the following ligand sequence annotations: Adrenomedullin, Amylin, Angiotensin, Angiotensin I, Angiotensin II, Angiotensin III, Apelin, Apstatin, Big Endothelin, Big Gastrin, Bradykinin, Caerulein, Calcitonin, Calcitonin Gene Related Peptide, CGRP, Cholecystokinin, Endothelin, Endothelin 1, Endothelin 2, Endothelin 3, GIP, GIPs, GLP, Galanin, Gastrin, Ghrelin, Glucagon, IAPP, Kisspeptin, Mca, Metasti, Neuromedin, Neuromedin N, Neuropeptide, Neuropeptide F, Neuropeptide Y, Neurotensin, Nociceptin, Orexin, Orexin A, Orphanin, Oxytocin, Oxytocin Galanin, PACAP, PACAPs, PAR (Protease Activated Receptor) Peptides, PAR-1 Agonist, Pramlintide, Scyliorhinin I, Secretin, Senktide, Somatostatin, Somatostatin 14, Somatostatin 28, Substance P, Urotensin II, VIP, VIPs, Vasopressin, Xenin, cinnamoyl, furoyl, gastrin, holecystokinin, α-Mating Factor Pheromone. It was observed that the peptides formed a stabilized interaction with the GPCR extracellular domain (ECD).
Motif variants were generated based on the interaction surface of the peptides with the ECD as well as with the N-terminal GPCR ligand interaction surface. This was done using structural modeling. Exemplary motif variants were created based on glucagon like peptide's interaction with its GPCR as seen in Table 9. The motif variant sequences were generated using the following sequence from glucagon like peptide:
(SEQ ID NO: 73)
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG.
TABLE 9
Variant amino acid sequences for
glucagon like peptide
SEQ
ID Var-
NO. iant Amino Acid Sequence
74 1 sggggsggggsggggHAEGTFTSDVSSYLEGQAAKEFIAWLV
75 2 sggggsggggsggggAEGTFTSDVSSYLEGQAAKEFIAWLV
76 3 sggggsggggsggggEGTFTSDVSSYLEGQAAKEFIAWLV
77 4 sggggsggggsggggGTFTSDVSSYLEGQAAKEFIAWLV
78 5 sggggsggggsggggTFTSDVSSYLEGQAAKEFIAWLV
79 6 sggggsggggsggggFTSDVSSYLEGQAAKEFIAWLV
80 7 sggggsggggsggggTSDVSSYLEGQAAKEFIAWLV
81 8 sggggsggggsggggSDVSSYLEGQAAKEFIAWLV
82 9 sggggsggggsggggDVSSYLEGQAAKEFIAWLV
Example 6: Design of G Protein-Coupled Receptor Binding Domains Based on Small Molecule Interactions GPCR binding domains were designed based on interaction surfaces between small molecule ligands that interact with GPCRs. By analyzing multiple GPCR ligands, an amino acid library of Tyr, Pro, Phe, His, and Gly was designed as being able to recapitulate many of the structural contacts of these ligands. An exemplary motif variant that was generated based on these observations comprises the following sequence:
(SEQ ID NO: 83)
sgggg(F, G, H, P, Y)(F, G, H, P, Y)
(F, G, H, P, Y)(F, G, H, P, Y)
(F, G, H, P, Y)(F, G, H, P, Y)
(F, G, H, P, Y)(F, G, H, P, Y).
Example 7: Design of G Protein-Coupled Binding Domains Based on Extracellular Domain Interactions GPCR binding domains were designed based on interaction surfaces on extracellular domains (ECDs) and extracellular loops (ECLs) of GPCRs. About 2,257 GPCRs from human (356), mouse (369), rat (259), cow (102), pig (60), primate, fish, fly, and over 200 other organisms were analyzed, and it was observed that ECDs provide multiple complementary contacts to other loops and helices of the GPCR at a length of 15 amino acids. Further analysis of the ECLs from the about 2,257 GPCRs and all solved structures of GPCRs demonstrated that the N-terminal ECD1 and ECL2 comprise longer extracellular sequences and provide GPCR extracellular contacts.
Motif variants were then generated based on these sequences. Exemplary variants based on the following sequence from retinoic acid induced protein 3 (GPRC5A) were generated:
(SEQ ID NO: 84)
EYIVLTMNRTNVNVFSELSAPRRNED.
TABLE 10
Amino acid sequences
SEQ
ID
NO. Variant Amino Acid Sequence
85 1 YIVLTMNRTNVNVFSELSAPRRNE
86 2 IVLTMNRTNVNVFSELSAPRRN
87 3 VLTMNRTNVNVFSELSAPRR
Example 8: Design of Antibody Scaffolds To generate scaffolds, structural analysis, repertoire sequencing analysis of the heavy chain, and specific analysis of heterodimer high-throughput sequencing datasets were performed. Each heavy chain was associated with each light chain scaffold. Each heavy chain scaffold was assigned 5 different long CDR-H3 loop options. Each light chain scaffold was assigned 5 different L3 scaffolds. The heavy chain CDR-H3 stems were chosen from the frequently observed long H3 loop stems (10 amino acids on the N-terminus and the C-terminus) found both across individuals and across V-gene segments. The light chain scaffold L3s were chosen from heterodimers comprising long H3s. Direct heterodimers based on information from the Protein Data Bank (PDB) and deep sequencing datasets were used in which CDR H1, H2, L1, L2, L3, and CDR-H3 stems were fixed. The various scaffolds were then formatted for display on phage to assess for expression.
Structural Analysis
About 2,017 antibody structures were analyzed from which 22 structures with long CDR-H3s of at least 25 amino acids in length were observed. The heavy chains included the following: IGHV1-69, IGHV3-30, IGHV4-49, and IGHV3-21. The light chains identified included the following: IGLV3-21, IGKV3-11, IGKV2-28, IGKV1-5, IGLV1-51, IGLV1-44, and IGKV1-13. In the analysis, four heterodimer combinations were observed multiple times including: IGHV4-59/61-IGLV3-21, IGHV3-21-IGKV2-28, IGHV1-69-IGKV3-11, and IGHV1-69-IGKV1-5. An analysis of sequences and structures identified intra-CDR-H3 disulfide bonds in a few structures with packing of bulky side chains such as tyrosine in the stem providing support for long H3 stability. Secondary structures including beta-turn-beta sheets and a “hammerhead” subdomain were also observed.
Repertoire Analysis
A repertoire analysis was performed on 1,083,875 IgM+/CD27−naïve B cell receptor (BCR) sequences and 1,433,011 CD27+ sequences obtained by unbiased 5′RACE from 12 healthy controls. The 12 healthy controls comprised equal numbers of male and female and were made up of 4 Caucasian, 4 Asian, and 4 Hispanic individuals. The repertoire analysis demonstrated that less than 1% of the human repertoire comprises BCRs with CDR-H3s longer than 21 amino acids. A V-gene bias was observed in the long CDR3 subrepertoire, with IGHV1-69, IGHV4-34, IGHV1-18, and IGHV1-8 showing preferential enrichment in BCRs with long H3 loops. A bias against long loops was observed for IGHV3-23, IGHV4-59/61, IGHV5-51, IGHV3-48, IGHV3-53/66, IGHV3-15, IGHV3-74, IGHV3-73, IGHV3-72, and IGHV2-70. The IGHV4-34 scaffold was demonstrated to be autoreactive and had a short half-life.
Viable N-terminal and C-terminal CDR-H3 scaffold variation for long loops were also designed based on the 5′RACE reference repertoire. About 81,065 CDR-H3s of amino acid length 22 amino acids or greater were observed. By comparing across V-gene scaffolds, scaffold-specific H3 stem variation was avoided as to allow the scaffold diversity to be cloned into multiple scaffold references.
Heterodimer Analysis
Heterodimer analysis was performed on scaffolds having sequences as seen in FIGS. 12A-12C. Variant sequences and lengths of the scaffolds were assayed.
Structural Analysis
Structural analysis was performed using GPCR scaffolds of variant sequences and lengths were assayed. See FIG. 13.
Example 9: Generation of GPCR Antibody Libraries Based on GPCR-ligand interaction surfaces and scaffold arrangements, libraries were designed and de novo synthesized. See Examples 4-8. Referring to FIG. 5, 10 variant sequences were designed for the variable domain, heavy chain 503, 237 variant sequences were designed for the heavy chain complementarity determining region 3 507, and 44 variant sequences were designed for the variable domain, light chain 513. The fragments were synthesized as three fragments as seen in FIG. 6 following similar methods as described in Examples 1-3.
Following de novo synthesis, 10 variant sequences were generated for the variable domain, heavy chain 602, 236 variant sequences were generated for the heavy chain complementarity determining region 3 604, and 43 variant sequences were designed for a region comprising the variable domain 606, light chain and CDR-L3 and of which 9 variants for variable domain, light chain were designed. This resulted in a library with about 105 diversity (10×236×43). This was confirmed using next generation sequencing (NGS) with 16 million reads. As seen in FIG. 14, the normalized sequencing reads for each of the 10 variants for the variable domain, heavy chain was about 1. As seen in FIG. 15, the normalized sequencing reads for each of the 43 variants for the variable domain, light chain was about 1. As seen in FIG. 16, the normalized sequencing reads for 236 variant sequences for the heavy chain complementarity determining region 3 were about 1.
The various light and heavy chains were then tested for expression and protein folding. Referring to FIGS. 17A-17D, the 10 variant sequences for variable domain, heavy chain included the following: IGHV1-18, IGHV1-69, IGHV1-8 IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV3-74, IGHV4-39, and IGHV4-59/61. Of the 10 variant sequences, IGHV1-18, IGHV1-69, and IGHV3-30/33rn exhibited improved characteristics such as improved thermostability. Referring to FIGS. 18A-18F, 9 variant sequences for variable domain, light chain included the following: IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, and IGLV2-14. Of the 9 variant sequences, IGKV1-39, IGKV3-15, IGLV1-51, and IGLV2-14 exhibited improved characteristics such as improved thermostability.
Example 10: Expression of GPCR Antibody Libraries in HEK293 Cells Following generation of GPCR antibody libraries as in Example 13, about 47 GPCRs were selected for screening. GPCR constructs about 1.8 kb to about 4.5 kb in size were designed in a pCDNA3.1 vector. The GPCR constructs were then synthesized following similar methods as described in Examples 2-4 including hierarchal assembly. Of the 47 GPCR constructs, 46 GPCR constructs were synthesized.
The synthesized GPCR constructs were transfected in HEK293 and assayed for expression using immunofluorescence. Referring to FIGS. 19A-19C, HEK293 cells were transfected with the GPCR constructs comprising an N-terminally hemagglutinin (HA)-tagged human Y1 receptor. Following 24-48 hours of transfection, cells were washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde. Cells were stained using fluorescent primary antibody directed towards the HA tag or secondary antibodies comprising a fluorophore and DAPI to visualize the nuclei in blue. Referring to FIGS. 19A-19C, human Y1 receptor was visualized on the cell surface in non-permeabilized cells and on the cell surface and intracellularly in permeabilized cells.
GPCR constructs were also visualized by designing GPCR constructs comprising auto-fluorescent proteins. Referring to FIGS. 20A-20C, human Y1 receptor comprised EYFP fused to its C-terminus, and human Y5 receptor comprised ECFP fused to its C-terminus. HEK293 cells were transfected with human Y1 receptor or co-transfected with human Y1 receptor and human Y5 receptor. Following transfection cells were washed and fixed with 4% paraformaldehyde. Cells were stained with DAPI. Localization of human Y1 receptor and human Y5 receptor were visualized by fluorescence microscopy.
Example 11: Design of Immunoglobulin Library An immunoglobulin scaffold library was designed for placement of GPCR binding domains and for improving stability for a range of GPCR binding domain encoding sequences. The immunoglobulin scaffold included a VH domain attached with a VL domain with a linker. Variant nucleic acid sequences were generated for the framework elements and CDR elements of the VH domain and VL domain. The structure of the design is shown in FIG. 21A. A full domain architecture is shown in FIG. 21B. Sequences for the leader, linker, and pIII are listed in Table 11.
TABLE 11
Nucleotide sequences
SEQ
ID NO Domain Sequence
88 Leader GCAGCCGCTGGCTTGCTGCT
GCTGGCAGCTCAGCCGGCCA
TGGCC
89 Linker GCTAGCGGTGGAGGCGGTTC
AGGCGGAGGTGGCTCTGGCG
GTGGCGGATCGCATGCATCC
90 pIII CGCGCGGCCGCTGGAAGCGG
CTCCCACCATCACCATCACC
AT
The VL domains that were designed include IGKV1-39, IGKV3-15, IGLV1-51, and IGLV2-14. Each of four VL domains were assembled with their respective invariant four framework elements (FW1, FW2, FW3, FW4) and variable 3 CDR (L1, L2, L3) elements. For IGKV1-39, there was 490 variants designed for L1, 420 variants designed for L2, and 824 variants designed for L3 resulting in a diversity of 1.7×108 (490*420*824). For IGKV3-15, there was 490 variants designed for L1, 265 variants designed for L2, and 907 variants designed for L3 resulting in a diversity of 1.2×108 (490*265*907). For IGLV1-51, there was 184 variants designed for L1, 151 variants designed for L2, and 824 variants designed for L3 resulting in a diversity of 2.3×107 (184*151*824). IGLV2-14, 967 variants designed for L1, 535 variants designed for L2, and 922 variants designed for L3 resulting in a diversity of 4.8 108 (967*535*922). Table 12 lists the amino acid sequences and nucleotide sequences for the four framework elements (FW1, FW2, FW3, FW4) for IGLV1-51. Table 13 lists the variable 3 CDR (L1, L2, L3) elements for IGLV1-51. Variant amino acid sequences and nucleotide sequences for the four framework elements (FW1, FW2, FW3, FW4) and the variable 3 CDR (L1, L2, L3) elements were also designed for IGKV1-39, IGKV3-15, and IGLV2-14.
TABLE 12
Sequences for IGLV1-51 framework elements
SEQ SEQ
ID Amino Acid ID Nucleotide
Element NO Sequence NO Sequence
IGLV1-51
FW1 91 QSVLTQPPSV 92 CAGTCTGTGT
SAAPGQKVTI TGACGCAGCC
SC GCCCTCAGTG
TCTGCGGCCC
CAGGACAGAA
GGTCACCATC
TCCTGC
FW2 93 WYQQLPGTAP 94 TGGTATCAGC
KLLIY AGCTCCCAGG
AACAGCCCCC
AAACTCCTCA
TTTAT
FW3 95 GIPDRFSGSK 96 GGGATTCCTG
SGTSATLGIT ACCGATTCTC
GLQTGDEADY TGGCTCCAAG
Y TCTGGCACGT
CAGCCACCCT
GGGCATCACC
GGACTCCAGA
CTGGGGACGA
GGCCGATTAT
TAC
FW4 97 GGGTKLTVL 98 GGCGGAGGGA
CCAAGCTGAC
CGTCCTA
TABLE 13
Sequences for IGLV1-51 CDR elements
SEQ Amino Acid SEQ
ID NO Sequence ID NO Nucleotide Sequence
IGLV1-51-L1
99 SGSSSNIGS 282 TCTGGAAGCAGCTCCAACATTGGGAGTAATCATGTA
NHVS TCC
100 SGSSSNIGN 283 TCTGGAAGCAGCTCCAACATTGGGAATAATTATCTA
NYLS TCC
101 SGSSSNIAN 284 TCTGGAAGCAGCTCCAACATTGCGAATAATTATGTA
NYVS TCC
102 SGSSPNIGN 285 TCTGGAAGCAGCCCCAACATTGGGAATAATTATGTA
NYVS TCG
103 SGSRSNIGS 286 TCTGGAAGCAGATCCAATATTGGGAGTAATTATGTT
NYVS TCG
104 SGSSSNVG 287 TCTGGAAGCAGCTCCAACGTTGGCGATAATTATGTT
DNYVS TCC
105 SGSSSNIGIQ 288 TCTGGAAGCAGCTCCAACATTGGGATTCAATATGTA
YVS TCC
106 SGSSSNVG 289 TCTGGAAGCAGCTCCAATGTTGGTAACAATTTTGTCT
NNFVS CC
107 SGSASNIGN 290 TCTGGAAGCGCCTCCAACATTGGGAATAATTATGTA
NYVS TCC
108 SGSGSNIGN 291 TCTGGAAGCGGCTCCAATATTGGGAATAATGATGTG
NDVS TCC
109 SGSISNIGN 292 TCTGGAAGCATCTCCAACATTGGTAATAATTATGTA
NYVS TCC
110 SGSISNIGK 293 TCTGGAAGCATCTCCAACATTGGGAAAAATTATGTG
NYVS TCG
111 SGSSSNIGH 294 TCTGGAAGCAGCTCCAACATTGGGCATAATTATGTA
NYVS TCG
112 PGSSSNIGN 295 CCTGGAAGCAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
113 SGSTSNIGI 296 TCTGGAAGCACCTCCAACATTGGAATTCATTATGTA
HYVS TCC
114 SGSSSNIGS 297 TCTGGAAGCAGCTCCAACATTGGCAGTCATTATGTT
HYVS TCC
115 SGSSSNIGN 298 TCCGGAAGCAGCTCCAACATTGGAAATGAATATGTA
EYVS TCC
116 SGSTSNIGN 299 TCTGGAAGCACCTCCAACATTGGAAATAATTATATA
NYIS TCG
117 SGSSSNIGN 300 TCTGGAAGCAGCTCCAATATTGGGAATCATTTTGTA
HFVS TCG
118 SGSSSNIGN 301 TCTGGAAGCAGCTCCAACATTGGGAATAATTATGTG
NYVA GCC
119 SGSSSNIGS 302 TCTGGAAGCAGCTCCAACATTGGAAGTTATTATGTA
YYVS TCC
120 SGSGFNIGN 303 TCTGGAAGTGGTTTCAACATTGGGAATAATTATGTC
NYVS TCT
121 SGSTSNIGN 304 TCTGGAAGCACCTCCAACATTGGGAATAATTATGTG
NYVS TCC
122 SGSSSDIGN 305 TCTGGAAGCAGCTCCGACATTGGCAATAATTATGTA
NYVS TCC
123 SGSSSNIGN 306 TCTGGAAGCAGCTCCAACATTGGGAATAATGTTGTA
NVVS TCC
124 SGSKSNIGK 307 TCTGGAAGCAAGTCTAACATTGGGAAAAATTATGTA
NYVS TCC
125 SGSSTNIGN 308 TCTGGAAGCAGCACCAACATTGGGAATAATTATGTA
NYVS TCC
126 SGSISNIGD 309 TCTGGAAGCATCTCCAACATTGGGGATAATTATGTA
NYVS TCC
127 SGSSSNIGS 310 TCTGGAAGCAGCTCCAACATTGGGAGTAAGGATGTA
KDVS TCA
128 SGSSSNIEN 311 TCTGGAAGCAGCTCCAACATTGAGAATAATGATGTA
NDVS TCG
129 SGSSSNIGN 312 TCTGGAAGCAGCTCCAACATTGGGAATCATTATGTA
HYVS TCC
130 SGSSSNIGK 313 TCTGGAAGCAGCTCCAACATTGGGAAGGATTTTGTC
DFVS TCC
131 SGSTSNIGS 314 TCTGGCAGTACTTCCAACATCGGAAGTAATTTTGTTT
NFVS CC
132 SGSTSNIGH 315 TCTGGAAGCACCTCCAACATTGGGCATAATTATGTA
NYVS TCC
133 SASSSNIGN 316 TCTGCAAGCAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
134 SGSSSSIGN 317 TCTGGAAGCAGCTCCAGCATTGGCAATAATTATGTA
NYVS TCC
135 SGSSSTIGN 318 TCTGGAAGCAGCTCCACCATTGGGAATAATTATGTA
NYVS TCC
136 SGSSSNIEN 319 TCTGGAAGCAGCTCCAACATTGAAAATAATTATGTA
NYVS TCC
137 SGSSSNIGN 320 TCTGGAAGCAGCTCCAACATTGGGAATCAGTATGTA
QYVS TCC
138 SGSSSNIGN 321 TCTGGAAGCAGCTCCAACATTGGGAATAATTATGTA
NYVF TTC
139 SGSSSNIGR 322 TCTGGAAGCAGCTCCAACATTGGGAGGAATTATGTC
NYVS TCC
140 SGGSSNIGN 323 TCTGGAGGCAGCTCCAACATTGGAAATTATTATGTA
YYVS TCG
141 SGSSSNIGD 324 TCTGGAAGCAGCTCCAACATTGGAGATAATTATGTC
NYVS TCC
142 SGGSSNIGI 325 TCTGGAGGCAGCTCCAACATTGGAATTAATTATGTA
NYVS TCC
143 SGGSSNIGK 326 TCTGGAGGCAGCTCCAACATTGGGAAGAATTATGTA
NYVS TCC
144 SGSSSNIGK 327 TCTGGAAGCAGCTCCAACATTGGGAAGAGATCTGTA
RSVS TCG
145 SGSRSNIGN 328 TCTGGAAGCAGATCCAACATTGGGAATAACTATGTA
NYVS TCC
146 SGSSSNIGN 329 TCGGGAAGCAGCTCCAACATTGGGAATAATCTTGTT
NLVS TCC
147 SGSSSNIGIN 330 TCTGGAAGCAGCTCCAACATTGGGATCAATTATGTA
YVS TCC
148 SGSSSNIGN 331 TCTGGAAGCAGCTCCAACATCGGGAATAATTTTGTA
NFVS TCC
149 SGTSSNIGR 332 TCTGGAACCAGCTCCAACATTGGCAGAAATTTTGTA
NFVS TCC
150 SGRRSNIGN 333 TCTGGAAGGAGGTCCAACATTGGAAATAATTATGTG
NYVS TCC
151 SGGSFNIGN 334 TCTGGAGGCAGCTTCAATATTGGGAATAATTATGTA
NYVS TCC
152 SGSTSNIGE 335 TCTGGAAGCACTTCCAACATTGGGGAGAATTATGTG
NYVS TCC
153 SGSSSNIGS 336 TCTGGAAGCAGCTCCAATATTGGGAGTGATTATGTA
DYVS TCC
154 SGTSSNIGS 337 TCTGGAACCAGCTCCAACATTGGGAGTAATTATGTA
NYVS TCC
155 SGSSSNIGT 338 TCTGGAAGCAGCTCCAACATTGGGACTAATTTTGTA
NFVS TCC
156 SGSSSNFGN 339 TCTGGAAGCAGCTCCAACTTTGGGAATAATTATGTA
NYVS TCC
157 SGSTSNIGN 340 TCTGGAAGCACCTCCAACATTGGGAATAATCATGTA
NHVS TCC
158 SGSSSNIGN 341 TCTGGAAGCAGCTCCAACATTGGGAATGATTTTGTA
DFVS TCC
159 SGSSSDIGD 342 TCTGGAAGCAGCTCCGACATTGGCGATAATTATGTG
NYVS TCC
160 SGSSSNIGK 343 TCTGGAAGCAGCTCCAACATTGGGAAATATTATGTA
YYVS TCC
161 SGSSSNIGG 344 TCTGGAAGCAGCTCCAACATTGGCGGTAATTATGTA
NYVS TCC
162 SGSSSNTGN 345 TCTGGAAGCAGCTCCAACACTGGGAATAATTATGTA
NYVS TCC
163 SGSSSNVG 346 TCTGGAAGCAGCTCCAACGTTGGGAATAATTATGTG
NNYVS TCT
164 SGSSSNIAN 347 TCTGGAAGCAGCTCCAACATTGCGAATAATTTTGTA
NFVS TCC
165 SGSSSNIGN 348 TCTGGAAGCAGCTCCAACATTGGGAATGATTATGTA
DYVS TCC
166 SGSTSNIEN 349 TCTGGAAGCACCTCCAATATTGAGAATAATTATGTT
NYVS TCC
167 SGGSSNIGN 350 TCTGGAGGCAGCTCCAATATTGGCAATAATGATGTG
NDVS TCC
168 SGSTSNIGN 351 TCTGGAAGCACCTCCAACATTGGGAATCATTATGTA
HYVS TCC
169 SGSSSNIGD 352 TCAGGAAGCAGCTCCAATATTGGGGATAATGATGTA
NDVS TCC
170 SGYSSNIGN 353 TCTGGATACAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
171 SGSGSNIGN 354 TCTGGAAGCGGCTCCAACATTGGAAATAATTTTGTA
NFVS TCC
172 SGSSSNIWN 355 TCTGGAAGCAGCTCCAACATTTGGAATAATTATGTA
NYVS TCC
173 FGSSSNIGN 356 TTTGGAAGCAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
174 SGSSSNIEK 357 TCTGGAAGCAGCTCCAACATTGAGAAGAATTATGTA
NYVS TCC
175 SGSRSNIGN 358 TCTGGAAGTAGATCCAATATTGGAAATTATTATGTA
YYVS TCC
176 SGTKSNIGN 359 TCTGGAACCAAGTCAAACATTGGGAATAATTATGTA
NYVS TCT
177 SGSTSNIGN 360 TCTGGAAGCACCTCCAACATTGGGAATTATTATGTA
YYVS TCC
178 SGTSSNIGN 361 TCTGGAACCAGCTCCAACATTGGGAATAATTATGTG
NYVA GCC
179 PGTSSNIGN 362 CCTGGAACCAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
180 SGSTSNIGI 363 TCCGGAAGCACCTCCAACATTGGGATTAATTATGTA
NYVS TCC
181 SGSSSNIGS 364 TCTGGAAGCAGCTCCAACATTGGGAGTAATCTGGTA
NLVS TCC
182 SGSSSNIEN 365 TCTGGAAGCAGCTCCAACATTGAGAATAATCATGTA
NHVS TCC
183 SGTRSNIGN 366 TCTGGAACCAGGTCCAACATCGGCAATAATTATGTT
NYVS TCG
184 SGSTSNIGD 367 TCTGGAAGCACCTCCAACATTGGGGACAATTATGTT
NYVS TCC
185 SGGSSNIGK 368 TCTGGAGGCAGTTCCAACATTGGGAAGAATTTTGTA
NFVS TCC
186 SGSRSDIGN 369 TCTGGAAGCAGGTCCGACATTGGGAATAATTATGTA
NYVS TCC
187 SGTSSNIGN 370 TCTGGAACTAGCTCCAACATTGGGAATAATGATGTA
NDVS TCC
188 SGSSSNIGS 371 TCTGGAAGCAGCTCCAACATTGGGAGTAAATATGTA
KYVS TCA
189 SGSSFNIGN 372 TCTGGAAGCAGCTTCAACATTGGGAATAATTATGTA
NYVS TCC
190 SGSSSNIGN 373 TCTGGAAGCAGCTCCAACATTGGGAATACTTATGTA
TYVS TCC
191 SGSSSNIGD 374 TCTGGAAGCAGCTCCAATATTGGGGATAATCATGTA
NHVS TCC
192 SGSSSNIGN 375 TCTGGAAGCAGCTCCAACATTGGCAATAATCATGTT
NHVS TCC
193 SGSTSNIGN 376 TCTGGAAGCACCTCCAACATTGGGAATAATGATGTA
NDVS TCC
194 SGSRSNVG 377 TCTGGAAGCAGATCCAACGTTGGCAATAATTATGTT
NNYVS TCA
195 SGGTSNIGK 378 TCCGGAGGCACCTCCAACATTGGGAAGAATTATGTG
NYVS TCT
196 SGSSSNIAD 379 TCTGGAAGCAGCTCCAACATTGCCGATAATTATGTT
NYVS TCC
197 SGSSSNIGA 380 TCTGGAAGCAGCTCCAACATTGGCGCCAATTATGTA
NYVS TCC
198 SGSSSNIGS 381 TCTGGAAGCAGCTCCAACATTGGGAGTAATTATGTG
NYVA GCC
199 SGSSSNIGN 382 TCTGGAAGCAGCTCCAACATTGGGAACAATTTTCTC
NFLS TCC
200 SGRSSNIGK 383 TCTGGAAGAAGCTCCAACATTGGGAAGAATTATGTA
NYVS TCC
201 SGSSPNIGA 384 TCTGGAAGCAGCCCCAACATTGGGGCTAATTATGTA
NYVS TCC
202 SGSSSNIGP 385 TCCGGAAGCAGCTCCAACATTGGGCCTAATTATGTG
NYVS TCC
203 SGSSSTIGN 386 TCTGGAAGCAGCTCCACCATTGGGAATAATTATATA
NYIS TCC
204 SGSSSNIGN 387 TCTGGAAGCAGCTCCAACATTGGGAATTATTTTGTA
YFVS TCC
205 SGSRSNIGN 388 TCTGGAAGCCGCTCCAACATTGGTAATAATTTTGTAT
NFVS CC
206 SGGSSNIGS 389 TCTGGAGGCAGCTCCAACATTGGGAGTAATTTTGTA
NFVS TCC
207 SGSSSNIGY 390 TCTGGAAGCAGCTCCAACATTGGGTATAATTATGTA
NYVS TCC
208 SGTSSNIEN 391 TCTGGAACCAGCTCGAACATTGAGAACAATTATGTA
NYVS TCC
209 SGSSSNIGN 392 TCTGGAAGTAGCTCCAACATTGGGAATTATTATGTA
YYVS TCC
210 SGSTSNIGK 393 TCTGGAAGCACCTCCAACATTGGGAAGAATTATGTA
NYVS TCC
211 SGSSSNIGT 394 TCTGGAAGCAGTTCCAACATTGGGACTTATTATGTCT
YYVS CT
212 SGSSSNVG 395 TCTGGAAGCAGCTCCAACGTTGGGAAAAATTATGTA
KNYVS TCT
213 SGSTSNIGD 396 TCTGGAAGCACCTCCAACATTGGGGATAATTTTGTA
NFVS TCC
214 SGSTSNIGT 397 TCTGGAAGCACCTCCAACATTGGAACTAATTATGTT
NYVS TCC
215 SGGTSNIGN 398 TCTGGAGGTACTTCCAACATTGGGAATAATTATGTC
NYVS TCC
216 SGSYSNIGN 399 TCTGGAAGCTACTCCAATATTGGGAATAATTATGTA
NYVS TCC
217 SGSSSNIED 400 TCTGGAAGCAGCTCCAACATTGAAGATAATTATGTA
NYVS TCC
218 SGSSSNIGK 401 TCTGGAAGCAGCTCCAACATTGGGAAACATTATGTA
HYVS TCC
219 SGSGSNIGS 402 TCCGGTTCCGGCTCAAACATTGGAAGTAATTATGTC
NYVS TCC
220 SGSSSNIGN 403 TCTGGAAGCAGCTCCAACATTGGAAATAATTATATA
NYIS TCA
221 SGASSNIGN 404 TCTGGAGCCAGTTCCAACATTGGGAATAATTATGTT
NYVS TCC
222 SGRTSNIGN 405 TCTGGACGCACCTCCAACATCGGGAACAATTATGTA
NYVS TCC
223 SGGSSNIGS 406 TCTGGAGGCAGCTCCAATATTGGGAGTAATTACGTA
NYVS TCC
224 SGSGSNIGN 407 TCTGGAAGCGGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
225 SGSTSNIGS 408 TCTGGAAGCACCTCCAACATTGGGAGTAATTATGTA
NYVS TCC
226 SGSSSSIGN 409 TCTGGAAGCAGCTCCAGCATTGGGAATAATTATGTG
NYVA GCG
227 SGSSSNLGN 410 TCTGGAAGCAGTTCCAACCTTGGAAATAATTATGTA
NYVS TCC
228 SGTSSNIGK 411 TCTGGAACCAGCTCCAACATTGGGAAAAATTATGTA
NYVS TCC
229 SGSSSDIGN 412 TCTGGAAGCAGCTCCGATATTGGGAACAAGTATATA
KYIS TCC
230 SGSSSNIGS 413 TCTGGAAGCAGCTCCAACATTGGAAGTAATTACATA
NYIS TCC
231 SGSTSNIGA 414 TCTGGAAGCACCTCCAACATTGGGGCTAACTATGTG
NYVS TCC
232 SGSSSNIGN 415 TCTGGAAGCAGCTCCAACATTGGGAATAAGTATGTA
KYVS TCC
233 SGSSSNIGN 416 TCTGGAAGCAGCTCCAACATTGGGAATAATTATGGA
NYGS TCC
234 SGSTSNIAN 417 TCTGGAAGCACCTCCAACATTGCGAATAATTATGTA
NYVS TCC
235 SGSYSNIGS 418 TCTGGAAGCTACTCCAATATTGGGAGTAATTATGTA
NYVS TCC
236 SGSSSNIGS 419 TCTGGAAGCAGCTCCAACATTGGGAGTAATTTTGTA
NFVS TCC
237 SGSSSNLEN 420 TCTGGAAGCAGCTCCAATCTTGAGAATAATTATGTA
NYVS TCC
238 SGSISNIGSN 421 TCTGGAAGCATCTCCAATATTGGCAGTAATTATGTA
YVS TCC
239 SGSSSDIGS 422 TCTGGAAGCAGCTCCGACATTGGGAGTAATTATGTA
NYVS TCC
240 SGSSSNIGT 423 TCTGGAAGCAGCTCCAACATTGGGACTAATTATGTA
NYVS TCC
241 SGSSSNIGK 424 TCTGGAAGCAGCTCCAACATTGGGAAGAATTTTGTA
NFVS TCC
242 SGSSSNIGN 425 TCTGGAAGCAGCTCCAACATTGGGAATAATTTTATA
NFIS TCC
243 SGGSSNIGN 426 TCTGGAGGCAGCTCCAACATTGGCAATAATTATGTT
NYVS TCC
244 SGSSSNIGE 427 TCTGGAAGCAGCTCCAACATTGGGGAGAATTATGTA
NYVS TCC
245 SGSSSNIGN 428 TCTGGAAGCAGCTCCAATATTGGGAATAATTTTGTG
NFVA GCC
246 SGGSSNIGN 429 TCTGGAGGCAGCTCCAACATTGGGAATAATTATGTA
NYVA GCC
247 SGSSSHIGN 430 TCTGGAAGCAGCTCCCACATTGGAAATAATTATGTA
NYVS TCC
248 SGSSSNIGS 431 TCTGGAAGCAGCTCCAATATTGGAAGTAATGATGTA
NDVS TCG
249 SGSSSNIGN 432 TCTGGAAGCAGCTCCAACATTGGGAATAATTATGTA
NYVT ACC
250 SGSSSNIGN 433 TCTGGAAGCAGCTCCAACATTGGGAATAATCCTGTA
NPVS TCC
251 SGGSSNIGN 434 TCTGGAGGCAGCTCCAATATTGGGAATCATTATGTA
HYVS TCC
252 SGTSSNIGN 435 TCTGGAACCAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
253 SGSSSNIGS 436 TCTGGAAGCAGCTCCAACATTGGAAGTAATTATGTC
NYVS TCG
254 SGGTSNIGS 437 TCTGGAGGCACCTCCAACATTGGAAGTAATTATGTA
NYVS TCC
255 SGSKSNIGN 438 TCTGGAAGCAAGTCCAACATTGGGAATAATTATGTA
NYVS TCC
256 SGRSSNIGN 439 TCTGGAAGAAGCTCCAACATTGGGAATAATTATGTA
NYVS TCG
257 SGSSSNVGS 440 TCTGGAAGCAGCTCCAACGTTGGGAGTAATTATGTT
NYVS TCC
258 SGSTSNIGN 441 TCTGGAAGCACCTCCAATATTGGGAATAATTTTGTA
NFVS TCC
259 SGSNFNIGN 442 TCTGGAAGCAACTTCAACATTGGGAATAATTATGTC
NYVS TCC
260 SGSTSNIGY 443 TCTGGAAGCACCTCCAATATTGGATATAATTATGTA
NYVS TCC
261 SGSSSNIVS 444 TCTGGAAGCAGCTCCAATATTGTAAGTAATTATGTA
NYVS TCC
262 SGTSSNIGN 445 TCTGGAACCAGCTCCAACATTGGGAATAATTTTGTA
NFVS TCC
263 SGSSSNIGR 446 TCTGGAAGCAGCTCCAACATTGGGAGGAATTTTGTG
NFVS TCC
264 SGTTSNIGN 447 TCTGGAACGACCTCCAACATTGGGAATAATTATGTC
NYVS TCC
265 SGSSSNIGN 448 TCTGGAAGCAGCTCCAACATTGGGAATAATGATGTA
NDVS TCC
266 SGSSSNIGN 449 TCTGGAAGCAGCTCCAACATTGGGAATCATGATGTA
HDVS TCC
267 SGSSSNIGS 450 TCTGGAAGCAGCTCCAACATTGGAAGTAGTCATGTA
SHVS TCC
268 SGSSSNIGIH 451 TCTGGAAGCAGCTCCAACATTGGGATTCATTATGTA
YVS TCC
269 SGGGSNIGY 452 TCTGGAGGCGGCTCCAACATTGGCTATAATTATGTC
NYVS TCC
270 SGSSSNIGD 453 TCTGGAAGCAGCTCCAACATTGGGGATCATTATGTG
HYVS TCG
271 SGSSSNLGK 454 TCTGGAAGCAGCTCCAACCTTGGGAAGAATTATGTA
NYVS TCT
272 SGSSSNIGD 455 TCTGGAAGCAGCTCCAACATTGGCGATAATTTTGTA
NFVS TCC
273 SGSTSNIEK 456 TCTGGAAGCACCTCCAACATTGAGAAAAACTATGTA
NYVS TCG
274 SGSSSNIGK 457 TCTGGAAGCAGCTCCAACATTGGGAAGGATTATGTA
DYVS TCC
275 SGSSSNIGK 458 TCTGGAAGCAGCTCCAACATTGGGAAGAATTATGTA
NYVS TCC
276 SGSSSNIGN 459 TCTGGAAGCAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
277 SGSSSNIGN 460 TCTGGAAGCAGCTCCAACATTGGGAATAATTATGCC
NYAS TCC
278 SGISSNIGN 461 TCTGGAATCAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
279 TGSSSNIGN 462 ACTGGAAGCAGCTCCAACATTGGGAATAATTATGTA
NYVS TCC
280 SGTSSNIGN 463 TCTGGAACCAGCTCCAACATTGGGAATAATCATGTT
NHVS TCC
281 SGSRSNIGK 464 TCTGGAAGTCGTTCCAACATTGGGAAAAATTATGTA
NYVS TCC
IGLV1-51-L2
465 DNNKRPP 616 GACAATAATAAGCGACCCCCA
466 ENNRRPS 617 GAGAATAATAGGCGACCCTCA
467 DNNKQPS 618 GACAATAATAAGCAACCCTCA
468 DNNKRPL 619 GACAATAACAAGCGACCCTTG
469 DNDKRPA 620 GACAATGATAAGCGACCCGCA
470 DNHERPS 621 GACAATCATGAGCGACCCTCA
471 ENRKRPS 622 GAAAACCGTAAGCGACCCTCA
472 DNDQRPS 623 GACAATGATCAGCGACCCTCA
473 ENYKRPS 624 GAGAATTATAAGCGACCCTCA
474 ENTKRPS 625 GAAAATACTAAGCGACCCTCA
475 DTEKRPS 626 GACACTGAGAAGAGGCCCTCA
476 DNDKRPP 627 GACAATGATAAGCGACCCCCA
477 DHNKRPS 628 GACCATAATAAGCGACCCTCA
478 GNNERPS 629 GGCAATAATGAGCGACCCTCA
479 DTSKRPS 630 GACACTAGTAAGCGACCCTCA
480 EYNKRPS 631 GAATATAATAAGCGCCCCTCA
481 ENIKRPS 632 GAAAATATTAAGCGACCCTCA
482 DNVKRPS 633 GACAATGTTAAGCGACCCTCA
483 ENDKRSS 634 GAAAACGATAAACGATCCTCA
484 ENNKRHS 635 GAAAATAATAAGCGACACTCA
485 GNDQRPS 636 GGAAATGATCAGCGACCCTCA
486 DNDRRPS 637 GACAATGATAGGCGACCCTCA
487 DNHKRPS 638 GACAATCATAAGCGGCCCTCA
488 DNNDRPS 639 GACAATAATGACCGACCCTCA
489 ENNQRPS 640 GAGAATAATCAGCGACCCTCA
490 DNNQRPS 641 GACAATAATCAGCGACCCTCA
491 ENVKRPS 642 GAGAATGTTAAGCGACCCTCA
492 DTYKRPS 643 GACACTTATAAGAGACCCTCA
493 NNNNRPS 644 AACAATAATAACCGACCCTCA
494 GNNNRPS 645 GGCAATAATAATCGACCCTCA
495 ENDQRPS 646 GAAAATGATCAGCGACCCTCA
496 DNNKRAS 647 GACAATAATAAGCGAGCCTCA
497 DNDKRPL 648 GACAATGATAAGCGACCCTTA
498 DTDERPS 649 GACACTGATGAGCGACCTTCA
499 DNRKRPS 650 GACAATAGGAAGCGACCCTCA
500 DNDARPS 651 GACAATGATGCTCGACCCTCA
501 DNNKRLS 652 GACAATAATAAGCGACTCTCA
502 DNDKRAS 653 GACAATGATAAGCGAGCCTCA
503 DNTERPS 654 GACAATACTGAGCGACCCTCA
504 DNNIRPS 655 GACAATAATATTCGACCCTCA
505 DNKRRPS 656 GACAATAAGAGGCGACCCTCA
506 DDNNRPS 657 GACGATAATAACCGACCCTCA
507 ANNRRPS 658 GCGAATAATCGACGACCCTCA
508 DNDKRLS 659 GACAATGATAAGCGACTGTCA
509 DNNKRPA 660 GACAATAATAAGCGACCCGCA
510 DNYRRPS 661 GACAATTATAGACGTCCCTCA
511 ANDQRPS 662 GCCAATGATCAGCGACCCTCA
512 DNDKRRS 663 GACAATGATAAGCGACGCTCA
513 DKNERPS 664 GACAAGAATGAGCGACCCTCA
514 DNKERPS 665 GACAATAAGGAGCGACCCTCA
515 DNNKGPS 666 GACAATAATAAGGGACCCTCA
516 ENDRRPS 667 GAAAATGATAGACGACCCTCA
517 ENDERPS 668 GAAAATGATGAGCGACCCTCA
518 QNNKRPS 669 CAAAATAATAAGCGACCCTCA
519 DNRERPS 670 GACAATCGTGAGCGACCCTCA
520 DNNRRPS 671 GACAATAATAGACGACCCTCA
521 GNNRRPS 672 GGAAATAATAGGCGACCCTCA
522 DNDNRPS 673 GACAATGATAACCGACCCTCA
523 EDNKRPS 674 GAAGATAATAAGCGACCCTCA
524 DDDERPS 675 GACGATGATGAGCGGCCCTCA
525 ASNKRPS 676 GCAAGTAATAAGCGACCCTCA
526 DNNKRSS 677 GACAATAATAAGCGATCCTCA
527 QNNERPS 678 CAAAATAATGAGCGACCCTCA
528 DDDRRPS 679 GACGATGATAGGCGACCCTCA
529 NNDKRPS 680 AACAATGATAAGCGACCCTCA
530 DNNNRPS 681 GACAATAATAACCGACCCTCA
531 DNNVRPS 682 GACAATAATGTGCGACCCTCA
532 ENNERPS 683 GAAAATAATGAGCGACCCTCA
533 DNNHRPS 684 GACAATAATCACCGACCCTCA
534 DNDERPS 685 GACAATGATGAGCGCCCCTCG
535 DNIRRPS 686 GACAATATCCGGCGACCCTCA
536 DFNKRPS 687 GACTTTAATAAGCGACCCTCA
537 ETNKRPS 688 GAAACTAATAAGCGACCCTCA
538 NDNKRPS 689 AACGATAATAAGCGACCCTCA
539 DDNKRPS 690 GACGATAATAAGCGACCCTCA
540 DNYKRPS 691 GACAATTATAAGCGACCCTCA
541 HNNKRPS 692 CACAATAATAAGCGACCCTCA
542 DNHQRPS 693 GACAATCATCAGCGACCCTCA
543 DNYKRAS 694 GACAATTATAAGCGAGCCTCA
544 DNIKRPS 695 GACAATATTAAGCGACCCTCA
545 DTHKRPS 696 GACACTCATAAGCGACCCTCA
546 DTNRRPS 697 GACACTAATAGGCGACCCTCT
547 DTNQRPS 698 GACACTAATCAGCGACCCTCA
548 ESDKRPS 699 GAAAGTGATAAGCGACCCTCA
549 DNDKRSS 700 GACAATGATAAGCGATCTTCG
550 GSNKRPS 701 GGCAGTAATAAGCGACCCTCA
551 DNNKRVS 702 GACAATAACAAGCGAGTTTCA
552 NNNRRPS 703 AACAATAATAGGCGACCCTCA
553 DNFKRPS 704 GACAATTTTAAGCGACCCTCA
554 ENDKRPS 705 GAAAATGATAAACGACCCTCA
555 ENNKRLS 706 GAAAATAATAAGCGACTCTCA
556 ADNKRPS 707 GCAGATAATAAGCGACCCTCA
557 EDNERPS 708 GAAGATAATGAGCGCCCCTCA
558 DTDQRPS 709 GACACTGATCAGCGACCCTCA
559 DNYQRPS 710 GACAATTATCAGCGACCCTCA
560 DENKRPS 711 GACGAGAATAAGCGACCCTCA
561 DTNKRPS 712 GACACTAATAAGCGACCCTCA
562 DDYRRPS 713 GACGATTATCGGCGACCCTCA
563 DNDKRHS 714 GACAACGATAAGCGGCACTCA
564 ENDNRPS 715 GAAAATGATAATCGACCCTCA
565 DDNERPS 716 GACGATAATGAGCGCCCCTCA
566 DNKKRPS 717 GACAATAAGAAGCGACCCTCA
567 DVDKRPS 718 GACGTTGATAAGCGACCCTCA
568 ENKKRPS 719 GAAAATAAAAAACGACCCTCT
569 VNDKRPS 720 GTCAATGATAAGCGACCCTCA
570 DNDHRPS 721 GACAATGATCACCGACCCTCA
571 DINKRPS 722 GACATTAATAAGCGACCCTCA
572 ANNERPS 723 GCCAATAATGAGCGACCCTCA
573 DNENRPS 724 GACAATGAAAACCGACCGTCA
574 GDDKRPS 725 GGCGATGATAAGCGACCCTCA
575 ANNQRPS 726 GCCAATAATCAGCGACCTTCA
576 DDDKRPS 727 GACGATGATAAGCGACCCTCA
577 YNNKRPS 728 TACAATAATAAGCGGCCCTCA
578 EDDKRPS 729 GAAGATGATAAGCGACCCTCA
579 ENNNRPS 730 GAAAACAATAACCGACCCTCG
580 DNNLRPS 731 GACAATAATCTGCGACCCTCA
581 ESNKRPS 732 GAGAGTAACAAGCGACCCTCA
582 DTDKRPS 733 GACACTGATAAGCGGCCCTCA
583 DDDQRPS 734 GACGATGATCAGCGACCCTCA
584 VNNKRPS 735 GTGAATAATAAGAGACCCTCC
585 DDYKRPS 736 GACGATTATAAGCGACCCTCA
586 DNTKRPS 737 GACAATACTAAGCGACCCTCA
587 DDTERPS 738 GACGATACTGAGCGACCCTCA
588 GNDKRPS 739 GGCAATGATAAGCGACCCTCA
589 DNEKRPS 740 GACAATGAAAAGCGACCCTCA
590 DNDDRPS 741 GACAATGATGACCGACCCTCA
591 DDNRRPS 742 GACGATAATAGGCGTCCCTCA
592 GNNKRPS 743 GGCAATAATAAGCGACCCTCA
593 ANDKRPS 744 GCCAATGATAAGCGACCCTCA
594 DNNKRHS 745 GACAATAATAAGCGACACTCA
595 DDNQRPS 746 GACGACAATCAGCGACCCTCA
596 GNDRRPS 747 GGCAATGATAGGCGACCCTCA
597 DNHNRPS 748 GACAATCATAACCGACCCTCA
598 DNYERPS 749 GACAATTATGAGCGACCCTCA
599 ENNKRSS 750 GAAAATAATAAGCGATCCTCA
600 DDHKRPS 751 GACGATCATAAGCGGCCCTCA
601 DNNKRRS 752 GACAATAATAAACGACGTTCA
602 DNDKRPS 753 GACAATGATAAGCGACCGTCA
603 DKNKRPS 754 GACAAGAATAAGCGACCCTCA
604 DNNKRPS 755 GACAATAATAAGCGACCCTCA
605 DIDKRPS 756 GACATTGATAAGCGACCCTCA
606 DDKKRPS 757 GACGATAAGAAGCGACCCTCA
607 ANNKRPS 758 GCCAATAATAAGCGACCCTCA
608 DNDKGPS 759 GACAATGATAAGGGACCCTCA
609 EDNRRPS 760 GAAGATAATAGGCGACCCTCA
610 ENNKRPS 761 GAGAATAATAAGCGACCCTCA
611 NNNKRPS 762 AACAATAATAAGCGACCCTCA
612 DNNERPS 763 GACAATAATGAGCGACCCTCA
613 DNIQRPS 764 GACAATATTCAGCGACCCTCA
614 DNNYRPS 765 GACAATAATTACCGACCCTCA
615 DNYNRPS 766 GACAATTATAACCGACCCTCA
IGLV1-51-L3
767 CGTWDTSL 1591 TGCGGAACATGGGATACCAGCCTGAGTGCTGTGGTG
SAVVF TTC
768 CGTWDTSL 1592 TGCGGAACATGGGATACCAGCCTGAGTGCTGGGGTG
SAGVF TTC
769 CGTWDTSL 1593 TGCGGAACATGGGATACCAGCCTGAGTGCTTGGGTG
SAWVF TTC
770 CGTWDRSL 1594 TGCGGAACATGGGATAGGAGCCTGAGTGCGGGGGT
SAGVF GTTC
771 CGTWDRSL 1595 TGCGGAACATGGGATAGGAGCCTGAGTGCTTGGGTA
SAWVF TTT
772 CGTWDTSL 1596 TGCGGAACATGGGATACCAGCCTGAGTGGTGGGGTG
SGGVF TTC
773 CGTWDTSL 1597 TGCGGAACATGGGATACTAGCCTGCGTGCTGGCGTC
RAGVF TTC
774 CGTWDRSL 1598 TGCGGAACATGGGATAGGAGCCTGAGTGTTTGGGTG
SVWVF TTC
775 CGTWDTSL 1599 TGCGGAACATGGGATACCAGTCTGAGTGTTGTGGTC
SVVVF TTC
776 CGTWDTSL 1600 TGCGGAACGTGGGATACCAGCCTGAGTGCTGCGGTG
SAAVF TTC
777 CGAWDTSL 1601 TGCGGAGCATGGGATACCAGCCTGAGTGCTGGAGTG
SAGVF TTC
778 CATWDTSL 1602 TGCGCAACATGGGATACCAGCCTGAGTGCTGTGGTA
SAVVF TTC
779 CATWDTSL 1603 TGCGCAACATGGGATACCAGCCTGAGTGCTGGTGTG
SAGVF TTC
780 CGTWESSL 1604 TGTGGAACATGGGAGAGCAGCCTGAGTGCTTGGGTG
SAWVF TTC
781 CGTWDTTL 1605 TGCGGAACATGGGATACCACCCTGAGTGCGGGTGTC
SAGVF TTC
782 CGTWDTSL 1606 TGCGGAACATGGGATACTAGCCTGAGTGTGTGGGTG
SVWVF TTC
783 CGTWDTSL 1607 TGCGGAACATGGGATACTAGCCTGAGTGTTGGGGTG
SVGVF TTC
784 CGTWDTSL 1608 TGCGGAACATGGGACACCAGTCTGAGCACTGGCGTC
STGVF TTC
785 CGTWDTSL 1609 TGCGGAACATGGGATACCAGCCTGAGTGGTGTGGTC
SGVVF TTC
786 CGTWDTSL 1610 TGCGGAACATGGGATACCAGCCTGAGTGCTTATGTC
SAYVF TTC
787 CGTWDTSL 1611 TGCGGAACATGGGATACCAGCCTGAGTGCTGAGGTG
SAEVF TTC
788 CGTWDTGL 1612 TGCGGAACATGGGATACCGGCCTGAGTGCTGGGGTA
SAGVF TTC
789 CGTWDRSL 1613 TGCGGAACGTGGGATAGGAGCCTGAGTGCTTATGTC
SAYVF TTC
790 CGTWDRSL 1614 TGCGGAACATGGGATAGGAGCCTCAGTGCCGTGGTA
SAVVF TTC
791 CGTWDNTL 1615 TGCGGAACATGGGATAACACCCTGAGTGCGTGGGTG
SAWVF TTC
792 CGTWDNRL 1616 TGCGGAACATGGGATAACAGGCTGAGTGCTGGGGT
SAGVF GTTC
793 CGTWDISLS 1617 TGCGGAACATGGGACATCAGCCTGAGTGCTTGGGTG
AWVF TTC
794 CGTWHSSL 1618 TGCGGAACATGGCATAGCAGCCTGAGTGCTGGGGTA
SAGVF TTC
795 CGTWGSSL 1619 TGCGGAACATGGGGTAGCAGTTTGAGTGCTTGGGTG
SAWVF TTC
796 CGTWESSL 1620 TGCGGAACATGGGAGAGCAGCCTGAGTGGTTGGGT
SGWVF GTTC
797 CGTWESSL 1621 TGCGGAACATGGGAGAGCAGCCTGAGTGCTGTGGTT
SAVVF TTC
798 CGTWDYSL 1622 TGCGGAACATGGGATTACAGCCTGAGTGCTGTGGTA
SAVVF TTC
799 CGTWDYSL 1623 TGCGGAACATGGGATTACAGCCTGAGTGCTGGGGTA
SAGVF TTC
800 CGTWDVSL 1624 TGCGGAACATGGGATGTCAGCCTGAGTGTTGGAGTG
SVGVF TTC
801 CGTWDTTL 1625 TGCGGAACATGGGATACCACCCTGAGTGCTGTGGTT
SAVVF TTC
802 CGTWDTTL 1626 TGCGGAACATGGGATACCACTCTGAATATTGGGGTG
NIGVF TTC
803 CGTWDTSL 1627 TGCGGAACATGGGATACCAGCCTGACTGCTGTGGTA
TAVVF TTC
804 CGTWDTSL 1628 TGCGGAACCTGGGATACCAGCCTGACTGCTGCTGTG
TAAVF TTC
805 CGTWDTSL 1629 TGCGGCACATGGGATACCAGCCTGAGTGTGGGGCTA
SVGLF TTC
806 CGTWDTSL 1630 TGCGGAACCTGGGATACCAGCCTGAGTGGTAGGGTG
SGRVF TTC
807 CGTWDTSL 1631 TGCGGAACATGGGATACCAGCCTGAGTGGTGCAGTG
SGAVF TTC
808 CGTWDTSL 1632 TGCGGAACATGGGATACCAGCCTGAGTGCTGGCCTG
SAGLF TTC
809 CGTWDTSL 1633 TGCGGAACATGGGATACCAGCCTGAGTGCTGGAGG
SAGGVF GGTCTTC
810 CGTWDTSL 1634 TGCGGAACATGGGATACCAGCCTGCGTGCTTATGTC
RAYVF TTC
811 CGTWDTSL 1635 TGCGGAACATGGGATACTAGTTTGCGTGCTTGGGTA
RAWVF TTC
812 CGTWDTSL 1636 TGCGGAACATGGGATACCAGCCTGAATACTGGGGTA
NTGVF TTC
813 CGTWDTSL 1637 TGCGGAACATGGGATACCAGCCTGAATATTTGGGTG
NIWVF TTC
814 CGTWDTSL 1638 TGCGGAACATGGGATACAAGCCTGAATATTGGGGTG
NIGVF TTC
815 CGTWDTSLI 1639 TGCGGAACATGGGATACCAGCCTGATTGCTGTGGTG
AVVF TTC
816 CGTWDRSL 1640 TGCGGAACGTGGGATAGGAGCCTGAGTGGTTGGGTG
SGWVF TTC
817 CGTWDNRL 1641 TGCGGAACATGGGATAACAGGCTGAGTGGTTGGGTG
SGWVF TTC
818 CGTWDKSL 1642 TGCGGAACGTGGGATAAGAGCCTGAGTGCTGTGGTC
SAVVF TTC
819 CGTWDKGL 1643 TGCGGAACATGGGATAAAGGCCTGAGTGCTTGGGTG
SAWVF TTC
820 CGTWDISLS 1644 TGCGGAACATGGGATATCAGCCTGAGTGCTGGGGTG
AGVF TTC
821 CGTWDESL 1645 TGCGGAACATGGGATGAGAGCCTGAGTGGTGGCGA
SGGEVVF GGTGGTCTTC
822 CGTWDASL 1646 TGCGGAACATGGGATGCCAGCCTGAGTGCCTGGGTG
SAWVF TTC
823 CGTWDAGL 1647 TGCGGAACTTGGGATGCCGGCCTGAGTGCTTGGGTG
SAWVF TTC
824 CGAWDTSL 1648 TGCGGAGCATGGGATACCAGCCTGAGTGCTTGGGTG
SAWVF TTC
825 CGAWDTSL 1649 TGCGGAGCATGGGATACCAGCCTGAGTGCTGTGGTG
SAVVF TTC
826 CGAWDTSL 1650 TGCGGAGCATGGGATACCAGCCTGCGTGCTGGGGTT
RAGVF TTC
827 CATWDTSV 1651 TGCGCAACATGGGATACCAGCGTGAGTGCTTGGGTG
SAWVF TTC
828 CATWDTSL 1652 TGCGCAACATGGGATACCAGCCTGAGTGCGTGGGTG
SAWVF TTC
829 CATWDNTL 1653 TGCGCAACATGGGACAACACCCTGAGTGCTGGGGTG
SAGVF TTC
830 CAAWDRSL 1654 TGCGCAGCATGGGATAGGAGCCTGAGTGTTTGGGTG
SVWVF TTC
831 CYTWHSSL 1655 TGCTACACATGGCATTCCAGTCTGCGTGGTGGGGTG
RGGVF TTC
832 CVTWTSSPS 1656 TGCGTAACGTGGACTAGTAGCCCGAGTGCTTGGGTG
AWVF TTC
833 CVTWRGGL 1657 TGCGTGACATGGCGTGGTGGCCTTGTGTTGTTC
VLF
834 CVTWDTSL 1658 TGCGTAACATGGGATACCAGCCTGACTTCTGTGGTA
TSVVL CTC
835 CVTWDTSL 1659 TGCGTAACATGGGATACCAGCCTGAGTGTTTATTGG
SVYWVF GTGTTC
836 CVTWDTSL 1660 TGCGTTACATGGGATACCAGCCTGAGTGCCTGGGTG
SAWVF TTC
837 CVTWDTDL 1661 TGCGTCACATGGGATACCGACCTCAGCGTTGCGCTC
SVALF TTC
838 CVTWDRSL 1662 TGCGTAACATGGGATAGGAGCCTGAGTGGTTGGGTG
SGWVF TTC
839 CVTWDRSL 1663 TGCGTAACATGGGATCGCAGCCTGAGAGAGGTGTTA
REVLF TTC
840 CVTWDRSL 1664 TGCGTAACATGGGATCGCAGCCTGAGAGCGGTGGTA
RAVVF TTC
841 CVTWDRSL 1665 TGCGTAACATGGGACAGGAGCCTCGATGCTGGGGTT
DAGVF TTC
842 CVTWDNTL 1666 TGCGTGACATGGGATAACACCCTGAGTGCTGGGGTC
SAGVF TTC
843 CVTWDNNL 1667 TGCGTAACATGGGATAACAACCTGTTTGGTGTGGTC
FGVVF TTC
844 CVSWDTSL 1668 TGCGTATCATGGGATACCAGCCTGAGTGGTGCGGTA
SGAVF TTC
845 CVSWDTSL 1669 TGCGTCTCATGGGATACCAGCCTGAGTGCTGGGGTA
SAGVF TTC
846 CTTWFRTPS 1670 TGCACAACATGGTTTAGGACTCCGAGTGATGTGGTC
DVVF TTC
847 CTTWFRTA 1671 TGCACAACATGGTTTAGGACTGCGAGTGATGTGGTC
SDVVF TTC
848 CTTWDYGL 1672 TGCACAACGTGGGATTACGGTCTGAGTGTCGTCTTC
SVVF
849 CTARDTSLS 1673 TGCACAGCAAGGGATACCAGCCTGAGTCCTGGCGGG
PGGVF GTCTTC
850 CSTWNTRP 1674 TGCTCAACATGGAATACGAGGCCGAGTGATGTGGTG
SDVVF TTC
851 CSTWESSLT 1675 TGTTCAACATGGGAGAGCAGTTTGACTACTGTGGTC
TVVF TTC
852 CSTWDTSL 1676 TGCTCAACATGGGATACCAGCCTCACTAATGTGCTA
TNVLF TTC
853 CSTWDTSL 1677 TGCTCAACATGGGATACCAGCCTGAGTGGAGTAGTC
SGVVF TTC
854 CSTWDHSL 1678 TGCTCAACATGGGATCACAGCCTGAAAGCTGCACTG
KAALF TTC
855 CSTWDARL 1679 TGCTCAACCTGGGATGCGAGGCTGAGTGTCCGGGTG
SVRVF TTC
856 CSSYTSSST 1680 TGCTCCTCATATACAAGCAGCAGCACTTGGGTGTTC
WVF
857 CSSYATRG 1681 TGCAGCTCATACGCAACCCGCGGCCTTCGTGTGTTG
LRVLF TTC
858 CSSWDATL 1682 TGTTCATCATGGGACGCCACCCTGAGTGTTCGCATA
SVRIF TTC
859 CQVWEGSS 1683 TGTCAGGTGTGGGAGGGTAGTAGTGATCATTGGGTG
DHWVF TTC
860 CQTWDNRL 1684 TGCCAAACCTGGGATAACAGACTGAGTGCTGTGGTG
SAVVF TTC
861 CQTWDHSL 1685 TGTCAAACGTGGGATCACAGCCTGCATGTTGGGGTG
HVGVF TTC
862 CQSYDDILN 1686 TGCCAGTCCTATGACGACATCTTGAATGTTTGGGTCC
VWVL TT
863 CNTWDKSL 1687 TGCAATACATGGGATAAGAGTTTGACTTCTGAACTC
TSELF TTC
864 CLTWDRSL 1688 TGCTTAACATGGGATCGCAGCCTGAATGTGAGGGTG
NVRVF TTC
865 CLTWDHSL 1689 TGCCTAACATGGGACCACAGCCTGACTGCTTATGTC
TAYVF TTC
866 CLTRDTSLS 1690 TGCTTAACAAGGGATACCAGTCTGAGTGCCCCTGTG
APVF TTC
867 CKTWESGL 1691 TGCAAAACATGGGAAAGTGGCCTTAATTTTGGCCAC
NFGHVF GTCTTC
868 CKTWDTSL 1692 TGCAAAACATGGGATACCAGCCTGAGTGCTGTGGTC
SAVVF TTC
869 CGVWDVSL 1693 TGCGGAGTCTGGGATGTCAGTCTGGGTGCTGGGGTG
GAGVF TTC
870 CGVWDTTP 1694 TGCGGAGTCTGGGATACCACCCCGAGTGCCGTTCTT
SAVLF TTC
871 CGVWDTTL 1695 TGCGGAGTCTGGGATACCACCCTGAGTGCCGTTCTT
SAVLF TTC
872 CGVWDTSL 1696 TGCGGAGTATGGGATACCAGCCTGGGGGTCTTC
GVF
873 CGVWDTNL 1697 TGCGGGGTATGGGATACCAACCTGGGTAAATGGGTT
GKWVF TTC
874 CGVWDTGL 1698 TGTGGAGTTTGGGATACTGGCCTGGATGCTGGTTGG
DAGWVF GTGTTC
875 CGVWDNV 1699 TGCGGAGTGTGGGATAACGTCCTGGAGGCCTATGTC
LEAYVF TTC
876 CGVWDISL 1700 TGCGGAGTCTGGGATATCAGCCTGAGTGCTAATTGG
SANWVF GTGTTC
877 CGVWDHSL 1701 TGCGGAGTATGGGATCACAGCCTGGGGATTTGGGCC
GIWAF TTC
878 CGVWDDIL 1702 TGCGGAGTTTGGGATGATATTCTGACTGCTGAAGTG
TAEVF TTC
879 CGVRDTSL 1703 TGCGGAGTTCGGGATACCAGCCTGGGGGTCTTC
GVF
880 CGTYDTSLP 1704 TGCGGAACATACGATACGAGCCTGCCTGCTTGGGTG
AWVF TTT
881 CGTYDNLV 1705 TGCGGAACTTACGATAATCTTGTATTTGGTTATGTCT
FGYVF TC
882 CGTYDDRL 1706 TGCGGAACATACGATGATAGACTCAGAGAGGTGTTC
REVF
883 CGTWVTSL 1707 TGCGGAACGTGGGTTACCAGCCTGAGTGCTGGGGTG
SAGVF TTC
884 CGTWVSSL 1708 TGCGGAACATGGGTTAGCAGCCTGACTACTGTAGTA
TTVVF TTC
885 CGTWVSSL 1709 TGCGGAACATGGGTTAGCAGCCTGAACGTCTGGGTG
NVWVF TTC
886 CGTWVGRF 1710 TGCGGAACATGGGTTGGCAGGTTTTGGGTATTC
WVF
887 CGTWSGGP 1711 TGCGGAACATGGTCTGGCGGCCCGAGTGGCCATTGG
SGHWLF TTGTTC
888 CGTWSGGL 1712 TGCGGAACATGGTCTGGCGGCCTGAGTGGCCATTGG
SGHWLF TTGTTC
889 CGTWQTGR 1713 TGCGGAACGTGGCAGACCGGCCGGGAGGCTGTCCTA
EAVLF TTT
890 CGTWQSRL 1714 TGCGGAACGTGGCAGAGCAGGCTGAGGTGGGTGTTC
RWVF
891 CGTWQSRL 1715 TGCGGAACGTGGCAGAGCAGGCTGGGGTGGGTGTTC
GWVF
892 CGTWPRSL 1716 TGCGGAACATGGCCTAGGAGCCTGAGTGCTGTTTGG
SAVWVF GTGTTC
893 CGTWNNYL 1717 TGCGGAACATGGAATAACTACCTGAGTGCTGGCGAT
SAGDVVF GTGGTTTTC
894 CGTWLGSQ 1718 TGCGGAACATGGCTTGGCAGCCAGAGTCCTTATTGG
SPYWVF GTCTTC
895 CGTWHTGL 1719 TGCGGAACATGGCATACCGGCCTGAGTGCTTATGTC
SAYVF TTC
896 CGTWHSTL 1720 TGCGGAACATGGCATAGTACCCTGAGTGCTGGCCAT
SAGHWVF TGGGTGTTC
897 CGTWHSSL 1721 TGCGGAACATGGCATAGTAGCCTGAGTACTTGGGTG
STWVF TTC
898 CGTWHSSL 1722 TGCGGAACATGGCATAGCAGCCTGAGTGCCTATGTC
SAYVF TTC
899 CGTWHSSL 1723 TGCGGAACATGGCATAGCAGCCTGAGTGCTGTGGTA
SAVVF TTC
900 CGTWHSGL 1724 TGCGGAACGTGGCATTCCGGCCTGAGTGGGTGGGTT
SGWVF TTC
901 CGTWHNTL 1725 TGCGGAACATGGCATAACACCCTGCGTAATGTGATA
RNVIF TTC
902 CGTWHASL 1726 TGCGGAACATGGCATGCCAGCCTGACTGCTGTGTTC
TAVF
903 CGTWGWY 1727 TGCGGGACATGGGGATGGTATGGCAGCCAGAGAGG
GSQRGVVF CGTCGTCTTC
904 CGTWGWY 1728 TGCGGGACATGGGGATGGTATGGCGGCCAGAGAGG
GGQRGVVF CGTCGTCTTC
905 CGTWGTSL 1729 TGCGGAACCTGGGGAACCAGCCTGAGTGCTTGGGTG
SAWVF TTC
906 CGTWGSSL 1730 TGCGGAACCTGGGGTAGCAGCCTGACTACTGGCCTG
TTGLF TTC
907 CGTWGSSL 1731 TGCGGAACATGGGGTAGCAGCCTGACTGCCTATGTC
TAYVF TTC
908 CGTWGSSL 1732 TGCGGAACATGGGGTAGCAGCCTGAGTGTTGTGTTC
SVVF
909 CGTWGSSL 1733 TGCGGAACATGGGGTAGCAGCCTGAGTGGTGGGGT
SGGVF GTTC
910 CGTWGSSL 1734 TGCGGAACATGGGGTAGCAGCCTGAGTGCTTATTGG
SAYWVF GTGTTC
911 CGTWGSSL 1735 TGCGGAACATGGGGTAGCAGCCTGAGTGCTTATGTG
SAYVVF GTGTTC
912 CGTWGSSL 1736 TGCGGAACATGGGGTAGCAGCCTGAGTGCTTATGTC
SAYVF TTC
913 CGTWGSSL 1737 TGCGGAACGTGGGGTAGTAGCCTGAGTGCTGTGGTG
SAVVF TTC
914 CGTWGSSL 1738 TGCGGAACATGGGGTAGCAGCCTGAGTGCTCCTTAT
SAPYVF GTCTTC
915 CGTWGSSL 1739 TGCGGAACATGGGGTAGCAGCCTGAGTGCCCCGGTG
SAPVF TTC
916 CGTWGSSL 1740 TGCGGAACATGGGGTAGCAGCCTGAGTGCTGGGGTG
SAGVF TTC
917 CGTWGSSL 1741 TGCGGAACTTGGGGTAGCAGCCTGAGTGCTGGACTG
SAGLF TTC
918 CGTWGSSL 1742 TGCGGAACATGGGGTAGCAGCCTGAGTGCTGGGGC
SAGALF ACTCTTC
919 CGTWGSSL 1743 TGCGGAACATGGGGCAGTAGCCTGCGTGCTTGGGTG
RAWVF TTC
920 CGTWFTSL 1744 TGCGGAACCTGGTTTACTAGTCTGGCTAGTGGGGTT
ASGVF TTC
921 CGTWETSL 1745 TGCGGAACTTGGGAGACCAGTCTGAGTGTCGTGGTC
SVVVI ATC
922 CGTWETSL 1746 TGCGGAACATGGGAGACCAGCCTGAGTGGTGTCTTC
SGVF
923 CGTWETSL 1747 TGCGGAACATGGGAAACCAGCCTGAGTGATTGGGTA
SDWVF TTC
924 CGTWETSL 1748 TGCGGAACATGGGAGACCAGCCTGAGTGCTGGGGT
SAGVF ATTC
925 CGTWETSL 1749 TGCGGAACATGGGAAACCAGCCTTAATTATGTGGCC
NYVAF TTC
926 CGTWETSL 1750 TGCGGAACATGGGAGACCAGCCTGAATACTTGGTTG
NTWLL CTC
927 CGTWETSE 1751 TGCGGAACATGGGAGACCAGCGAGAGTGGTAATTA
SGNYIF CATCTTC
928 CGTWETRL 1752 TGCGGAACATGGGAAACCAGACTGGGTACTTGGGTG
GTWVI ATC
929 CGTWETQL 1753 TGCGGAACATGGGAGACCCAGTTATATTGGGTGTTC
YWVF
930 CGTWETGL 1754 TGCGGAACATGGGAGACTGGCCTAAGTGCTGGAGA
SAGEVF GGTGTTC
931 CGTWESTL 1755 TGCGGAACTTGGGAAAGCACCCTGAGTGTTTTCCTA
SVFLF TTC
932 CGTWESSL 1756 TGCGGGACATGGGAAAGTAGCCTGACTGTTGTGGTC
TVVVF TTC
933 CGTWESSL 1757 TGCGGAACATGGGAAAGTAGCCTGACTGGAGTGGT
TGVVF ATTC
934 CGTWESSL 1758 TGCGGAACATGGGAAAGCAGCCTGACTGGTTTTGTC
TGFVF TTC
935 CGTWESSL 1759 TGTGGAACATGGGAGAGCAGCCTGAGTGTTGGGGTG
SVGVF TTC
936 CGTWESSL 1760 TGCGGAACCTGGGAAAGTAGCCTCAGTGAATGGGTG
SEWVF TTC
937 CGTWESSL 1761 TGCGGAACATGGGAGAGCAGCCTGAGTGCTGTATTC
SAVF
938 CGTWESSL 1762 TGCGGAACATGGGAGAGCAGCCTGAGTGCTGGTTAT
SAGYIF ATCTTC
939 CGTWESSL 1763 TGCGGAACATGGGAGAGCAGCCTGAGTGCTGGAGT
SAGVF GTTC
940 CGTWESSL 1764 TGCGGAACATGGGAAAGCAGCCTGAGCGCTGGCCC
SAGPVF GGTGTTC
941 CGTWESSL 1765 TGCGGAACATGGGAAAGCAGCCTGAGTGCTGGAGG
SAGGQVF CCAGGTGTTC
942 CGTWESSL 1766 TGCGGAACATGGGAGAGCAGCCTGAGTGCCTTCGGC
SAFGGYVF GGTTATGTCTTC
943 CGTWESSL 1767 TGCGGAACATGGGAAAGCAGCCTGAGGGTTTGGGT
RVWVF GTTC
944 CGTWESSL 1768 TGCGGAACATGGGAAAGCAGCCTCTTTACTGGGCCT
FTGPWVF TGGGTGTTC
945 CGTWESLS 1769 TGCGGAACATGGGAGAGCCTGAGTGCCACCTATGTC
ATYVF TTC
946 CGTWESGL 1770 TGCGGAACATGGGAGAGCGGCCTGAGTGCTGGTGTC
SAGVF TTC
947 CGTWESDF 1771 TGCGGAACATGGGAAAGCGACTTTTGGGTGTTT
WVF
948 CGTWENRL 1772 TGCGGTACATGGGAAAACAGACTGAGTGCTGTGGTC
SAVVF TTC
949 CGTWENRL 1773 TGCGGAACATGGGAAAACAGACTGAGTGCCGGGGT
SAGVF ATTC
950 CGTWEISLT 1774 TGCGGAACATGGGAAATCAGCCTGACTACTTCTGTG
TSVVF GTATTC
951 CGTWEISLS 1775 TGCGGAACATGGGAAATCAGCCTGAGTACTTCTGTG
TSVVF GTATTC
952 CGTWEGSL 1776 TGCGGAACATGGGAAGGCAGCCTCAGTGTTGTTTTC
SVVF
953 CGTWEGSL 1777 TGCGGAACATGGGAAGGCAGCCTGAGGGTGTTC
RVF
954 CGTWEGSL 1778 TGCGGAACATGGGAGGGCAGCCTGAGGCACGTGTTC
RHVF
955 CGTWDYSP 1779 TGCGGAACATGGGATTACAGCCCTGTACGTGCTGGG
VRAGVF GTGTTC
956 CGTWDYSL 1780 TGCGGAACGTGGGATTACAGCCTGAGTGTTTATCTC
SVYLF TTC
957 CGTWDYSL 1781 TGCGGAACATGGGATTACAGCCTGAGTTCTGGCGTG
SSGVVF GTATTC
958 CGTWDYSL 1782 TGCGGAACATGGGATTACAGCCTGAGTGCCTGGGTG
SAWVF TTC
959 CGTWDYSL 1783 TGCGGAACATGGGATTACAGTCTGAGTGCTGAGGTG
SAEVF TTC
960 CGTWDYSL 1784 TGCGGAACATGGGATTACAGCCTGCGTCGTGCGATA
RRAIF TTC
961 CGTWDWSL 1785 TGCGGAACATGGGATTGGAGCCTCATTCTTCAATTG
ILQLF TTC
962 CGTWDVTL 1786 TGCGGAACATGGGATGTCACCTTGCATACTGGGGTG
HTGVF TTC
963 CGTWDVTL 1787 TGCGGAACATGGGATGTCACCTTGCATATTGGGGTG
HIGVF TTC
964 CGTWDVTL 1788 TGCGGAACATGGGATGTCACCTTGCATGCTGGGGTG
HAGVF TTC
965 CGTWDVSL 1789 TGCGGAACATGGGATGTCAGTTTGTATAGTGGCGGG
YSGGVF GTCTTC
966 CGTWDVSL 1790 TGTGGAACATGGGATGTCAGCCTGACTTCTTTCGTCT
TSFVF TC
967 CGTWDVSL 1791 TGCGGAACATGGGATGTCAGCCTGAGTGTTGGGGTG
SVGVL CTC
968 CGTWDVSL 1792 TGCGGAACGTGGGATGTCAGCCTGAGTGCTGGCGAT
SAGDVVF GTAGTTTTC
969 CGTWDVSL 1793 TGCGGAACATGGGATGTCAGCCTGAATGTCGTGGTT
NVVVF TTC
970 CGTWDVSL 1794 TGCGGAACATGGGATGTCAGCCTGAATACTCAGGTG
NTQVF TTC
971 CGTWDVSL 1795 TGCGGCACATGGGATGTGAGCCTGGGTGCGCTGTTC
GALF
972 CGTWDVNL 1796 TGCGGAACGTGGGACGTTAATCTGAAAACTGTCGTT
KTVVF TTC
973 CGTWDVIL 1797 TGCGGAACATGGGATGTCATCCTGAGTGCTGAGGTA
SAEVF TTC
974 CGTWDTTV 1798 TGCGGAACATGGGATACCACCGTGAGTGCTGTGGTT
SAVVF TTC
975 CGTWDTTL 1799 TGCGGAACATGGGATACCACCCTGACTGCCTGGGTG
TAWVF TTC
976 CGTWDTTL 1800 TGCGGAACATGGGACACCACCTTGAGTGTTTTCCTA
SVFLF TTC
977 CGTWDTSV 1801 TGCGGGACTTGGGATACCAGTGTGAGTGCTGGGGTG
SAGVF TTC
978 CGTWDTSV 1802 TGCGGAACATGGGATACCAGTGTGATTTCTTGGGTT
ISWVF TTC
979 CGTWDTSR 1803 TGCGGAACATGGGATACCAGTCGGAGTTCTCTCTAT
SSLYVVF GTGGTCTTC
980 CGTWDTSR 1804 TGCGGAACATGGGATACCAGCCGGAGTGCTTGGGTA
SAWVF TTC
981 CGTWDTSR 1805 TGCGGAACATGGGATACCAGCCGGAATCCTGGAGG
NPGGIF AATTTTC
982 CGTWDTSR 1806 TGCGGAACATGGGACACCAGTCGGGGTCATGTTTTC
GHVF
983 CGTWDTSP 1807 TGCGGAACATGGGATACCAGCCCGAGTACTGGCCAG
STGQVLF GTGCTTTTC
984 CGTWDTSP 1808 TGCGGAACATGGGATACCAGCCCGAGTGCCTGGGTG
SAWVF TTC
985 CGTWDTSL 1809 TGCGGAACATGGGATACTAGCCTGACCTGGGTGTTC
TWVF
986 CGTWDTSL 1810 TGCGGAACATGGGATACCAGCCTGACGTGGTTCGCA
TWFAVF GTGTTC
987 CGTWDTSL 1811 TGCGGAACATGGGATACCAGCCTGACTGTTGTGGTA
TVVVF TTC
988 CGTWDTSL 1812 TGCGGAACATGGGATACCAGCCTGACTACTTCTTGG
TTSWVF GTGTTC
989 CGTWDTSL 1813 TGCGGAACATGGGATACCAGCCTGACCACTGGTCCT
TTGPFWVF TTTTGGGTGTTC
990 CGTWDTSL 1814 TGCGGAACATGGGATACCAGCCTGACTCCTTTTTAT
TPFYVF GTCTTC
991 CGTWDTSL 1815 TGCGGAACATGGGATACCAGCCTGACTGCTTATGTC
TAYVF TTC
992 CGTWDTSL 1816 TGCGGAACATGGGATACCAGCCTGACTGCTTGGGTG
TAWVF TTC
993 CGTWDTSL 1817 TGCGGAACATGGGATACCAGCCTGACTGCGTGGGGG
TAWGVF GTGTTC
994 CGTWDTSL 1818 TGCGGCACATGGGATACCAGCCTGACTGCGGTGGTT
TAVVL CTC
995 CGTWDTSL 1819 TGCGGAACCTGGGATACCAGCCTGACTGCTCGGGTT
TARVF TTC
996 CGTWDTSL 1820 TGCGGAACATGGGATACCAGCCTGACTGCGATTGTC
TAIVF TTC
997 CGTWDTSL 1821 TGCGGAACATGGGATACCAGCCTGACTGCTGGTGTC
TAGVF TTC
998 CGTWDTSL 1822 TGCGGAACATGGGATACCAGCCTGAGTGTTTATGTC
SVYVF TTC
999 CGTWDTSL 1823 TGCGGAACATGGGATACCAGCCTGAGTGTGGTGTTC
SVVF
1000 CGTWDTSL 1824 TGCGGGACATGGGATACCAGCCTGAGTGTTGGGGAA
SVGEF TTC
1001 CGTWDTSL 1825 TGCGGAACATGGGATACCAGCCTGAGTACTTGGGTG
STWVF TTC
1002 CGTWDTSL 1826 TGCGGAACATGGGATACCAGCCTGAGTACTGTGGTA
STVVF TTC
1003 CGTWDTSL 1827 TGCGGAACATGGGATACCAGCCTGAGTACTGGCCAG
STGQVLF GTGCTTTTC
1004 CGTWDTSL 1828 TGCGGCACATGGGATACCAGCCTGAGCACTGGTCCT
STGPLWVF CTTTGGGTGTTC
1005 CGTWDTSL 1829 TGCGGAACTTGGGATACCAGCCTGAGTTCTTATGTC
SSYVF TTC
1006 CGTWDTSL 1830 TGCGGAACATGGGATACCAGCCTGAGTTCTGTGGTC
SSVVF TTC
1007 CGTWDTSL 1831 TGCGGAACATGGGATACCAGCCTGAGTTCTAGATAC
SSRYIF ATATTC
1008 CGTWDTSL 1832 TGCGGAACATGGGATACCAGCCTGAGTTCTAGATTC
SSRFIF ATATTC
1009 CGTWDTSL 1833 TGCGGAACATGGGATACCAGCCTGAGTTCTGGGTGG
SSGWVF GTGTTC
1010 CGTWDTSL 1834 TGCGGAACATGGGATACCAGCCTGAGTCGGTATGTG
SRYVF TTC
1011 CGTWDTSL 1835 TGCGGAACTTGGGATACCAGTCTGAGTCAATGGCTG
SQWLF TTC
1012 CGTWDTSL 1836 TGCGGAACATGGGATACCAGCCTGAGTCCTGGCCTT
SPGLWVF TGGGTGTTC
1013 CGTWDTSL 1837 TGCGGAACATGGGATACCAGCCTGAGTAATTATGTC
SNYVF TTC
1014 CGTWDTSL 1838 TGCGGAACATGGGATACCAGCCTAAGTATTTGGGTG
SIWVF TTC
1015 CGTWDTSL 1839 TGCGGCACATGGGATACCAGCCTGAGCATTGGTCCT
SIGPFWVF TTTTGGGTGTTC
1016 CGTWDTSL 1840 TGCGGAACATGGGATACCAGCCTGAGTGGTTGGGTG
SGWVF TTC
1017 CGTWDTSL 1841 TGCGGAACATGGGATACCAGCCTGAGTGGTACAGTG
SGTVF TTC
1018 CGTWDTSL 1842 TGCGGAACATGGGATACTAGTCTGAGTGGTGGCCAG
SGGQVF GTGTTC
1019 CGTWDTSL 1843 TGCGGAACATGGGATACCAGCCTGAGTGGTGGGATA
SGGIF TTC
1020 CGTWDTSL 1844 TGCGGAACATGGGATACCAGCCTGAGTGGTGAGGAT
SGEDVVI GTGGTAATC
1021 CGTWDTSL 1845 TGCGGAACATGGGATACCAGCCTGAGTTTCCTTTAT
SFLYAF GCTTTC
1022 CGTWDTSL 1846 TGCGGAACATGGGATACCAGCCTGAGTGAGGTCGTA
SEVVF TTC
1023 CGTWDTSL 1847 TGCGGAACATGGGATACCAGCCTGAGTGAAGTGTTC
SEVF
1024 CGTWDTSL 1848 TGCGGAACATGGGATACTAGCCTGAGTGAAAATTGG
SENWVF GTGTTC
1025 CGTWDTSL 1849 TGCGGAACATGGGATACCAGCCTGAGTGCCTACATA
SAYIF TTC
1026 CGTWDTSL 1850 TGCGGAACATGGGATACCAGCCTGAGTGCTGTGGTA
SAVVL CTC
1027 CGTWDTSL 1851 TGCGGAACATGGGATACCAGCCTGAGTGCTGTTTTC
SAVF
1028 CGTWDTSL 1852 TGCGGAACATGGGATACCAGCCTGAGTGCCCGGGTG
SARVF TTC
1029 CGTWDTSL 1853 TGCGGCACATGGGATACCAGCCTGAGTGCCCGCCAG
SARQVF GTATTC
1030 CGTWDTSL 1854 TGCGGAACATGGGATACCAGCCTGAGTGCTTTGGTT
SALVF TTC
1031 CGTWDTSL 1855 TGCGGAACATGGGATACCAGCCTGAGTGCTAAGGTG
SAKVF TTC
1032 CGTWDTSL 1856 TGCGGAACATGGGATACCAGCCTGAGTGCGAAAATC
SAKIF TTC
1033 CGTWDTSL 1857 TGCGGAACATGGGATACCAGCCTGAGTGCCAAGGC
SAKAVF GGTATTC
1034 CGTWDTSL 1858 TGCGGAACATGGGATACCAGCCTGAGTGCCCATGCT
SAHAVF GTGTTC
1035 CGTWDTSL 1859 TGCGGAACATGGGATACCAGCCTGAGTGCTGGCTAT
SAGYVF GTCTTC
1036 CGTWDTSL 1860 TGCGGAACATGGGACACCAGTCTGAGTGCTGGCCGC
SAGRWVF TGGGTGTTC
1037 CGTWDTSL 1861 TGCGGAACATGGGATACCAGCCTGAGTGCTGGGATA
SAGIF TTC
1038 CGTWDTSL 1862 TGCGGAACATGGGATACCAGCCTGAGTGCTGGTGGG
SAGGFRVF TTCCGGGTCTTC
1039 CGTWDTSL 1863 TGCGGAACATGGGATACCAGCCTGAGTGCTGGGGCA
SAGAF TTC
1040 CGTWDTSL 1864 TGCGGAACATGGGATACCAGTCTGAGTGCTGATTGG
SADWFF TTTTTC
1041 CGTWDTSL 1865 TGCGGAACATGGGATACCAGCCTGAGTGCTGATGAA
SADEYVF TATGTCTTC
1042 CGTWDTSL 1866 TGCGGCACATGGGATACCAGCCTGAGTGCGGCTTGG
SAAWVF GTGTTC
1043 CGTWDTSL 1867 TGCGGAACATGGGATACCAGCCTGAGTGCTGCGCTA
SAALF TTC
1044 CGTWDTSL 1868 TGCGGAACATGGGATACCAGCCTGAGTGCTGCGGGG
SAAGVF GTTTTC
1045 CGTWDTSL 1869 TGCGGAACATGGGATACCAGCCTGAGAGTTGTGGTT
RVVVF TTC
1046 CGTWDTSL 1870 TGCGGAACATGGGATACCAGCCTGAGAACCTGGGTA
RTWVF TTC
1047 CGTWDTSL 1871 TGCGGAACGTGGGATACCAGCCTGAGGGGTGCAGT
RGAVF GTTC
1048 CGTWDTSL 1872 TGCGGAACATGGGATACCAGCCTGCGTGCTGTGGTA
RAVVF TTC
1049 CGTWDTSL 1873 TGCGGAACATGGGATACAAGCCTGAATGTAGTTTAT
NVVYVF GTCTTC
1050 CGTWDTSL 1874 TGCGGAACATGGGATACCAGCCTCAACACCTACCTG
NTYLF TTC
1051 CGTWDTSL 1875 TGCGGAACATGGGATACTAGCCTGAACTTCGCTTGG
NFAWLF CTGTTC
1052 CGTWDTSL 1876 TGCGGCACATGGGATACCAGCCTTCTTGTGTGGCTTT
LVWLF TC
1053 CGTWDTSL 1877 TGCGGAACATGGGATACCAGTCTGAAGACGTGGGTG
KTWVF TTC
1054 CGTWDTSLI 1878 TGCGGAACATGGGATACCAGTCTGATTGTCTGGGTG
VWVF TTC
1055 CGTWDTSLI 1879 TGCGGAACATGGGATACCAGCCTAATTACTGGGGTG
TGVF TTC
1056 CGTWDTSLI 1880 TGCGGAACATGGGATACCAGCCTGATTAGCGTGGTA
SVVF TTC
1057 CGTWDTSLI 1881 TGCGGAACATGGGATACCAGCCTGATTGCTTATGTC
AYVF TTC
1058 CGTWDTSL 1882 TGCGGAACATGGGATACCAGCCTGCACACTGAGTTG
HTELF TTC
1059 CGTWDTSL 1883 TGCGGAACTTGGGATACCAGCCTGGGTTCTTATGTC
GSYVF TTC
1060 CGTWDTSL 1884 TGCGGAACATGGGATACCAGCCTGGGTTCTCTTTGG
GSLWVF GTGTTC
1061 CGTWDTSL 1885 TGCGGTACATGGGATACCAGCCTGGGTTCTGGGGTA
GSGVF TTC
1062 CGTWDTSL 1886 TGCGGAACTTGGGATACCAGTCTGGGTGGTAGAGGG
GGRGVF GTCTTC
1063 CGTWDTSL 1887 TGCGGAACATGGGATACCAGCCTGGGTGCTTGGGTG
GAWVF TTC
1064 CGTWDTSL 1888 TGCGGAACATGGGATACCAGCCTGGGTGCCGTGGTA
GAVVF TTC
1065 CGTWDTSL 1889 TGCGGAACATGGGATACCAGCCTGGGTGCTGGGGTA
GAGVF TTC
1066 CGTWDTSL 1890 TGCGGAACATGGGATACCAGCCTGGGTGCTGGCCTA
GAGLF TTC
1067 CGTWDTSL 1891 TGCGGAACATGGGATACCAGTCTGGATGCTGTGGTT
DAVVF TTC
1068 CGTWDTSL 1892 TGCGGGACTTGGGATACCAGCCTGGATGCTGTGCTG
DAVLF TTC
1069 CGTWDTSL 1893 TGCGGAACATGGGATACCAGCCTGGCTTGGGTGTTC
AWVF
1070 CGTWDTSL 1894 TGCGGAACATGGGATACCAGCCTGGCGACTGGACTG
ATGLF TTC
1071 CGTWDTSL 1895 TGCGGGACATGGGATACCAGCCTGGCCCCTGTAGTC
APVVF TTC
1072 CGTWDTRL 1896 TGCGGAACATGGGACACCCGCCTGACTATTGTGATC
TIVIF TTC
1073 CGTWDTRL 1897 TGTGGAACATGGGACACCAGGCTGAGTGTTTGGCTG
SVWLF TTC
1074 CGTWDTRL 1898 TGCGGAACGTGGGACACCAGACTGAGTGTTGGGGTT
SVGVF TTC
1075 CGTWDTRL 1899 TGCGGCACATGGGATACCAGACTGAGTACTGTAATT
STVIF TTC
1076 CGTWDTRL 1900 TGCGGAACATGGGATACCCGCCTGAGTTCTGTGGTC
SSVVF TTC
1077 CGTWDTRL 1901 TGCGGAACATGGGATACCCGCCTGAGTATTGTGGTT
SIVVF TTC
1078 CGTWDTRL 1902 TGCGGAACATGGGATACCAGACTGAGTGCCTATGTG
SAYVVF GTATTC
1079 CGTWDTRL 1903 TGCGGAACCTGGGACACCCGCCTGAGTGCGTGGGTG
SAWVF TTC
1080 CGTWDTRL 1904 TGCGGAACATGGGATACCAGACTGAGTGCTGTGGTG
SAVVF TTC
1081 CGTWDTRL 1905 TGCGGAACATGGGATACCCGCCTGAGTGCTGGGTTG
SAGLF TTC
1082 CGTWDTRL 1906 TGCGGAACATGGGATACCAGACTGAGTGCTGGTGGG
SAGGVF GTGTTC
1083 CGTWDTRL 1907 TGCGGAACATGGGATACCAGATTGAATGTGTGGCTA
NVWLF TTC
1084 CGTWDTNR 1908 TGCGGAACATGGGATACCAACCGGGAAGTTGTGCTC
EVVLL CTC
1085 CGTWDTNL 1909 TGCGGAACATGGGATACCAACCTGCGTGCCCATGTC
RAHVF TTC
1086 CGTWDTNL 1910 TGCGGAACATGGGATACTAATCTGCCCGCTGTAGTG
PAVVF TTC
1087 CGTWDTNL 1911 TGCGGAACATGGGACACCAATTTGGGTGGGGTGTTC
GGVF
1088 CGTWDTIV 1912 TGCGGAACATGGGATACCATCGTGAGTATTGGGGTG
SIGVF TTC
1089 CGTWDTILS 1913 TGCGGAACATGGGATACCATCCTGAGTGCGGTGGTG
AVVF TTC
1090 CGTWDTILS 1914 TGCGGCACATGGGATACCATCCTGAGTGCTGAGGTG
AEVF TTC
1091 CGTWDTHL 1915 TGCGGAACATGGGATACCCACCTGGGTGTGGTTTTC
GVVF
1092 CGTWDTGP 1916 TGCGGAACATGGGATACCGGCCCGAGCCCTCATTGG
SPHWLF CTGTTC
1093 CGTWDTGL 1917 TGCGGAACATGGGATACCGGCCTGACTTTTGGAGGC
TFGGVF GTGTTC
1094 CGTWDTGL 1918 TGCGGAACATGGGATACCGGCCTGACTGCTTTTGTC
TAFVF TTC
1095 CGTWDTGL 1919 TGCGGAACATGGGATACCGGCCTGAGTGTTTGGGTG
SVWVF TTC
1096 CGTWDTGL 1920 TGCGGAACATGGGATACCGGCCTGAGTACTGGGATT
STGIF TTC
1097 CGTWDTGL 1921 TGCGGAACATGGGATACCGGCCTGAGTTCCCTGCTC
SSLLF TTC
1098 CGTWDTGL 1922 TGCGGAACGTGGGACACCGGCCTGAGTATTGTGGTG
SIVVF TTC
1099 CGTWDTGL 1923 TGCGGAACGTGGGACACCGGCCTGAGTTTTGTGGTG
SFVVF TTC
1100 CGTWDTGL 1924 TGCGGAACATGGGATACCGGCCTGAGTGCTTGGGTG
SAWVF TTC
1101 CGTWDTGL 1925 TGCGGAACATGGGATACCGGCCTGAGTGCTGGTGTG
SAGVVF GTATTC
1102 CGTWDTGL 1926 TGCGGAACATGGGATACCGGTCTGAGGGGTTGGATT
RGWIF TTC
1103 CGTWDTEL 1927 TGCGGAACATGGGATACCGAGCTAAGTGCGGGGGT
SAGVF CTTC
1104 CGTWDTAL 1928 TGCGGAACGTGGGATACCGCCCTGACTGCTGGGGTG
TAGVF TTC
1105 CGTWDTAL 1929 TGCGGAACATGGGATACTGCCCTGAGTCTTGTGGTC
SLVVF TTC
1106 CGTWDTAL 1930 TGCGGAACATGGGATACCGCCCTGAGTGCCTGGCTG
SAWLF TTC
1107 CGTWDTAL 1931 TGCGGCACATGGGATACCGCCCTGAGTGCTGGGGTG
SAGVF TTC
1108 CGTWDTAL 1932 TGCGGAACATGGGATACCGCCCTGCGTGGCGTGCTG
RGVLF TTC
1109 CGTWDTAL 1933 TGCGGAACATGGGATACCGCCCTGAAAGAATGGCTG
KEWLF TTC
1110 CGTWDRTL 1934 TGCGGAACATGGGATAGGACCCTGACTGCTGGCGAT
TAGDVLF GTGCTCTTC
1111 CGTWDRSV 1935 TGCGGAACATGGGATAGAAGCGTGACTTATGTCTTC
TYVF
1112 CGTWDRSR 1936 TGCGGAACATGGGATCGCAGCCGAAATGAATGGGT
NEWVF GTTC
1113 CGTWDRSL 1937 TGCGGAACATGGGATCGCAGTCTGACTGTTTGGGTC
TVWVF TTC
1114 CGTWDRSL 1938 TGCGGAACATGGGATCGCAGCCTGACTCCTGGGTGG
TPGWLF TTGTTC
1115 CGTWDRSL 1939 TGCGGAACATGGGATAGAAGCCTGACTGCTTGGGTG
TAWVF TTC
1116 CGTWDRSL 1940 TGCGGAACATGGGACCGCAGCCTGAGTGTTGTGGTA
SVVVF TTC
1117 CGTWDRSL 1941 TGCGGCACATGGGATCGCAGCCTGAGTGTAGTCTTC
SVVF
1118 CGTWDRSL 1942 TGCGGAACATGGGATAGGAGCCTGAGTGTTCAATTG
SVQLF TTC
1119 CGTWDRSL 1943 TGCGGAACATGGGATCGCAGCCTCAGTGTTCTTTGG
SVLWVF GTGTTC
1120 CGTWDRSL 1944 TGCGGAACATGGGATCGCAGCCTGAGTGTTGGATTA
SVGLF TTC
1121 CGTWDRSL 1945 TGCGGAACATGGGATCGCAGCCTGAGTACTTGGGTG
STWVF TTC
1122 CGTWDRSL 1946 TGCGGAACATGGGATAGAAGCCTGAGTACTCATTGG
STHWVL GTGCTC
1123 CGTWDRSL 1947 TGCGGAACATGGGATAGAAGCCTGAGTACTCATTGG
STHWVF GTGTTC
1124 CGTWDRSL 1948 TGCGGAACCTGGGATCGAAGCCTGAGTTCTGCGGTG
SSAVF TTC
1125 CGTWDRSL 1949 TGCGGAACATGGGACAGAAGCCTGAGTCCCTCTTAT
SPSYVF GTCTTC
1126 CGTWDRSL 1950 TGCGGAACATGGGATAGGAGCCTGAGTGGTGAGGT
SGEVF GTTC
1127 CGTWDRSL 1951 TGCGGAACATGGGATAGGAGCCTGAGTGGTGCGGT
SGAVF GTTC
1128 CGTWDRSL 1952 TGCGGAACATGGGATCGCAGCCTGAGTGCTGTGGCA
SAVAF TTC
1129 CGTWDRSL 1953 TGCGGAACATGGGATAGGAGCCTGAGTGCCGGGGG
SAGGEF GGAATTC
1130 CGTWDRSL 1954 TGCGGAACATGGGATCGCAGCCTGAGTGCTTTTTGG
SAFWVF GTGTTC
1131 CGTWDRSL 1955 TGCGGAACATGGGATAGGAGCCTGAGTGCTGCGGTG
SAAVF TTC
1132 CGTWDRSL 1956 TGCGGAACATGGGATAGGAGCCTGAGTGCTGCACTC
SAALF TTC
1133 CGTWDRSL 1957 TGCGGAACATGGGATCGCAGCCTGAGAGTGTTC
RVF
1134 CGTWDRSL 1958 TGCGGTACATGGGACAGAAGCCTTAATTGGGTGTTC
NWVF
1135 CGTWDRSL 1959 TGCGGAACATGGGATCGCAGCCTGAATGTTTATGTC
NVYVF TTC
1136 CGTWDRSL 1960 TGCGGAACATGGGATAGGAGCCTGAATGTTGGGGTG
NVGVF TTC
1137 CGTWDRSL 1961 TGCGGAACATGGGATCGGAGCCTGCATGTGGTCTTC
HVVF
1138 CGTWDRSL 1962 TGTGGAACATGGGATCGCAGCCTGGGTGGTTGGGTG
GGWVF TTC
1139 CGTWDRSL 1963 TGCGGAACATGGGATCGCAGCCTGGGTGCTTTTTGG
GAFWVF GTGTTC
1140 CGTWDRSL 1964 TGCGGAACATGGGATAGAAGCCTGTTTTGGGTGTTC
FWVF
1141 CGTWDRSL 1965 TGCGGAACGTGGGATCGCAGCCTGGCTGCTGGGGTG
AAGVF TTC
1142 CGTWDRRL 1966 TGCGGAACATGGGATAGGAGGTTGAGTGGTGTCGTA
SGVVF TTC
1143 CGTWDRRL 1967 TGCGGAACGTGGGATCGCCGCCTAAGTGATGTGGTA
SDVVF TTC
1144 CGTWDRRL 1968 TGCGGAACATGGGATAGGAGGCTGAGTGCTGTGGTA
SAVVF TTC
1145 CGTWDRRL 1969 TGCGGAACATGGGATAGACGCCTGAATGTTGCGTTC
NVAFF TTC
1146 CGTWDRRL 1970 TGTGGAACATGGGATAGGAGGCTGCTTGCTGTTTTC
LAVF
1147 CGTWDRNL 1971 TGCGGAACTTGGGATAGGAACCTGCGCGCCGTGGTC
RAVVF TTC
1148 CGTWDRLS 1972 TGCGGAACATGGGATAGGCTGAGTGCTGGGGTGTTC
AGVF
1149 CGTWDRGP 1973 TGCGGAACATGGGATAGAGGCCCGAATACTGGGGT
NTGVF ATTC
1150 CGTWDRGL 1974 TGCGGAACATGGGATAGAGGCCTGAATACTGTTTAC
NTVYVF GTCTTC
1151 CGTWDNY 1975 TGCGGAACATGGGATAACTATGTGAGTGCCCCTTGG
VSAPWVF GTGTTC
1152 CGTWDNYL 1976 TGCGGAACATGGGATAACTACCTGAGTGCTGGCGAT
SAGDVVF GTGGTTTTC
1153 CGTWDNYL 1977 TGCGGAACATGGGATAACTACCTGAGAGCTGGGGTC
RAGVF TTC
1154 CGTWDNYL 1978 TGCGGAACATGGGACAATTATCTGGGTGCCGTGGTT
GAVVF TTC
1155 CGTWDNYL 1979 TGCGGAACATGGGATAACTACCTGGGTGCGGGGGTG
GAGVF TTC
1156 CGTWDNTV 1980 TGCGGAACATGGGATAACACCGTGAGTGCCCCTTGG
SAPWVF GTTTTC
1157 CGTWDNTL 1981 TGCGGAACATGGGATAACACCCTGAGTCTTTGGGTG
SLWVF TTC
1158 CGTWDNTL 1982 TGCGGAACATGGGATAACACCCTGAGTGCTGGGGTC
SAGVF TTC
1159 CGTWDNTL 1983 TGCGGAACATGGGACAACACTCTGCTTACTGTGTTA
LTVLF TTC
1160 CGTWDNRL 1984 TGCGGAACATGGGATAACAGACTGAGTAGTGTGATT
SSVIF TTC
1161 CGTWDNRL 1985 TGCGGAACATGGGATAACAGGTTGAGTGCTGTGGTC
SAVVF TTC
1162 CGTWDNRL 1986 TGCGGAACATGGGATAACAGGCTGAGTGCTGGTGG
SAGGIF GATATTC
1163 CGTWDNRL 1987 TGCGGAACATGGGATAACAGACTGAGTGCTGAGGT
SAEVF GTTC
1164 CGTWDNRL 1988 TGTGGAACATGGGATAACAGACTGCGTGTTGGGGTT
RVGVL CTC
1165 CGTWDNRL 1989 TGCGGAACATGGGATAATCGCCTGCTTGAGAATGTC
LENVF TTC
1166 CGTWDNNL 1990 TGCGGAACATGGGATAACAACCTGCGTGCTGTCTTC
RAVF
1167 CGTWDNNL 1991 TGCGGAACTTGGGATAATAACCTGCGTGCTGGAGTG
RAGVF TTC
1168 CGTWDNNL 1992 TGCGGAACATGGGACAACAATTTGGGCGGTGGCCG
GGGRVF GGTGTTC
1169 CGTWDNNL 1993 TGCGGAACATGGGATAACAACCTGGGTGCTGGCGTC
GAGVL CTC
1170 CGTWDNNL 1994 TGCGGAACATGGGATAACAACCTGGGTGCTGGCGTC
GAGVF TTC
1171 CGTWDNIL 1995 TGCGGAACTTGGGATAACATCCTGAGCGCTGCGGTG
SAAVF TTC
1172 CGTWDNIL 1996 TGCGGAACCTGGGATAACATCTTGGATGCAGGGGTT
DAGVF TTC
1173 CGTWDNDL 1997 TGCGGAACATGGGATAACGACCTGAGTGGTTGGCTG
SGWLF TTC
1174 CGTWDNDL 1998 TGCGGAACATGGGATAACGACCTGAGTGCCTGGGTG
SAWVF TTC
1175 CGTWDLTL 1999 TGCGGAACATGGGATCTCACCCTGGGTGGTGTGGTG
GGVVF TTC
1176 CGTWDLSL 2000 TGCGGAACATGGGATCTCAGCCTGAGTGCTGGGGTA
SAGVF TTC
1177 CGTWDLSL 2001 TGCGGAACATGGGATCTCAGCCTGAAAGAATGGGTG
KEWVF TTC
1178 CGTWDLSL 2002 TGCGGAACGTGGGATCTCAGCCTGGATGCTGTTGTT
DAVVF TTC
1179 CGTWDLKV 2003 TGCGGAACCTGGGACCTGAAGGTTTTC
F
1180 CGTWDKTL 2004 TGCGGAACATGGGATAAGACTCTGAGTGTTTGGGTG
SVWVF TTC
1181 CGTWDKSL 2005 TGCGGAACATGGGATAAGAGCCTGAGTGTTTGGGTG
SVWVF TTC
1182 CGTWDKSL 2006 TGCGGAACATGGGATAAGAGCCTGAGTGGTGTGGTA
SGVVF TTT
1183 CGTWDKSL 2007 TGCGGAACATGGGATAAGAGCCTGAGTGATTGGGTG
SDWVF TTC
1184 CGTWDKSL 2008 TGCGGAACATGGGATAAGAGCCTGAGTGCTTTGGTT
SALVF TTC
1185 CGTWDKSL 2009 TGCGGAACATGGGATAAGAGCCTGAGTGCTGGCGTC
SAGVF TTC
1186 CGTWDKSL 2010 TGCGGAACATGGGATAAGAGCCTGAGTGCCGACGTC
SADVF TTC
1187 CGTWDKRL 2011 TGCGGAACATGGGATAAACGCCTGACTATTGTGGTC
TIVVF TTC
1188 CGTWDKRL 2012 TGCGGAACATGGGATAAACGCCTGAGTGCCTGGGTG
SAWVL CTC
1189 CGTWDKNL 2013 TGCGGAACATGGGATAAGAACCTGCGTGCTGTGGTC
RAVVF TTC
1190 CGTWDITLS 2014 TGCGGAACATGGGATATCACCCTGAGTGGGTTTGTC
GFVF TTC
1191 CGTWDITL 2015 TGCGGAACATGGGATATCACCTTGCATACTGGAGTA
HTGVF TTC
1192 CGTWDISV 2016 TGCGGAACATGGGATATCAGTGTGACTGTGGTGTTC
TVVF
1193 CGTWDISV 2017 TGCGGAACATGGGATATCAGTGTGAGGGGTTATGCC
RGYAF TTC
1194 CGTWDISR 2018 TGCGGAACATGGGATATCAGCCGTTGGGTTTTC
WVF
1195 CGTWDISPS 2019 TGCGGAACATGGGATATCAGCCCGAGTGCTTGGGTG
AWVF TTC
1196 CGTWDISLS 2020 TGCGGAACATGGGATATTAGCCTGAGTGTCTGGGTG
VWVF TTC
1197 CGTWDISLS 2021 TGCGGAACATGGGATATCAGCCTGAGTGTTGTATTC
VVF
1198 CGTWDISLS 2022 TGCGGAACTTGGGATATCAGCCTGAGTTCTGTGGTG
SVVF TTC
1199 CGTWDISLS 2023 TGCGGAACATGGGATATCAGCCTGAGTCACTGGTTG
HWLF TTC
1200 CGTWDISLS 2024 TGCGGAACATGGGATATCAGTCTGAGTGGTTGGGTG
GWVF TTC
1201 CGTWDISLS 2025 TGCGGAACATGGGATATCAGCCTGAGTGGTCGAGTG
GRVF TTC
1202 CGTWDISLS 2026 TGCGGAACATGGGACATCAGCCTGAGTGCTTGGGCG
AWAF TTC
1203 CGTWDISLS 2027 TGCGGAACATGGGATATCAGCCTGAGTGCTGTGGTT
AVVF TTC
1204 CGTWDISLS 2028 TGCGGGACATGGGACATCAGCCTGAGTGCTGTGATA
AVIF TTC
1205 CGTWDISLS 2029 TGCGGAACATGGGATATCAGCCTGAGTGCTGTGTTC
AVF
1206 CGTWDISLS 2030 TGCGGAACATGGGATATCAGCCTGAGTGCCCGGGTG
ARVF TTC
1207 CGTWDISLS 2031 TGCGGAACATGGGATATCAGCCTGAGTGCCCTGGTG
ALVF TTC
1208 CGTWDISLS 2032 TGCGGAACATGGGATATTAGCCTGAGTGCCCATGTC
AHVF TTC
1209 CGTWDISLS 2033 TGCGGAACATGGGATATCAGCCTGAGTGCTGGGGTG
AGVVF GTATTC
1210 CGTWDISLS 2034 TGCGGAACATGGGATATCAGCCTGAGTGCCGGCCCT
AGPYVF TATGTCTTC
1211 CGTWDISLS 2035 TGCGGCACATGGGATATCAGCCTGAGTGCTGGAGGG
AGGVF GTGTTC
1212 CGTWDISLS 2036 TGCGGAACATGGGATATCAGCCTGAGTGCTGAGGTT
AEVF TTC
1213 CGTWDISLS 2037 TGCGGAACATGGGATATCAGCCTGAGTGCTGCTGTG
AAVF TTC
1214 CGTWDISL 2038 TGCGGAACATGGGATATCAGCCTGCGTGCTGTGTTC
RAVF
1215 CGTWDISL 2039 TGCGGAACATGGGATATTAGCCTGAATACTGGGGTG
NTGVF TTC
1216 CGTWDISL 2040 TGCGGAACATGGGATATCAGCCTAAATAATTATGTC
NNYVF TTC
1217 CGTWDISLI 2041 TGCGGAACATGGGATATCAGCCTAATTGCTGGGGTA
AGVF TTC
1218 CGTWDISL 2042 TGCGGAACATGGGATATCAGCCTGCATACTTGGCTG
HTWLF TTC
1219 CGTWDIRL 2043 TGCGGAACATGGGATATCCGCCTGACCGATGAGCTG
TDELLF TTATTC
1220 CGTWDIRL 2044 TGCGGAACATGGGATATCAGACTGAGCGGTTTTGTT
SGFVF TTC
1221 CGTWDINL 2045 TGCGGAACATGGGATATCAACCTGGGTGCTGGGGGC
GAGGLYVF CTTTATGTCTTC
1222 CGTWDIILS 2046 TGCGGAACATGGGATATCATCCTGAGTGCTGAGGTA
AEVF TTC
1223 CGTWDHTL 2047 TGCGGAACATGGGATCACACCCTGAGTGCTGTCTTC
SAVF
1224 CGTWDHTL 2048 TGCGGAACATGGGACCACACTCTGCTTACTGTGTTA
LTVLF TTC
1225 CGTWDHSL 2049 TGCGGAACATGGGATCACAGCCTGACTGCTGTGGTA
TAVVF TTC
1226 CGTWDHSL 2050 TGCGGAACCTGGGATCACAGCCTGACTGCTGGGATA
TAGIF TTC
1227 CGTWDHSL 2051 TGCGGAACATGGGATCACAGCCTGAGTGTTGTATTA
SVVLF TTC
1228 CGTWDHSL 2052 TGCGGAACATGGGATCACAGCCTGAGTTTGGTATTC
SLVF
1229 CGTWDHSL 2053 TGCGGAACATGGGATCACAGCCTGTCTATTGGGGTT
SIGVF TTC
1230 CGTWDHSL 2054 TGCGGAACATGGGATCACAGCCTGAGTGCTGGGGTG
SAGVF TTC
1231 CGTWDHSL 2055 TGTGGAACTTGGGATCACAGCCTGAGTGCTTTCGTG
SAFVF TTC
1232 CGTWDHSL 2056 TGCGGAACATGGGATCACAGTCTGAGTGCTGCTGTT
SAAVF TTC
1233 CGTWDHNL 2057 TGCGGAACATGGGACCACAATCTGCGTGCTGTCTTC
RAVF
1234 CGTWDFTL 2058 TGCGGGACATGGGATTTCACCCTGAGTGTTGGGCGC
SVGRF TTC
1235 CGTWDFTL 2059 TGCGGAACATGGGATTTCACCCTGAGTGCTCCTGTC
SAPVF TTC
1236 CGTWDFSV 2060 TGCGGAACGTGGGATTTCAGCGTGAGTGCTGGGTGG
SAGWVF GTGTTC
1237 CGTWDFSL 2061 TGCGGAACGTGGGATTTCAGTCTTACTACCTGGTTAT
TTWLF TC
1238 CGTWDFSL 2062 TGCGGAACATGGGATTTCAGCCTGAGTGTTTGGGTG
SVWVF TTC
1239 CGTWDFSL 2063 TGCGGAACATGGGATTTCAGCCTGAGTACTGGGGTT
STGVF TTC
1240 CGTWDFSL 2064 TGCGGCACATGGGATTTCAGCCTGAGTGGTGTGGTA
SGVVF TTC
1241 CGTWDFSL 2065 TGCGGAACATGGGATTTCAGCCTGAGTGGTTTCGTG
SGFVF TTC
1242 CGTWDFSL 2066 TGCGGAACATGGGATTTCAGCCTGAGTGCTGGGGTG
SAGVF TTC
1243 CGTWDETV 2067 TGCGGAACATGGGATGAAACCGTGAGAGGTTGGGT
RGWVF GTTC
1244 CGTWDESL 2068 TGCGGAACATGGGATGAAAGTCTGAGAAGCTGGGT
RSWVF GTTC
1245 CGTWDERQ 2069 TGCGGAACTTGGGATGAGAGGCAGACTGATGAGTCC
TDESYVF TATGTCTTC
1246 CGTWDERL 2070 TGCGGAACATGGGATGAGAGACTCGTTGCTGGCCAG
VAGQVF GTCTTC
1247 CGTWDERL 2071 TGCGGAACATGGGATGAGAGACTGAGTCCTGGAGCT
SPGAFF TTTTTC
1248 CGTWDEKV 2072 TGCGGAACATGGGATGAGAAGGTGTTC
F
1249 CGTWDEGQ 2073 TGCGGAACCTGGGATGAAGGCCAGACTACTGATTTC
TTDFFVF TTTGTCTTC
1250 CGTWDDTL 2074 TGCGGAACATGGGATGACACCCTGGCTGGTGTGGTC
AGVVF TTC
1251 CGTWDDRL 2075 TGCGGAACATGGGATGACAGGCTGACTTCTGCGGTC
TSAVF TTC
1252 CGTWDDRL 2076 TGCGGAACATGGGATGACAGACTGTTTGTTGTGGTA
FVVVF TTC
1253 CGTWDDNL 2077 TGCGGAACATGGGATGATAACCTGAGAGGTTGGGTG
RGWVF TTC
1254 CGTWDDNL 2078 TGCGGAACATGGGATGACAACCTGCGTGGTGTCGTG
RGVVF TTC
1255 CGTWDDNL 2079 TGCGGAACCTGGGATGACAATTTGAATATTGGAAGG
NIGRVF GTGTTC
1256 CGTWDDIL 2080 TGCGGAACATGGGATGACATCCTGAGTGCTGTGATA
SAVIF TTC
1257 CGTWDDIL 2081 TGCGGAACATGGGATGATATCCTGAGAGGTTGGGTG
RGWVF TTC
1258 CGTWDATL 2082 TGCGGAACATGGGATGCCACCCTGAGTCCTGGGTGG
SPGWLF TTATTC
1259 CGTWDASV 2083 TGCGGAACATGGGATGCCAGCGTGACTTCTTGGGTG
TSWVF TTC
1260 CGTWDASL 2084 TGCGGAACATGGGATGCCAGCCTGACTTCTGTGGTC
TSVVF TTC
1261 CGTWDASL 2085 TGCGGAACATGGGATGCCAGCCTGAGTGTTTGGGTG
SVWVF TTC
1262 CGTWDASL 2086 TGCGGAACATGGGATGCCAGCCTGAGTGTTCCTTGG
SVPWVF GTGTTC
1263 CGTWDASL 2087 TGCGGAACATGGGATGCCAGCCTGAGTGTGGCGGTA
SVAVF TTC
1264 CGTWDASL 2088 TGCGGAACATGGGATGCCAGCCTGAGTACCTGGGTA
STWVF TTC
1265 CGTWDASL 2089 TGCGGAACATGGGATGCCAGCCTGAGTGGTGTGGTA
SGVVF TTC
1266 CGTWDASL 2090 TGCGGAACATGGGATGCCAGCCTGAGTGGTGGGGG
SGGGEF AGAATTC
1267 CGTWDASL 2091 TGCGGAACATGGGATGCCAGCCTGAGTGCTGGGGTG
SAGVF TTC
1268 CGTWDASL 2092 TGCGGAACATGGGATGCCAGCCTGAGTGCTGGGCTT
SAGLF TTC
1269 CGTWDASL 2093 TGTGGCACATGGGATGCCAGCCTGAGTGCTGAAGTC
SAEVF TTC
1270 CGTWDASL 2094 TGCGGAACATGGGATGCCAGCCTGAGTGCTGACTTT
SADFWVF TGGGTGTTC
1271 CGTWDASL 2095 TGCGGAACATGGGATGCCAGCCTGAGAGTCTTCTTC
RVFF
1272 CGTWDASL 2096 TGCGGAACATGGGATGCCAGTCTGAGGGCTGTGGTA
RAVVL CTC
1273 CGTWDASL 2097 TGCGGAACATGGGATGCCAGCCTGAATATTTGGGTT
NIWVF TTC
1274 CGTWDASL 2098 TGCGGGACATGGGATGCCAGCCTGAAGAATCTGGTC
KNLVF TTC
1275 CGTWDASL 2099 TGCGGAACATGGGATGCCAGCCTGGGTGCCTGGGTA
GAWVF TTC
1276 CGTWDASL 2100 TGCGGAACATGGGATGCCAGCCTGGGTGCTGTGGTC
GAVVF TTC
1277 CGTWDASL 2101 TGCGGAACATGGGATGCCAGCCTGGGTGCGGGGGTC
GAGVF TTC
1278 CGTWDARL 2102 TGCGGAACATGGGATGCTAGGCTGAGTGGCCTTTAT
SGLYVF GTCTTC
1279 CGTWDARL 2103 TGTGGAACCTGGGATGCGAGACTGGGTGGTGCAGTC
GGAVF TTC
1280 CGTWDANL 2104 TGCGGAACATGGGATGCCAATCTGCGTGCTGGGGTC
RAGVF TTC
1281 CGTWDAIIS 2105 TGCGGAACATGGGATGCTATCATAAGTGGTTGGGTG
GWVF TTC
1282 CGTWDAG 2106 TGCGGAACATGGGATGCCGGCCAGAGTGTTTGGGTG
QSVWVF TTC
1283 CGTWDAGL 2107 TGCGGCACATGGGATGCCGGGCTGACTGGCCTTTAT
TGLYVF GTCTTC
1284 CGTWDAGL 2108 TGCGGAACTTGGGATGCCGGTCTGAGTGTTTATGTC
SVYVF TTC
1285 CGTWDAGL 2109 TGCGGGACATGGGATGCCGGCCTGAGTACTGGGGTC
STGVF TTC
1286 CGTWDAGL 2110 TGCGGAACATGGGATGCCGGCCTGAGTGGGGACGTT
SGDVF TTC
1287 CGTWDAGL 2111 TGCGGAACATGGGATGCCGGCCTGAGTGCTGGTTAT
SAGYVF GTCTTC
1288 CGTWDAGL 2112 TGCGGAACATGGGATGCCGGCCTGCGTGTTTGGGTG
RVWVF TTC
1289 CGTWDAGL 2113 TGCGGAACATGGGATGCCGGCCTGAGGGAAATTTTC
REIF
1290 CGTWASSL 2114 TGCGGAACATGGGCCAGCAGCCTGAGTTCTTGGGTG
SSWVF TTC
1291 CGTWAGSL 2115 TGCGGAACATGGGCTGGCAGCCTGAGTGGTCATGTC
SGHVF TTC
1292 CGTWAGSL 2116 TGCGGAACATGGGCTGGCAGCCTGAGTGCCGCTTGG
SAAWVF GTGTTC
1293 CGTWAGSL 2117 TGCGGAACATGGGCTGGCAGCCTGAATGTTTATTGG
NVYWVF GTGTTC
1294 CGTWAGNL 2118 TGCGGAACATGGGCTGGCAACCTGAGACCTAATTGG
RPNVVVF GTGTTC
1295 CGTRGSLG 2119 TGCGGAACAAGGGGTAGCCTGGGTGGTGCGGTGTTC
GAVF
1296 CGTRDTTLS 2120 TGCGGAACAAGGGATACCACCCTGAGTGTCCCGGTG
VPVF TTC
1297 CGTRDTSL 2121 TGCGGAACACGGGATACCAGCCTCAATATTGAAATC
NIEIF TTC
1298 CGTRDTSL 2122 TGTGGAACACGGGATACCAGCCTGAATGATGTCTTC
NDVF
1299 CGTRDTRL 2123 TGCGGAACACGGGATACCCGCCTGAGTATTGTGGTT
SIVVF TTC
1300 CGTRDTILS 2124 TGCGGCACACGGGATACCATCCTGAGTGCTGAGGTG
AEVF TTC
1301 CGTRDRSLS 2125 TGCGGAACACGGGATAGAAGCCTGAGTGGTTGGGT
GWVF GTTC
1302 CGSWYYNV 2126 TGCGGATCATGGTATTACAATGTCTTCCTTTTC
FLF
1303 CGSWHSSL 2127 TGCGGATCTTGGCATAGCAGCCTCAACCTTGTCGTCT
NLVVF TC
1304 CGSWGSGL 2128 TGCGGATCATGGGGTAGTGGCCTGAGTGCCCCTTAT
SAPYVF GTCTTC
1305 CGSWESGL 2129 TGCGGTTCGTGGGAAAGCGGCCTGGGTGCTTGGCTG
GAWLF TTC
1306 CGSWDYGL 2130 TGCGGATCCTGGGATTACGGCCTCCTACTCTTC
LLF
1307 CGSWDVSL 2131 TGCGGTTCATGGGATGTCAGCCTGACTGCTGTTTTC
TAVF
1308 CGSWDVSL 2132 TGCGGATCCTGGGATGTCAGTCTCAATGTTGGCATTT
NVGIF TC
1309 CGSWDTTL 2133 TGCGGATCATGGGATACCACCCTGCGTGCTTGGGTG
RAWVF TTC
1310 CGSWDTSP 2134 TGCGGCTCGTGGGATACCAGCCCTGTCCGTGCTTGG
VRAWVF GTGTTC
1311 CGSWDTSL 2135 TGCGGATCATGGGATACCAGCCTGAGTGTTTGGGTG
SVWVF TTC
1312 CGSWDTSL 2136 TGCGGATCATGGGATACCAGCCTGAGTGCTGAGGTG
SAEVF TTC
1313 CGSWDTSL 2137 TGCGGCTCGTGGGATACCAGCCTGCGTGCTTGGGTG
RAWVF TTC
1314 CGSWDTSL 2138 TGCGGCTCGTGGGATACCAGCCTGCGTGCTTGGGCG
RAWAF TTC
1315 CGSWDTSL 2139 TGCGGATCATGGGATACCAGCCTGGATGCTAGGCTG
DARLF TTC
1316 CGSWDTILL 2140 TGCGGATCATGGGATACCATCCTGCTTGTCTATGTCT
VYVF TC
1317 CGSWDRW 2141 TGCGGATCATGGGATCGCTGGCAGGCTGCTGTCTTC
QAAVF
1318 CGSWDRSL 2142 TGCGGATCATGGGATAGGAGCCTGAGTGGGTATGTC
SGYVF TTC
1319 CGSWDRSL 2143 TGCGGATCATGGGATAGAAGCCTGAGTGCTTATGTC
SAYVF TTC
1320 CGSWDRSL 2144 TGCGGATCATGGGATAGGAGCCTGAGTGCCGTGGTT
SAVVF TTC
1321 CGSWDNTL 2145 TGCGGATCATGGGATAACACCTTGGGTGTTGTTCTCT
GVVLF TC
1322 CGSWDNRL 2146 TGCGGATCGTGGGATAACAGACTAAGTACTGTCATC
STVIF TTC
1323 CGSWDNRL 2147 TGCGGAAGCTGGGATAATCGATTGAACACTGTGATT
NTVIF TTC
1324 CGSWDLSP 2148 TGCGGTTCATGGGATCTCAGCCCTGTACGTGTCCTTG
VRVLVF TGTTC
1325 CGSWDLSL 2149 TGCGGATCATGGGATCTCAGCCTGAGTGCTGTCGTT
SAVVF TTC
1326 CGSWDKNL 2150 TGCGGATCATGGGATAAAAACCTGCGTGCTGTGCTG
RAVLF TTC
1327 CGSWDISLS 2151 TGCGGCTCATGGGATATCAGCCTGAGTGCTGGGGTG
AGVF TTC
1328 CGSWDIRLS 2152 TGCGGATCATGGGATATCAGACTGAGTGCAGAGGTC
AEVF TTC
1329 CGSWDIKL 2153 TGCGGATCATGGGACATCAAACTGAATATTGGGGTA
NIGVF TTC
1330 CGSWDFSL 2154 TGCGGATCATGGGATTTCAGTCTCAATTATTTTGTCT
NYFVF TC
1331 CGSWDASL 2155 TGCGGATCATGGGATGCCAGCCTGAGTACTGAGGTG
STEVF TTC
1332 CGSWDAGL 2156 TGCGGATCCTGGGATGCCGGCCTGCGTGGCTGGGTT
RGWVF TTC
1333 CGRWESSL 2157 TGCGGAAGATGGGAGAGCAGCCTGGGTGCTGTGGTT
GAVVF TTC
1334 CGRWDFSL 2158 TGCGGAAGATGGGATTTTAGTCTGAGTGCTTATGTC
SAYVF TTC
1335 CGQWDND 2159 TGCGGACAATGGGATAACGACCTGAGTGTTTGGGTG
LSVWVF TTC
1336 CGPWHSSV 2160 TGCGGACCCTGGCATAGCAGCGTGACTAGTGGCCAC
TSGHVL GTGCTC
1337 CGLWDASL 2161 TGCGGATTATGGGATGCCAGCCTGAGTGCTCCTACT
SAPTWVF TGGGTGTTC
1338 CGIWHTSLS 2162 TGTGGAATATGGCACACTAGCCTGAGTGCTTGGGTG
AWVF TTC
1339 CGIWDYSL 2163 TGCGGAATATGGGATTACAGCCTGGATACTTGGGTG
DTWVF TTC
1340 CGIWDTSLS 2164 TGCGGCATATGGGATACCAGCCTGAGTGCTTGGGTG
AWVF TTC
1341 CGIWDTRL 2165 TGCGGAATTTGGGATACCAGGCTGAGTGTTTATGTC
SVYVF TTC
1342 CGIWDTRL 2166 TGCGGAATTTGGGATACCAGGCTGAGTGTTTATATC
SVYIF TTC
1343 CGIWDTNL 2167 TGTGGAATATGGGATACGAATCTGGGTTATCTCTTC
GYLF
1344 CGIWDTGL 2168 TGCGGTATATGGGATACCGGCCTGAGTGCTGTGGTA
SAVVF TTC
1345 CGIWDRSLS 2169 TGCGGAATATGGGATCGCAGCCTGAGTGCTTGGGTG
AWVF TTT
1346 CGIRDTRLS 2170 TGCGGAATTCGGGATACCAGGCTGAGTGTTTATGTC
VYVF TTC
1347 CGGWSSRL 2171 TGCGGAGGATGGAGTAGCAGACTGGGTGTTGGCCCA
GVGPVF GTGTTT
1348 CGGWGSGL 2172 TGCGGAGGATGGGGTAGCGGCCTGAGTGCTTGGGTG
SAWVF TTC
1349 CGGWDTSL 2173 TGCGGAGGATGGGATACCAGCCTGAGTGCTTGGGTG
SAWVF TTC
1350 CGGWDRGL 2174 TGCGGAGGATGGGATAGGGGCCTGGATGCTTGGGTT
DAWVF TTC
1351 CGAWRNN 2175 TGCGGAGCATGGCGTAATAACGTGTGGGTGTTC
VWVF
1352 CGAWNRRL 2176 TGCGGAGCATGGAACAGGCGCCTGAATCCTCATTCT
NPHSHWVF CATTGGGTGTTC
1353 CGAWHNK 2177 TGCGGAGCCTGGCACAACAAACTGAGCGCGGTCTTC
LSAVF
1354 CGAWGSSL 2178 TGCGGAGCATGGGGTAGCAGCCTGAGAGCTAGTGTC
RASVF TTC
1355 CGAWGSGL 2179 TGCGGAGCATGGGGTAGCGGCCTGAGTGCTTGGGTG
SAWVF TTC
1356 CGAWESSL 2180 TGCGGAGCATGGGAAAGTAGCCTGAGTGCCCCTTAT
SAPYVF GTCTTC
1357 CGAWESSL 2181 TGCGGAGCATGGGAGAGCAGCCTCAATGTTGGACTG
NVGLI ATC
1358 CGAWESGR 2182 TGCGGAGCATGGGAGAGCGGCCGGAGTGCTGGGGT
SAGVVF GGTGTTC
1359 CGAWDYSV 2183 TGCGGAGCTTGGGATTACAGTGTGAGTGGTTGGGTG
SGWVF TTC
1360 CGAWDYSL 2184 TGCGGAGCATGGGATTACAGCCTGACTGCCGGAGTA
TAGVF TTC
1361 CGAWDYRL 2185 TGCGGAGCCTGGGATTACAGACTGAGTGCCGTGCTA
SAVLF TTC
1362 CGAWDVRL 2186 TGCGGAGCGTGGGATGTTCGTCTGGATGTTGGGGTG
DVGVF TTC
1363 CGAWDTYS 2187 TGCGGAGCATGGGATACCTACAGTTATGTCTTC
YVF
1364 CGAWDTTL 2188 TGCGGAGCATGGGATACGACCCTGAGTGGTGTGGTA
SGVVF TTC
1365 CGAWDTTL 2189 TGCGGAGCGTGGGATACTACCCTGAGTGCTGTGATA
SAVIF TTC
1366 CGAWDTSQ 2190 TGCGGCGCATGGGATACCAGCCAGGGTGCGTCTTAT
GASYVF GTCTTT
1367 CGAWDTSP 2191 TGCGGAGCATGGGATACCAGCCCTGTACGTGCTGGG
VRAGVF GTGTTC
1368 CGAWDTSL 2192 TGCGGAGCATGGGATACCAGCCTGTGGCTTTTC
WLF
1369 CGAWDTSL 2193 TGCGGAGCATGGGATACCAGCCTGACTGTTTATGTC
TVYVF TTC
1370 CGAWDTSL 2194 TGCGGAGCATGGGACACCAGTCTGACTGCTGGGGTG
TAGVF TTC
1371 CGAWDTSL 2195 TGCGGAGCTTGGGATACCAGCCTGAGTACTGTGGTT
STVVF TTC
1372 CGAWDTSL 2196 TGCGGAGCATGGGATACCAGCCTGAGTTCTAGATAC
SSRYIF ATATTC
1373 CGAWDTSL 2197 TGCGGAGCATGGGATACCAGCCTGAGTGGTTATGTC
SGYVF TTC
1374 CGAWDTSL 2198 TGCGGAGCCTGGGATACCAGCCTGAGTGGCTGGGTG
SGWVF TTC
1375 CGAWDTSL 2199 TGCGGAGCATGGGATACCAGTCTGAGTGGTGTGCTA
SGVLF TTC
1376 CGAWDTSL 2200 TGCGGAGCTTGGGATACCAGCTTGAGTGGTCTTGTT
SGLVF TTC
1377 CGAWDTSL 2201 TGCGGAGCTTGGGATACCAGCTTGAGTGGTTTTGTTT
SGFVF TC
1378 CGAWDTSL 2202 TGCGGAGCATGGGATACCAGCCTGAGTGGTGAGGTC
SGEVF TTT
1379 CGAWDTSL 2203 TGCGGAGCTTGGGATACCAGCTTGAGTGATTTTGTTT
SDFVF TC
1380 CGAWDTSL 2204 TGCGGAGCATGGGATACCAGCCTGCGAACTGCGATA
RTAIF TTC
1381 CGAWDTSL 2205 TGCGGAGCATGGGATACCAGCCTGCGGCTTTTC
RLF
1382 CGAWDTSL 2206 TGCGGAGCATGGGATACCAGCCTGAATGTTCATGTC
NVHVF TTC
1383 CGAWDTSL 2207 TGCGGAGCATGGGATACCAGCCTCAATAAATGGGTG
NKWVF TTC
1384 CGAWDTRL 2208 TGCGGAGCATGGGATACCCGCCTCAGTGCGCGGCTG
SARLF TTC
1385 CGAWDTRL 2209 TGCGGAGCATGGGATACCAGACTGAGGGGTTTTATT
RGFIF TTC
1386 CGAWDTNL 2210 TGCGGAGCATGGGATACTAATTTGGGGAATGTTCTC
GNVLL CTC
1387 CGAWDTNL 2211 TGCGGGGCATGGGATACCAACCTGGGTAAATGGGTT
GKWVF TTC
1388 CGAWDTGL 2212 TGCGGAGCATGGGATACCGGCCTTGAGTGGTATGTT
EWYVF TTT
1389 CGAWDRTS 2213 TGCGGAGCATGGGATAGGACTTCTGGATTGTGGCTT
GLWLF TTC
1390 CGAWDRSL 2214 TGCGGAGCGTGGGATCGTAGCCTGGTTGCTGGACTC
VAGLF TTC
1391 CGAWDRSL 2215 TGCGGAGCGTGGGATAGAAGCCTGACTGTTTATGTC
TVYVF TTC
1392 CGAWDRSL 2216 TGCGGAGCATGGGATAGAAGCCTGAGTGGTTATGTC
SGYVF TTC
1393 CGAWDRSL 2217 TGCGGAGCATGGGATAGAAGCCTGAGTGCTTATGTC
SAYVF TTC
1394 CGAWDRSL 2218 TGCGGAGCATGGGATAGAAGCCTGAGTGCGGTGGT
SAVVF ATTC
1395 CGAWDRSL 2219 TGCGGAGCATGGGATCGCAGCCTGAGTGCTGGGGTT
SAGVF TTC
1396 CGAWDRSL 2220 TGCGGAGCGTGGGATCGCAGCCTGCGTATTGTGGTA
RIVVF TTC
1397 CGAWDRSL 2221 TGCGGAGCATGGGATAGAAGTCTGAGGGCTTACGTC
RAYVF TTC
1398 CGAWDRSL 2222 TGCGGAGCATGGGATAGAAGTCTGAATGTTTGGCTG
NVWLF TTC
1399 CGAWDRGL 2223 TGCGGCGCCTGGGATAGGGGCCTGAATGTCGGTTGG
NVGWLF CTTTTC
1400 CGAWDNRL 2224 TGCGGCGCATGGGATAATAGACTGAGTATTTTGGCC
SILAF TTC
1401 CGAWDND 2225 TGCGGAGCTTGGGATAATGACCTGACAGCTTATGTC
LTAYVF TTC
1402 CGAWDFSL 2226 TGCGGGGCATGGGATTTCAGCCTGACTCCTCTCTTC
TPLF
1403 CGAWDDY 2227 TGCGGAGCCTGGGATGACTATCGGGGTGTGAGTATT
RGVSIYVF TATGTCTTC
1404 CGAWDDRP 2228 TGTGGAGCATGGGATGACCGGCCTTCGAGTGCCGTG
SSAVVF GTTTTC
1405 CGAWDDRL 2229 TGCGGAGCATGGGATGACAGACTGACTGTCGTTGTT
TVVVF TTC
1406 CGAWDDRL 2230 TGCGGAGCGTGGGATGACAGGCTGGGTGCTGTGTTC
GAVF
1407 CGAWDASL 2231 TGCGGAGCGTGGGATGCCAGCCTGAATCCTGGCCGG
NPGRAF GCATTC
1408 CGAWDAG 2232 TGCGGAGCATGGGATGCCGGCCTGAGGGAAATTTTC
LREIF
1409 CGAWAGSP 2233 TGCGGAGCTTGGGCTGGCAGTCCGAGTCCTTGGGTT
SPWVF TTC
1410 CGAFDTTLS 2234 TGCGGAGCATTCGACACCACCCTGAGTGCTGGCGTT
AGVF TTC
1411 CETWESSLS 2235 TGCGAAACATGGGAGAGCAGCCTGAGTGTTGGGGTC
VGVF TTC
1412 CETWESSL 2236 TGCGAAACATGGGAAAGCAGCCTGAGGGTTTGGGT
RVWVF GTTC
1413 CETWDTSL 2237 TGCGAAACGTGGGATACCAGCCTGAGTGGTGGGGTG
SGGVF TTC
1414 CETWDTSL 2238 TGCGAAACATGGGATACCAGCCTGAGTGACTTTTAT
SDFYVF GTCTTC
1415 CETWDTSL 2239 TGCGAAACATGGGATACCAGCCTGAGTGCCCTCTTC
SALF
1416 CETWDTSL 2240 TGCGAAACATGGGATACCAGCCTGCGTGCTGAAGTC
RAEVF TTC
1417 CETWDTSL 2241 TGCGAAACATGGGATACCAGCCTGAATGTTGTGGTA
NVVVF TTC
1418 CETWDTSL 2242 TGCGAAACATGGGATACCAGCCTGGGTGCCGTGGTG
GAVVF TTC
1419 CETWDRSL 2243 TGCGAAACATGGGATAGAAGCCTGAGTGGTGTGGTA
SGVVF TTC
1420 CETWDRSL 2244 TGCGAAACATGGGATAGGAGCCTGAGTGCTTGGGTG
SAWVF TTT
1421 CETWDRSL 2245 TGCGAAACATGGGATCGCAGCCTGAGTGCTGTGGTC
SAVVF TTC
1422 CETWDRGL 2246 TGCGAGACGTGGGATAGAGGCCTGAGTGTTGTGGTT
SVVVF TTC
1423 CETWDRGL 2247 TGCGAAACATGGGATAGGGGCCTGAGTGCAGTGGT
SAVVF ATTC
1424 CETWDHTL 2248 TGCGAAACATGGGATCACACCCTGAGTGTTGTGATA
SVVIF TTC
1425 CETWDASL 2249 TGCGAAACATGGGATGCCAGCCTGACTGTTGTGTTA
TVVLF TTC
1426 CETWDASL 2250 TGCGAAACATGGGATGCCAGCCTGAGTGCTGGGGTG
SAGVF TTC
1427 CETWDAGL 2251 TGCGAAACGTGGGATGCCGGCCTGAGTGAGGTGGTG
SEVVF TTC
1428 CETFDTSLS 2252 TGCGAAACATTTGATACCAGCCTGAGTGTTGTAGTC
VVVF TTC
1429 CETFDTSLN 2253 TGCGAAACATTTGATACCAGCCTAAATATTGTAGTC
IVVF TTT
1430 CESWDRSRI 2254 TGCGAATCATGGGATAGAAGCCGGATTGGTGTGGTC
GVVF TTC
1431 CESWDRSL 2255 TGCGAAAGTTGGGACAGGAGTCTGAGTGCCCGGGTG
SARVY TAC
1432 CESWDRSL 2256 TGCGAATCCTGGGATAGGAGCCTGCGTGCCGTGGTC
RAVVF TTC
1433 CESWDRSLI 2257 TGCGAATCTTGGGATCGTAGTTTGATTGTGGTGTTC
VVF
1434 CESWDNNL 2258 TGCGAAAGTTGGGATAACAATTTAAATGAGGTGGTT
NEVVF TTC
1435 CEIWESSPS 2259 TGCGAAATATGGGAGAGCAGCCCGAGTGCTGACGA
ADDLVF TTTGGTGTTC
1436 CEAWDTSL 2260 TGCGAAGCATGGGATACCAGCCTGAGTGGTGCGGTG
SGAVF TTC
1437 CEAWDTSL 2261 TGCGAAGCATGGGATACCAGCCTGAGTGCCGGGGTG
SAGVF TTC
1438 CEAWDTSL 2262 TGCGAAGCATGGGATACCAGCCTGGGTGGTGGGGTG
GGGVF TTC
1439 CEAWDRSL 2263 TGCGAAGCATGGGATCGCAGCCTGACTGGTAGCCTG
TGSLF TTC
1440 CEAWDRGL 2264 TGCGAAGCGTGGGATAGGGGCCTGAGTGCAGTGGT
SAVVF ATTC
1441 CEAWDNIL 2265 TGCGAAGCCTGGGATAACATCCTGAGTACTGTGGTG
STVVF TTC
1442 CEAWDISLS 2266 TGCGAAGCATGGGACATCAGCCTGAGTGCTGGGGTG
AGVF TTC
1443 CEAWDADL 2267 TGCGAAGCATGGGATGCCGACCTGAGTGGTGCGGTG
SGAVF TTC
1444 CATWTGSF 2268 TGCGCAACATGGACTGGTAGTTTCAGAACTGGCCAT
RTGHYVF TATGTCTTC
1445 CATWSSSP 2269 TGCGCAACATGGAGTAGCAGTCCCAGGGGGTGGGT
RGWVF GTTC
1446 CATWHYSL 2270 TGCGCAACATGGCATTACAGCCTGAGTGCTGGCCGA
SAGRVF GTGTTC
1447 CATWHTSL 2271 TGCGCAACATGGCATACCAGCCTGAGTATTGTGCAG
SIVQF TTC
1448 CATWHSTL 2272 TGCGCAACATGGCATAGCACCCTGAGTGCTGATGTG
SADVLF CTTTTC
1449 CATWHSSL 2273 TGCGCAACATGGCATAGCAGCCTGAGTGCTGGCCGA
SAGRLF CTCTTC
1450 CATWHIAR 2274 TGCGCAACATGGCATATCGCTCGGAGTGCCTGGGTG
SAWVF TTC
1451 CATWGSSQ 2275 TGCGCAACATGGGGTAGTAGTCAGAGTGCCGTGGTA
SAVVF TTC
1452 CATWGSSL 2276 TGCGCAACATGGGGTAGCAGCCTGAGTGCTGGGGGT
SAGGVF GTTTTC
1453 CATWEYSL 2277 TGTGCAACATGGGAATACAGCCTGAGTGTTGTGCTG
SVVLF TTC
1454 CATWETTR 2278 TGCGCAACATGGGAGACCACCCGACGTGCCTCTTTT
RASFVF GTCTTC
1455 CATWETSL 2279 TGCGCAACATGGGAGACCAGCCTGAATGTTTATGTC
NVYVF TTC
1456 CATWETSL 2280 TGCGCAACATGGGAAACTAGCCTGAATGTTGTGGTC
NVVVF TTC
1457 CATWETSL 2281 TGCGCAACATGGGAGACCAGCCTGAATCTTTATGTC
NLYVF TTC
1458 CATWETGL 2282 TGCGCAACATGGGAGACTGGCCTAAGTGCTGGAGA
SAGEVF GGTGTTC
1459 CATWESTL 2283 TGCGCGACGTGGGAGAGTACCCTAAGTGTTGTGGTT
SVVVF TTC
1460 CATWESSL 2284 TGCGCAACGTGGGAGAGCAGCCTGAGTATTTTTGTC
SIFVF TTC
1461 CATWESSL 2285 TGCGCAACATGGGAAAGCAGCCTCAACACTTTTTAT
NTFYVF GTCTTC
1462 CATWESRV 2286 TGCGCAACATGGGAGAGTAGGGTGGATACTCGAGG
DTRGLLF GTTGTTATTC
1463 CATWESGL 2287 TGCGCAACATGGGAGAGCGGCCTGAGTGGTGCGGG
SGAGVF GGTGTTC
1464 CATWEGSL 2288 TGCGCAACATGGGAAGGCAGCCTCAACACTTTTTAT
NTFYVF GTCTTC
1465 CATWDYSL 2289 TGCGCAACTTGGGATTATAGCCTGAGTGCTGTGGTG
SAVVF TTC
1466 CATWDYRL 2290 TGCGCAACATGGGATTACAGACTGAGTATTGTGGTA
SIVVF TTC
1467 CATWDYNL 2291 TGCGCAACATGGGATTATAACCTGGGAGCTGCGGTG
GAAVF TTC
1468 CATWDVTL 2292 TGCGCCACATGGGATGTCACCCTGGGTGTCTTGCAT
GVLHF TTC
1469 CATWDTTL 2293 TGCGCAACATGGGATACAACACTGAGTGTCTGGGTC
SVWVF TTC
1470 CATWDTTL 2294 TGCGCAACATGGGATACCACCCTGAGTGTAGTACTT
SVVLF TTC
1471 CATWDTTL 2295 TGCGCAACATGGGATACCACCCTGAGTGTTGAGGTC
SVEVF TTC
1472 CATWDTSP 2296 TGCGCAACATGGGATACCAGCCCCAGCCTGAGTGGT
SLSGFWVF TTTTGGGTGTTC
1473 CATWDTSL 2297 TGCGCAACATGGGATACCAGCCTGACTGGTGTGGTA
TGVVF TTC
1474 CATWDTSL 2298 TGCGCAACATGGGATACCAGCCTGACTGGTGCGGTG
TGAVF TTC
1475 CATWDTSL 2299 TGCGCAACATGGGATACCAGCCTGACTGCCTGGGTA
TAWVF TTC
1476 CATWDTSL 2300 TGCGCAACATGGGATACCAGCCTGACTGCTGTGGTT
TAVVF TTC
1477 CATWDTSL 2301 TGCGCAACATGGGATACTAGCCTGACTGCTAAGGTG
TAKVF TTC
1478 CATWDTSL 2302 TGCGCAACATGGGACACCAGCCTGAGTGTTGTGGTT
SVVVF TTC
1479 CATWDTSL 2303 TGCGCTACTTGGGATACCAGCCTGAGTGTTGGGGTA
SVGVF TTT
1480 CATWDTSL 2304 TGCGCAACATGGGATACCAGCCTGAGTTCTTGGGTG
SSWVF TTC
1481 CATWDTSL 2305 TGCGCAACATGGGATACCAGCCTGAGTGGTGGGGTA
SGGVL CTC
1482 CATWDTSL 2306 TGCGCAACATGGGATACCAGCCTGAGTGGTGGGGTG
SGGVF TTC
1483 CATWDTSL 2307 TGCGCAACATGGGATACCAGCCTGAGTGGTGGCCGA
SGGRVF GTGTTC
1484 CATWDTSL 2308 TGCGCAACATGGGATACCAGCCTGAGTGGTGACCGA
SGDRVF GTGTTC
1485 CATWDTSL 2309 TGCGCAACGTGGGATACTAGCCTGAGTGAAGGGGTG
SEGVF TTC
1486 CATWDTSL 2310 TGCGCAACCTGGGATACCAGCCTGAGTGCCGTGGTG
SAVVL CTC
1487 CATWDTSL 2311 TGCGCAACATGGGATACCAGCCTGAGTGCTGTCTTC
SAVF
1488 CATWDTSL 2312 TGCGCGACATGGGATACCAGCCTGAGTGCTCGGGTG
SARVF TTC
1489 CATWDTSL 2313 TGCGCAACATGGGATACCAGCCTGAGTGCCTTATTC
SALF
1490 CATWDTSL 2314 TGCGCAACATGGGATACCAGCCTGAGTGCTCATGTC
SAHVF TTC
1491 CATWDTSL 2315 TGCGCAACATGGGATACCAGCCTGAGTGCTGGCCGG
SAGRVF GTGTTC
1492 CATWDTSL 2316 TGCGCAACATGGGATACCAGCCTGAGTGCGGAGGTC
SAEVF TTC
1493 CATWDTSL 2317 TGCGCAACATGGGATACCAGCCTGAGTGCTGATGCT
SADAGGGV GGTGGGGGGGTCTTC
F
1494 CATWDTSL 2318 TGCGCAACATGGGATACCAGCCTGCGTGTCGTGGTA
RVVVF TTC
1495 CATWDTSL 2319 TGCGCAACATGGGATACCAGCCTGAGAGGGGTGTTC
RGVF
1496 CATWDTSL 2320 TGCGCAACATGGGATACCAGCCTGCCTGCGTGGGTG
PAWVF TTC
1497 CATWDTSL 2321 TGTGCAACATGGGATACCAGCCTGAATGTTGGGGTA
NVGVF TTC
1498 CATWDTSL 2322 TGCGCAACATGGGATACCAGCCTGGGTATTGTGTTA
GIVLF TTT
1499 CATWDTSL 2323 TGCGCAACATGGGACACCAGCCTGGGTGCGCGTGTG
GARVVF GTCTTC
1500 CATWDTSL 2324 TGTGCAACGTGGGATACCAGTCTAGGTGCCTTGTTC
GALF
1501 CATWDTSL 2325 TGCGCAACATGGGATACCAGCCTGGCGACTGGACTG
ATGLF TTC
1502 CATWDTSL 2326 TGCGCAACATGGGATACCAGCCTGGCTGCCTGGGTA
AAWVF TTC
1503 CATWDTRL 2327 TGCGCAACCTGGGATACCAGGCTGAGTGCTGTGGTC
SAVVF TTC
1504 CATWDTRL 2328 TGCGCAACATGGGATACCAGGCTGAGTGCTGGGGTG
SAGVF TTC
1505 CATWDTRL 2329 TGTGCAACGTGGGACACACGTCTACTTATTACGGTT
LITVF TTC
1506 CATWDTLL 2330 TGCGCAACATGGGACACCCTCCTGAGTGTTGAACTC
SVELF TTC
1507 CATWDTGR 2331 TGCGCAACATGGGATACTGGCCGCAATCCTCATGTG
NPHVVF GTCTTC
1508 CATWDTGL 2332 TGCGCAACATGGGATACCGGCCTGTCTTCGGTGTTG
SSVLF TTC
1509 CATWDTGL 2333 TGCGCAACGTGGGATACCGGCCTGAGTGCGGTTTTC
SAVF
1510 CATWDRTL 2334 TGCGCTACGTGGGATAGGACCCTGAGTATTGGAGTC
SIGVF TTC
1511 CATWDRSV 2335 TGCGCAACGTGGGATCGCAGTGTGACTGCTGTGCTC
TAVLF TTC
1512 CATWDRSL 2336 TGCGCAACCTGGGATAGGAGCCTGAGTGGTGTGGTG
SGVVF TTC
1513 CATWDRSL 2337 TGCGCAACATGGGATAGAAGCCTGAGTGCTGTGGTC
SAVVF TTC
1514 CATWDRSL 2338 TGCGCAACATGGGATAGAAGCCTGAGTGCTGTTCCT
SAVPWVF TGGGTGTTC
1515 CATWDRSL 2339 TGCGCAACATGGGATCGCAGCCTGAGTGCTGGGGTG
SAGVF TTC
1516 CATWDRSL 2340 TGCGCAACGTGGGATAGGAGCCTGCGTGCTGGGGTG
RAGVF TTC
1517 CATWDRSL 2341 TGCGCAACATGGGATCGCAGTCTGAATGTTTATGTC
NVYVL CTC
1518 CATWDRIL 2342 TGCGCAACGTGGGATCGCATCCTGAGCGCTGAGGTG
SAEVF TTC
1519 CATWDRGL 2343 TGCGCAACGTGGGATAGAGGCCTGAGTACTGGGGTG
STGVF TTC
1520 CATWDNYL 2344 TGCGCAACATGGGATAACTACCTGGGTGCTGCCGTG
GAAVF TTC
1521 CATWDNTP 2345 TGCGCAACATGGGATAACACGCCTTCGAATATTGTG
SNIVVF GTATTC
1522 CATWDNTL 2346 TGCGCAACATGGGATAATACACTGAGTGTGTGGGTC
SVWVF TTC
1523 CATWDNTL 2347 TGCGCAACATGGGATAACACCCTGAGTGTCAATTGG
SVNWVF GTGTTC
1524 CATWDNTL 2348 TGCGCAACCTGGGATAACACACTGAATGTCTTTTAT
NVFYVF GTTTTC
1525 CATWDNRL 2349 TGTGCGACATGGGATAATCGGCTCAGTTCTGTGGTC
SSVVF TTC
1526 CATWDNRL 2350 TGCGCAACATGGGATAACCGCCTGAGTGCTGGGGTG
SAGVL CTC
1527 CATWDNRL 2351 TGCGCAACGTGGGATAACAGGCTGAGTGCTGGGGTG
SAGVF TTC
1528 CATWDNRD 2352 TGCGCAACATGGGATAACAGGGATTGGGTCTTC
WVF
1529 CATWDNNL 2353 TGCGCAACATGGGATAACAACCTGGGTGCTGGGGTG
GAGVF TTC
1530 CATWDNKL 2354 TGCGCAACATGGGATAACAAGCTGACTTCTGGGGTC
TSGVF TTC
1531 CATWDNIL 2355 TGCGCAACATGGGATAACATCCTGAGTGCCTGGGTG
SAWVF TTT
1532 CATWDNDI 2356 TGCGCAACCTGGGACAACGATATACATTCTGGGCTG
HSGLF TTC
1533 CATWDLSL 2357 TGCGCAACTTGGGATCTCAGCCTGAGTGCCCTGTTC
SALF
1534 CATWDITLS 2358 TGCGCAACATGGGATATCACCCTGAGTGCTGAGGTG
AEVF TTC
1535 CATWDISPS 2359 TGCGCAACGTGGGATATCAGCCCGAGTGCTGGCGGG
AGGVF GTGTTC
1536 CATWDISLS 2360 TGCGCAACATGGGATATCAGTCTAAGTACTGGCCGG
TGRAVF GCTGTGTTC
1537 CATWDISLS 2361 TGCGCAACATGGGATATCAGTCTGAGTCAGGTATTC
QVF
1538 CATWDIRL 2362 TGCGCAACATGGGATATCAGGCTGAGTAGTGGAGTG
SSGVF TTC
1539 CATWDIGP 2363 TGCGCAACGTGGGATATCGGCCCGAGTGCTGGCGGG
SAGGVF GTGTTC
1540 CATWDHSR 2364 TGCGCAACATGGGATCACAGCCGGGCTGGTGTGCTA
AGVLF TTC
1541 CATWDHSP 2365 TGCGCAACATGGGATCACAGTCCGAGTGTTGGAGAA
SVGEVF GTCTTC
1542 CATWDHSL 2366 TGCGCAACATGGGATCACAGCCTGCGTGTTGGGGTG
RVGVF TTC
1543 CATWDHSL 2367 TGCGCAACATGGGATCACAGCCTGAACATTGGGGTG
NIGVF TTC
1544 CATWDHSL 2368 TGCGCAACATGGGATCACAGCCTGGGTCTTTGGGCA
GLWAF TTC
1545 CATWDHNL 2369 TGCGCCACATGGGATCACAATCTGCGTCTTGTTTTC
RLVF
1546 CATWDHIL 2370 TGCGCGACTTGGGATCACATCCTGGCTTCTGGGGTG
ASGVF TTC
1547 CATWDFSL 2371 TGCGCAACATGGGATTTCAGCCTGAGTGTTTGGGTG
SVWVF TTC
1548 CATWDFSL 2372 TGCGCAACATGGGATTTCAGCCTGAGTGCTTGGGTG
SAWVF TTC
1549 CATWDDTL 2373 TGCGCAACATGGGATGACACCCTCACTGCTGGTGTG
TAGVF TTC
1550 CATWDDRL 2374 TGCGCAACATGGGACGACAGGCTGAGTGCTGTGCTT
SAVLF TTC
1551 CATWDDRL 2375 TGCGCAACATGGGATGACAGGCTGGATGCTGCGGTG
DAAVF TTC
1552 CATWDATL 2376 TGCGCAACATGGGATGCGACCCTGAATACTGGGGTG
NTGVF TTC
1553 CATWDASL 2377 TGCGCAACATGGGATGCCAGCCTGAGTGTTTGGCTG
SVWLL CTC
1554 CATWDASL 2378 TGCGCGACATGGGATGCCAGCCTGAGTGGTGGGGTG
SGGVF TTC
1555 CATRDTTLS 2379 TGCGCAACACGGGATACCACCCTCAGCGCCGTTCTG
AVLF TTC
1556 CATLGSSLS 2380 TGCGCTACATTGGGTAGTAGCCTGAGTCTCTGGGTG
LWVF TTC
1557 CATIETSLP 2381 TGCGCAACAATCGAAACTAGCCTGCCTGCCTGGGTA
AWVF TTC
1558 CATGDRSL 2382 TGCGCAACAGGGGACAGAAGCCTGACTGTTGAGGT
TVEVF ATTC
1559 CATGDLGL 2383 TGCGCTACAGGGGATCTCGGCCTGACCATAGTCTTC
TIVF
1560 CASWDYRG 2384 TGCGCATCATGGGATTACAGGGGGAGATCTGGTTGG
RSGWVF GTGTTC
1561 CASWDTTL 2385 TGCGCATCATGGGATACCACCCTGAATGTTGGGGTG
NVGVF TTC
1562 CASWDTTL 2386 TGCGCTTCATGGGATACCACCCTGGGTTTTGTGTTAT
GFVLF TC
1563 CASWDTSL 2387 TGCGCATCATGGGATACCAGCCTGAGTGGTGGTTAT
SGGYVF GTCTTC
1564 CASWDTSL 2388 TGCGCATCATGGGATACCAGCCTCCGTGCTGGGGTG
RAGVF TTC
1565 CASWDTSL 2389 TGCGCATCATGGGATACCAGCCTGGGTGCTGGGGTG
GAGVF TTC
1566 CASWDRGL 2390 TGCGCATCATGGGACAGAGGCCTGAGTGCAGTGGTG
SAVVF TTC
1567 CASWDNVL 2391 TGTGCTAGTTGGGATAACGTCCTGCGTGGTGTGGTA
RGVVF TTC
1568 CASWDNRL 2392 TGCGCGTCATGGGATAACAGGCTGACTGCCGTGGTT
TAVVF TTC
1569 CASWDASL 2393 TGCGCATCATGGGATGCAAGCCTGTCCGTCGCTTTC
SVAF
1570 CASWDAGL 2394 TGCGCTTCGTGGGATGCCGGCCTGAGTTCTTATGTCT
SSYVF TC
1571 CASGDTSLS 2395 TGCGCATCCGGGGATACCAGCCTGAGTGGTGTGATA
GVIF TTC
1572 CARWHTSL 2396 TGCGCAAGATGGCATACGAGCCTAAGTATTTGGGTC
SIWVF TTC
1573 CAIWDTGL 2397 TGCGCAATATGGGATACCGGCCTGAGTCCTGGCCAA
SPGQVAF GTTGCCTTC
1574 CAAWHSGL 2398 TGCGCAGCATGGCATAGCGGCCTGGGTCTCCCGGTC
GLPVF TTC
1575 CAAWDYSL 2399 TGCGCAGCATGGGATTACAGCCTGAGTGCTGGGGTG
SAGVF TTC
1576 CAAWDTTL 2400 TGCGCAGCCTGGGATACTACCCTGCGTGTTAGGCTG
RVRLF TTC
1577 CAAWDTSL 2401 TGCGCAGCATGGGATACCAGCCTGACTGCCTGGGTT
TAWVF TTC
1578 CAAWDTSL 2402 TGCGCAGCATGGGATACCAGCTTGAGTGGTGGGGTG
SGGVF TTC
1579 CAAWDTSL 2403 TGCGCAGCATGGGATACCAGCCTGAGTGGCGAGGCT
SGEAVF GTGTTC
1580 CAAWDTSL 2404 TGCGCAGCATGGGATACCAGCTTGAGTGGTGCGGTG
SGAVF TTC
1581 CAAWDTSL 2405 TGCGCAGCATGGGATACCAGCCTGAGTGCCTGGGTG
SAWVF TTC
1582 CAAWDTSL 2406 TGCGCAGCATGGGATACCAGCCTGAGTGCTGGGGTA
SAGVF TTC
1583 CAAWDTSL 2407 TGCGCAGCATGGGATACCAGCCTGGATACTTATGTC
DTYVF TTC
1584 CAAWDTRL 2408 TGCGCTGCATGGGATACCCGTCTGAGTGGTGTGTTA
SGVLF TTC
1585 CAAWDTRL 2409 TGCGCAGCATGGGATACCAGGCTGAGTGCTGGGGTG
SAGVF TTC
1586 CAAWDRSL 2410 TGCGCAGCATGGGATCGCAGTCTGAGTACTGGAGTT
STGVF TTC
1587 CAAWDIRR 2411 TGCGCAGCGTGGGATATCCGCCGGTCTGTCCTTTTC
SVLF
1588 CAAWDHT 2412 TGCGCTGCGTGGGATCACACTCAGCGTCTTTCCTTC
QRLSF
1589 CAAWDHSL 2413 TGCGCAGCATGGGATCACAGCCTGAGTGCTGGCCAG
SAGQVF GTGTTC
1590 CAAVDTGL 2414 TGCGCAGCAGTCGATACTGGTCTGAAAGAATGGGTG
KEWVF TTC
The CDRs were prescreened to contain no amino acid liabilities, cryptic splice sites or nucleotide restriction sites. The CDR variation was observed in at least two individuals and comprises the near-germline space of single, double and triple mutations. The order of assembly is seen in FIG. 21C.
The VH domains that were designed include IGHV1-69 and IGHV3-30. Each of two heavy chain VH domains are assembled with their respective invariant 4 framework elements (FW1, FW2, FW3, FW4) and variable 3 CDR (H1, H2, H3) elements. For IGHV1-69, 417 variants were designed for H1 and 258 variants were designed for H2. For IGHV3-30, 535 variants were designed for H1 and 165 variants were designed for H2. For the CDR H3, the same cassette was used in both IGHV1-69 and IGHV-30 since both designed use an identical FW4, and because the edge of FW3 is also identical for both IGHV1-69 and IGHV3-30. The CDR H3 comprises an N-terminus and C-terminus element that are combinatorially joined to a central middle element to generate 1×1010 diversity. The N-terminal and middle element overlap with a “GGG” glycine codon. The middle and C-terminal element overlap with a “GGT” glycine codon. The CDR H3 comprises 5 subpools that were assembled separately. The various N-terminus and C-terminus elements comprise sequences as seen in Table 14.
TABLE 14
Sequences for N-terminus and C-terminus elements
SEQ
ID
Element NO Sequence
Stem A 2415 CARDLRELECEEWT XXX SRGPCVDPRGVAGSFDVW
Stem B 2416 CARDMYYDF XXX EVVPADDAFDIW
Stem C 2417 CARDGRGSLPRPKGGP XXX YDSSEDSGGAFDIW
Stem D 2418 CARANQHF XXX GYHYYGMDVW
Stem E 2419 CAKHMSMQ XXX RADLVGDAFDVW
Example 12. Enrichment for GPCR GLP1R Binding Proteins Antibodies having CDR-H3 regions with a variant fragments of GPCR binding protein were generated by methods described herein were panned using cell-based methods to identified variants which are enriched for binding to particular GPCRs, as described in Example 10.
Variants of the GLP C-terminus peptide were identified (listed in Table 15) that when embedded in the CDR-H3 region of an antibody, were repeatedly and selectively enriched for binding to GPCR GLP1R.
TABLE 15
Sequences of GLP1 embedded in CDR-H3
SEQ
ID
NO Sequence
2420 CAKHMSMQEGAVTGEGQAAKEFIAWLVKGRVRADLVGDAFDVW
2421 CARDGRGSLPRPKGGPQTVGEGQAAKEFIAWLVKGGLTYDSSEDS
GGAFDIW
2422 CAKHMSMQDYLVIGEGQAAKEFIAWLVKGGPARADLVGDAFDVW
2423 CAKHMSMQEGAVTGEGQDAKEFIAWLVKGRVRADLVGDAFDVW
2424 WAKHMSMQEGAVTGEGQAAKEFIAWLVKGRVRADLVGDAFDVW
2425 CARDGRGSLPRPKGGPQTVGEGQAAKEFIAWLVKGRVRADLVGDA
FDVW
2426 CARANQHFYEQEGTFTSDVSSYLEGQAAKEFIAWLVKGGIRGYHY
YGMDVW
2427 CARANQHFTELHGEGQAAKEFIAWLVKGRGQIDIGYHYYGMDVW
2428 CARANQHFLGAGVSSYLEGQAAKEFIAWLVKGDTTGYHYYGMDVW
2429 CARANQHFLDKGTFTSDVSSYLEGQAAKEFIAWLVKGIYPGYHYY
GMDVW
2430 CARANQHFGTLSAGEGQAAKEFIAWLVKGGSQYDSSEDSGGAFDIW
2431 CARANQHFGLHAQGEGQAAKEFIAWLVKGSGTYGYHYYGMDVW
2432 CARANQHFGGKGEGQAAKEFIAWLVKGGGSGAGYHYYGMDVW
2433 CAKQMSMQEGAVTGEGQAAKEFIAWLVKGRVRADLVGDAFDVW
2434 CAKHMSMQEGAVTGEGQAAKEFIAWLVKGGPARADLVGDAFDVW
2435 CAKHMSMQEGAVTGEGQAAKEFIAWLVKGGLTYDSSEDSGGAFDIW
2436 CAKHMSMQDYLVIGEGQAAKEFIAWLVKGRVRADLVGDAFDVW
While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.
